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1 Aim of present investigation  
Historically, oral drug administration has been the predominant route for drug 
delivery. During the past two decades, numerous oral delivery systems have 
been developed to act as drug reservoirs from which the active substance can 
be released over a defined period of time at a predetermined and controlled 
rate. From a pharmacokinetic point of view, the ideal sustained and controlled 
release dosage form should be comparable with an intravenous infusion, 
which supplies continuously the amount of drug needed to maintain constant 
plasma levels once the steady state is reached. 
Although some important applications, including oral administration of peptide 
and protein drugs, can be used to prepare colonic drug delivery systems, 
targeting drugs to the colon by the oral route. More often, drug absorption is 
unsatisfactory and highly variable among and between individuals, despite 
excellent in vitro release patterns. The reasons for this are essentially 
physiological and usually affected by the gastrointestinal (GI) transit of the 
form, especially its gastric residence time (GRT), which appears to be one of 
the major causes of the overall transit time variability. 
Over the past three decades, the pursuit and exploration of devices designed 
to be retained in the upper part of the GI tract has advanced consistently in 
terms of technology and diversity, encompassing a variety of systems and 
devices such as floating systems, raft systems, expanding systems, swelling 
systems, bioadhesive systems and low-density systems.   
Stomach specific (gastricretention) will provide advantages such as the 
delivery of drugs with narrow absorption windows in the small intestinal 
region. Also, longer residence time in the stomach could be advantageous for 
local action in the upper part of the small intestine, for example treatment of 
peptic ulcer disease.  
Furthermore, improved bioavailability is expected for drugs that are absorbed 
readily upon release in the GI tract. These drugs can be delivered ideally by 
slow release from the stomach. Many drugs categorized as once-a-day 
delivery have been demonstrated to have suboptimal absorption due to 
dependence on the transit time of the dosage form, making traditional 
extended release development challenging. Therefore, a system designed for 
 Aim of present investigation  
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longer gastric retention will extend the time within which drug absorption can 
occur in the small intestine. 
Optimization techniques have been applied in the present study to 
systemically study the influence of process variables on the formulation of 
dosage forms. These designs provide an effective means for studying the 
effect of various parameters on the dependent variables. Thus, factorial 
designs were applied to optimize the formulation and development of 
mucoadhesive microspheres and in situ gel. In vivo studies of the formulations 
were also conducted to ascertain the effect of the designed dosage forms in 
vivo. 
The present study was aimed at the development of stomach specific drug 
delivery systems using various approaches like mucoadhesive or floating. 
Mucoadhesive microspheres of amoxicillin, in situ gelling system of famotidine 
and mucoadhesive/floating tablets of glipizide were prepared. Different 
formulation variables were studied and optimized to achieve the desired 
mucoadhesive or floating properties and release profiles. The stability of the 
formulations was evaluated after 3 months of storage at accelerated stability 
conditions.  
 
  
 
Chapter 1.1 
Introduction to Stomach 
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systems 
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1.1 Stomach Specific drug delivery systems 
1.1.1 Introduction 
The design of oral control drug delivery systems (DDS) should be primarily aimed 
to achieve more predictable and increased bioavailability 1. Approximately 505 of 
the drug available in the market are oral DDS and these systems have more 
advantages due to patients acceptance and ease of administration. Nowadays 
most of the pharmaceutical scientist is involved in developing the ideal DDS. This 
ideal system should have advantage of single dose for the whole duration of 
treatment and it should deliver the active drug directly at the specific site. 
Scientists have succeeded to develop a system and it encourages the scientists 
to develop control release systems. Control release implies the predictability and 
reproducibility to control the drug release, drug concentration in target tissue and 
optimization of the therapeutic effect of a drug by controlling its release in the 
body with lower and less frequent dose 2,3. 
Under certain circumstances prolonging the gastric retention of a delivery system 
is desirable for achieving greater therapeutic benefit of the drug substances. For 
example, drugs that are absorbed in the proximal part of the gastrointestinal tract 
4
,and the drugs that are less soluble or are degraded by the alkaline pH may 
benefit from the prolong gastric retention 5,6. In addition, for local and sustained 
drug delivery to the stomach and the proximal small intestine to treat certain 
conditions, prolonging gastric retention of the therapeutic moiety may offer 
numerous advantages including improved bioavailibility, therapeutic efficacy and 
possible reduction of the dose size 7,8. It has been suggested that prolong local 
availability of antibacterial agents may augment their effectiveness in treating 
H.Pylori related peptic ulcers.Gastroretentive Drug delivery systems (GRDDS)9-
14
, however are not suitable for drugs that may cause gastric lesions,e.g., Non-
steroidal anti-inflammatory agents.  
1.1.2 Basic physiology of the gastrointestinal tract 
The complex anatomy and physiology of the GIT, including variations in acidity, 
bile salts, enzyme content, and the mucosal absorptive surface, significantly 
influence the release, dissolution, and absorption of orally administered dosage 
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forms. Two distinct patterns of gastrointestinal (GI) motility and secretion exist, 
corresponding to the fasted and fed states. As a result, the BA of orally 
administered drugs will vary depending on the state of feeding. The fasted state 
is associated with various cyclic events, commonly referred to as the migrating 
motor complex (MMC), which regulates GI motility patterns. The MMC is 
organized into alternating cycles of activity and quiescence and can be 
subdivided into basal (Phase I), preburst (Phase II), and burst (Phase III) 
intervals (Figure 1.1.1) 1. Phase I, the quiescent period, lasts from 30 to 60 min 
and is characterized by a lack of secretory, electrical, and contractile activity. 
Phase II exhibits intermittent action for 20–40 min during which contractile 
motions increase in frequency and size. Bile enters the duodenum during this 
phase, whereas gastric mucus discharge occurs during the latter part of Phase II 
and throughout Phase III. Phase III is characterized by intense, large, and regular 
contractions, termed housekeeper waves, that sweep off undigested food and 
last 10–20 min. Phase IV is the transition period of 0–5 min between Phases III 
and I. This series of electrical events originates in the foregut and continues to 
the terminal ileum in the fasted state, repeating every 2–3 hrs. Feeding sets off a 
continuous pattern of spike potentials and contractions called postprandial 
motility.  
The particular phase during which a dosage form is administered influences the 
performance of peroral CRDDS and GRDDS. When CRDDS are administered in 
the fasted state, the MMC may be in any of its phases, which can significantly 
influence the total gastric residence time (GRT) and transit time in the GIT. This 
assumes even more significance for drugs that have an absorption window 
because it will affect the amount of time the dosage form spends in the region 
preceding and around the window. The less time spent in that region, the lower 
the degree of absorption. Therefore, the design of GRDDS should take into 
consideration the resistance of the dosage form to gastric emptying during Phase 
III of the MMC in the fasted state and also to continuous gastric emptying through 
the pyloric sphincter in the fed state. This means that GRDDS must be functional 
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quickly after administration and able to resist the onslaught of physiological 
events for the required period of time. 
 II: Anatomical and physiol 
Features of  
 
                           Figure 1.1.1: Motility patterns of the GIT in fasted state 
1.1.3 Gastric emptying and problems  
It is well recognized that the stomach may be used as a depot for Sustained 
release dosage forms, both in human and veterinary applications, stomach is 
anatomically divided in to three parts: Fundus, body and pylorus 15. 
The proximal stomach made up of the fundus and body region serves as a 
reservoir for ingested materials, while the distal region (antrum) is the major site 
for the mixing motion, acting as a pump to accomplish gastric emptying. The 
process of the gastric emptying occurs both during fasting and fed stages. 
Scintigraphy study involving measurement of gastric emptying rates in healthy 
human subject have revealed that an orally administered Controlled release 
dosage form is mainly subjected to two physiological adversities 15, 
a) The short GRT (Gastric Residence Time) 
b) Variable (unpredictable) GET (Gastric Emptying Time) 
Yet another major adversity encountered through the oral route is the first pass 
effect, which leads to reduce systematic availability of a large number of a drug. 
These problems can be exacerbated by alteration in the gastric emptying that 
occur due to factors such as age, race, sex and disease states, as they may 
seriously affect the release of a drug from DDS. It is therefore desirable to have a 
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Controlled release product that exhibits an extended, GI residence and a drug 
release profile independent of patients’ related variables. 
1.1.4 Potential drug candidates for stomach specific drug delivery systems 
 
1. Drugs those are locally active in the stomach e.g. misroprostol, antacids 
etc. 
2. Drugs that have narrow absorption window in gastrointestinal tract (GIT) 
e.g. l-dopa, paraaminobenzoic acid, furosemide, riboflavin etc. 
3. Drugs those are unstable in the intestinal or colonic environment e.g. 
captopril, ranitidine HCl, metronidazole. 
4. Drugs that disturb normal colonic microbes e.g. antibiotics against 
Helicobacter pylori. 
5. Drugs that exhibit low solubility at high pH values e.g. diazepam, 
chlordiazepoxide, verapamil HCl. 
1.1.5 Drugs those are unsuitable for stomach specific drug delivery 
systems 
1. Drugs that have very limited acid solubility e.g. phenytoin etc. 
2. Drugs that suffer instability in the gastric environment e.g. erythromycin 
etc. 
3. Drugs intended for selective release in the colon e.g. 5- amino salicylic 
acid and corticosteroids etc. 
1.1.6 Approaches to gastric retention/ stomach specific delivery  
Various approaches have been paused to increase the duration of oral dosage 
form in the stomach, including floating systems, swelling and expanding system, 
modified shape system, high density systems and other delayed gastric emptying 
devices. (Magnetic systems, super porous –biodegradable hydrogel systems). 
1.1.6.1 High density (sinking) system or non- floating drug delivery system  
This approach involves formulation of dosage forms with the density that must 
exceed density of normal stomach content (~ 1.004 gm/cm3). These formulations 
are prepared by coating drug on a heavy core or mixed with inert materials such 
as iron powder, barium sulphate, zinc oxide and titanium oxide etc. The materials 
increase density by up to 1.5- 2.4 gm/cm3. A density close to 2.5 gm/cm3 seems 
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necessary for significant prolongation of gastric residence time. But, 
effectiveness of this system in human beings was not observed and no system 
has been marketed 16. 
1.1.6.2 Bioadhesive or mucoadhesive drug delivery systems 
Bioadhesive drug delivery systems are used as a delivery device within the 
human to enhance drug absorption in a site-specific manner. In this approach, 
bio adhesive polymers are used and they can adhere to the epithelial surface in 
the stomach. Thus, they improve the prolongation of gastric retention. The basis 
of adhesion in that a dosage form can stick to the mucosal surface by different 
mechanism.  
These mechanisms are: 
1. The wetting theory, which is based on the ability of bioadhesive polymers 
to spread and develop intimate contact with the mucous layers. 
2. The diffusion theory, which proposes physical entanglement of mucin 
strands the flexible polymer chains, or an interpenetration of mucin 
strands into the porous structure of the polymer substrate. 
3. The absorption theory, suggests that bioadhesion is due to secondary 
forces such as Vander Waal forces and hydrogen bonding. 
4. The electron theory, which proposes attractive electrostatic forces 
between the glycoprotein mucin net work and the bio adhesive material. 
Materials commonly used for bioadhesion are poly acrylic acid, chitosan, 
cholestyramine, sodium alginate, hydroxypropyl methylcellulose (HPMC), 
sucralfate, tragacanth, dextrin, polyethylene glycol (PEG) and polylactic acids 
etc. Even though some of these polymers are effective at producing bioadhesive, 
it is very difficult to maintain it effectively because of the rapid turnover of mucus 
in the gastrointestinal tract (GIT). 
1.1.6.3 Expandable, unfoldable and swellable systems 
A dosage form in the stomach will withstand gastric transit if it bigger than pyloric 
sphincter. However, the dosage form must be small enough to be swallowed, 
and must not cause gastric obstruction either singly or by accumulation. Thus, 
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their configurations are required to develop an expandable system to prolong 
gastric retention time (GRT): 
1. a small configuration for oral intake, 
2. an expanded gastroretentive form, and 
3. a final small form enabling evacuation following drug release from the 
device. 
Thus, gastroretentivity is improved by the combination of substantial dimension 
with high rigidity of dosage form to withstand peristalsis and mechanical 
contractility of the stomach. Unfoldable and swellable systems have been 
investigated and recently tried to develop an effective gastroretentive drug 
delivery. Unfoldable systems are made of biodegradable polymers. They are 
available in different geometric forms like tetrahedron, ring or planner membrane 
(4 - label disc or 4 - limbed cross form) of bioerodible polymer compressed within 
a capsule which extends in the stomach. Swellable systems are also retained in 
the gastrointestinal tract (GIT) due to their mechanical properties. The swelling is 
usually results from osmotic absorption of water and the dosage form is small 
enough to be swallowed by the gastric fluid (Figure 1.1.2). Expandable systems 
have some drawbacks like problematical storage of much easily hydrolysable, 
biodegradable polymers relatively short-lived mechanical shape memory for the 
unfolding system most difficult to industrialize and not cost effective. Again, 
permanent retention of rigid, large single-unit expandable drug delivery dosage 
forms may cause brief obstruction, intestinal adhesion and gastropathy17. 
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Figure 1.1.2: Drug release from swellable systems 
 
1.1.6.4 Super porous hydrogel systems 
These swellable systems differ sufficiently from the conventional types to warrant 
separate classification. In this approach to improve gastric retention time (GRT) 
super porous hydrogels of average pore size >100 micro miter, swell to 
equilibrium size within a minute due to rapid water uptake by capillary wetting 
through numerous interconnected open pores. They swell to a large size 
(swelling ratio: 100 or more) and are intended to have sufficient mechanical 
strength to withstand pressure by gastric contraction. This is advised by co-
formulation of hydrophilic particulate material 17. 
1.1.6.5 Magnetic systems 
This approach to enhance the gastric retention time (GRT) is based on the 
simple principle that the dosage form contains a small internal magnet, and a 
magnet placed on the abdomen over the position of the stomach. Although 
magnetic system seems to work, the external magnet must be positioned with a 
degree of precision that might compromise patient compliance. 
1.1.6.6 Ion exchange resins 
Ion exchange resins are loaded with bicarbonate, and a negatively charged drug 
is bound to the resin. Resultant beads are then encapsulated in a semi-
permeable membrane to overcome the rapid loss of carbon dioxide. Upon arrival 
in the acidic environment of the stomach, an exchange of chloride and 
bicarbonate ions takes place. As a result of this reaction, carbon dioxide is 
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released and trapped in the membrane thereby carrying beads towards the top of 
the gastric contents and producing a floating layer of resin beads – in contrast to 
uncoated beads, which sink quickly.  
1.1.6.7 Raft systems 
Raft systems incorporate alginate gel solution (e.g. sodium alginate solution 
containing carbonates or bicarbonates) that upon reaction with gastric fluid, swell 
and form a viscous cohesive gel containing entrapped carbon dioxide bubbles, 
enabling floatation of the drug delivery system. Because raft-forming systems 
(Figure 1.1.3) produce a layer on the top of the gastric fluids, they are often used 
for gastroesophageal reflux treatment, as with Liquid Gaviscon 
(GlaxoSmithKline). 
 
Figure 1.1.3: Schematic representation of the barrier created by a raft-
forming system 
  
Other delayed gastric emptying approaches of interest include sham feeding of 
digestible polymers or fatty acid salts that charges the motility pattern, of the 
stomach to a fed stage thereby decressing the gastric emptying rate and 
permitting considerable prolongation of the drug release. But some of this has 
certain drawbacks, which could limit their uses described in the following Table 
1.1.1 19.  
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  Table 1.1.1: Drawback associated with different types of GRDDS 19 
Formulations Drawback 
Incorporation of passage delaying 
food excipient such as fatty acids 
Affect the emptying mechanism of 
the entire content 
Bio adhesive drug delivery systems a. Adhesive is non specific 
b. Efficiency is limited by the 
possible interaction with food. 
Biodegradable and non biodegradable 
(swelling) formulation in which the size 
and shape retain in the dosage form. 
Present the hazard of permanent 
retention and might lead to serious 
life threatening effects if multiple 
dosing is predicted. 
 
1.1.6.8 Floating drug delivery systems 
Floating systems, first described by Davis in 1968, have bulk density lower than 
that of the gastric fluid, and thus remain buoyant in stomach for a prolong period. 
This results in an increase in the GRT and a better control of fluctuations in the 
plasma drug concentrations. Floating system can be effervescent or Non 
effervescent in nature.  
1.1.6.8 .1 Effervescent systems 
1.1.6.8 .1 .1 Volatile liquid containing systems 
The GRT of a drug delivery system can be sustained by incorporating an 
inflatable chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies 
at body temperature to cause the inflatation of the chamber in the stomach. The 
device may also consist of a bioerodible plug made up of PVA, Polyethylene, etc. 
that gradually dissolves causing the inflatable chamber to release gas and 
collapse after a predetermined time to permit the spontaneous ejection of the 
inflatable systems from the stomach 20. 
1.1.6.8 .1 .2 Gas-generating systems 
These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets 
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entrapped in the gellified hydrocolloid layer of the systems thus decreasing its 
specific gravity and making it to float over chime 1,18. How the dosage form float 
is shown in the following figure (Figure 1.1.4) 21. 
 
 
Figure 1.1.4: The mechanism of floating systems  
1.1.6.8 .2 Non-effervescent systems 
1.1.6.8 .2.1 Colloidal gel barrier systems 
Hydrodymamically balance system (HBSTM) was first design by Sheth and 
Tossounian in 1975.Such systems contains drug with gel forming hydrocolloids 
meant to remain buoyant on stomach contents. This system incorporate a high 
level of one or more gel forming highly swellable cellulose type 
hydrocolloids.e.g.HEC, HPMC, NaCMC, Polysacchacarides and matrix forming 
polymer such as polycarbophil, polyacrylates and polystyrene, incorporated 
either in tablets or in capsule. On coming in contact with gastric fluid, the 
hydrocolloid in the system hydrates and forms a colloidal gel barrier around the 
gel surface. The air trapped by the swollen polymer maintains a density less than 
unity and confers buoyancy to these dosage forms 22. 
1.1.6.8 .2.2 Microporous compartment system 
This technology is based on the encapsulation of drug reservoir inside a 
microporous compartment with aperture along its top and bottom wall. The 
peripheral walls of the drug reservoir compartment are completely sealed to 
prevent any direct contact of the gastric mucosal surface with the undissolved 
drug. In stomach the floatation chamber containing entrapped air causes the 
delivery system to float over the gastric contents. Gastric fluid enters through the 
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apertures, dissolves the drug, and carries the dissolve drug for continuous 
transport across the intestine for absorption. 
1.1.6.8 .2.3 Alginate beads 
Multiple unit floating dosage forms have been developed from freeze-dried 
calcium alginate. Spherical beads of approximately 2.5 mm in diameter can be 
prepared by dropping a sodium alginate solution in to aqueous solutions of 
calcium chloride, causing precipitation of calcium alginate. The beads are then 
separated snap and frozen in liquid nitrogen and freeze dried at -40°C for 24 hrs, 
leading to the formation of porous system, which can maintain a floating force 
over 12 hrs 22.  
1.1.6.8 .2.4 Hollow microspheres 
Hollow microspheres (microballoons), loaded with ibuprofen in their outer 
polymer shells were prepared by a novel emulsion-solvent diffusion method. The 
ehanol: dichloromethane solution of the drug and enteric acrylic polymers was 
poured in to an agitated aqueous solution of PVA that was thermally controlled at 
40°C.The gas phase generated in dispersed polymer droplet by evaporation of 
dichloromethane formed in internal cavity in microspheres of the polymer with 
drug. The microballoons floated continuously over the surface of acidic 
dissolution media containing surfactant for greater than 12 hrs in-vitro 22. 
1.1.7 Factors affecting gastric retention   
1.1.7.1 Density 
Density of the dosage form should be less than the gastric contents 
(1.004gm/mL).  
1.1.7.2 Size and shape 
Dosage form unit with a diameter of more than 7.5 mm are reported to have an 
increased GRT compared to those with a diameter of 9.9 mm. The dosage form 
with a shape tetrahedron and ring shape devices with a flexural modulus of 48 
and 22.5 kilopond per square inch (KSI) are reported to have better GIT ≅ 90 to 
100 % retention at 24 hrs compared with other shapes 1,23. 
 
 
Chapter 1.1 
                                             Introduction to stomach specific drug delivery system 
J.R.Chavda                                                                                           PhD. Thesis 14 
1.1.7.3 Fed or unfed state 
Under fasting conditions, the GI motility is characterized by periods of strong 
motor activity or the migrating myoelectric complexes (MMC) that occurs every 
1.5 to 2 hrs. The MMC sweeps undigested material from the stomach and if the 
timing of administration of the formulation coincides with that of the MMC, the 
GRT of the unit can be expected to be very short. However, in the fed state, 
MMC is delayed and GRT is considerably longer 18. 
1.1.7.4 Nature of the meal 
Feeding of indigestible polymers of fatty acid salts can change the motility pattern 
of the stomach to a fed state, thus decreasing the gastric emptying rate and 
prolonging the drug release 14. 
1.1.7.5 Caloric content 
GRT can be increased between 4 to 10 hrs with a meal that is high in proteins 
and fats. 
1.1.7.6 Frequency of feed 
The GRT can increase by over 400 min when successive meals are given 
compared with a single meal due to the low frequency of MMC 22. 
1.1.7.7 Gender 
Mean ambulatory GRT in meals (3.4 ± 0.4 hrs) is less compared with their age 
and race-matched female counterparts (4.6± 1.2 hrs), regardless of the weight, 
height and body surface. 
1.1.7.8 Age  
Elderly people, especially those over 70 years have a significantly longer GRT 23. 
1.1.7.9 Posture  
GRT can very between supine and upright ambulatory states of the patients 24. 
1.1.7.10 Concomitant drug administration 
Anticholinergic like atropine and propentheline opiates like codeine and 
prokinetic agents like metoclopramide and cisapride. 
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1.1.8 Formulation of stomach specific dosage form 
Following types of the ingredients can be incorporated in to HBS dosage form in 
addition to drugs 23,25. 
 
• Hydrocolloids 
• Inert fatty materials 
• Release rate accelerants 
• Release rate retardant 
• Buoyancy increasing agents 
• Miscellaneous 
 
1.1.8.1 Hydrocolloids 
Suitable hydrocolloids are synthethics, anionic or non ionic like hydrophilic 
gumes, modified cellulose derivatives. E.g. accasia, pectin, agar, alginates, 
gelatin, casein, bentonite, veegum, MC, HPC, HEC, and Na CMC can be used. 
The hydrocolloids must hydrate in acidic medium i.e. gastric fluid is having pH 
1.2. Although the bulk density of the formulation may initially be more than one, 
but when gastric fluid is enter in the system, it should be hydrodynamically 
balanced to have a bulk density of less than one to assure buoyancy.  
1.1.8.2 Inert fatty materials 
Edible, pharmaceutical inert fatty material, having a specific gravity less than one 
can be added to the formulation to decrease the hydrophilic property of 
formulation and hence increases the buoyancy. Example: Purified grades of 
beeswax, fatty acids, long chain alcohols, glycerides, and minaral oils can be 
used. Such materials may be present from about 5-75 % by weight. 
1.1.8.3 Release rate accelerant 
The release rate of the medicament from the formulation can be modified by 
including excipient like lactose and/or mannitol. These may be present from 
about 5-60% by weight. 
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1.1.8.4 Release rate retardant 
Insoluble substances such as dicalcium phosphate, talc, magnesium strearete 
decresesd the solubility and hence retard the release of medicaments. Such, 
materials may be present about 5-60 % by weight. 
1.1.8.5 Buoyancy increasing agents 
Materials like ethyl cellulose, which has bulk density less than one, can be used 
for enhancing the buoyancy of the formulation. It may be added up to 80 % by 
weight. 
1.1.8.6 Miscellaneous 
Pharmaceutically acceptable adjuvant like preservatives, stabilizers, and 
lubricants can be incorporates in the dosage forms as per the requirements. 
They do not adversely affect the hydrodynamic balance of the systems.  
1.1.9 Evaluation of stomach specific systems  
Various parameters need to be evaluated for their effects on gastric residence 
time of different formulations. These parameters can be categorised into the 
following classes: 
• Galenic: diametral size (‘cut-off size’), resultant weight flexibility and 
density of matrices. 
• Control: floating time, dissolution, specific gravity, content uniformity, and 
hardness and friability (of tablets). 
• Geometric: shape. 
• Physiological: age, sex, posture, food and bioadhesion. 
 
1.1.9.1 Bio/mucoadhesive systems 
1.1.9.1 .1 Bioadhesive strength 
Bioadhesive strength of a polymer can be determined by measuring the force 
required to separate a polymer specimen sandwiched between layers of either 
an artificial (e.g. cellophane) or a biological (e.g. rabbit stomach tissue) 
membrane. This force can be measured by using a modified precision balance or 
an auto mated texture analyzer. 
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1.1.9.1 .2 In-vivo evaluation 
The effects of the mode of riboflavin-5-phosphate administration on the resulting 
mean drug plasma concentrations and cumulative amounts of riboflavin 
absorbed in dogs were studied. In contrast, with both a non-gastroretentive 
control formulation (multilayer film without rigid frame; 5.0 × 2.5 mm) and an oral 
solution, which resulted in shorter time periods with elevated riboflavin 
concentrations, the gastroretentive device (multilayer film with rigid frame; 5.0 × 
2.5 mm) produced elevated plasma drug concentrations for at least 48 hrs. The 
absolute bioavailabilities were 17.1 ± 3.5%, 3.9 ± 0.4% and 3.9 ± 1% for the 
gastroretentive dosage form, control formulation and oral solution, respectively. 
 
1.1.9.2 Magnetic systems 
1.1.9.2 .1 In-vitro dissolution study 
In-vitro release experiments were carried out according to the US Pharmacopeia 
(USP) XXIII Paddle method at 37oC and 100 rpm, using 0.01 N HCl as 
dissolution medium. The measured values were continuously recorded using an 
IBM compatible AT (Advanced Technology) computer (Friedrich, Munster, 
Germany). During the release experiments, the magnetic tablets were located at 
the wall of the release vessel 5 cm under the surface of the liquid, using an 
external magnet. The distance between the external magnet and the magnetic 
depot tablet was 8cm.The release from the tablet is directly proportional to the 
distance between the external magnet and tablet. 
1.1.9.2 .2 In-vivo evaluation 
Groning et al developed a method for determining the gastrointestinal transit of 
magnetic dosage forms of acyclovir under the influence of an extracorporeal 
magnet, using a pH telemetering capsule (Heidelberg capsule). Small magnets 
were attached to the capsule and administered to humans. In-vivo human studies 
showed that, in the presence of an extracorporeal magnet, the plasma 
concentrations of aciclovir were significantly higher after 7, 8, 10 and 12 hrs. 
Furthermore, the mean area under the plasma concentration-time curve from 
zero to 24 hrs (AUC 0–24) was ≈2800 ng • h/mL with the external magnet and 
≈1600 ng • h/mL without the external magnet. 
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1.1.9.3 Swelling and expanding systems 
1.1.9.3 .1 Water uptake study 
The swelling of the polymers can be measured by their ability to absorb water 
and swell. Water uptake studies of the formulation (tablet or granules) are 
performed using USP dissolution apparatus II. The medium used is usually 
distilled water or 0.1 N HCl (900 mL) rotated at 50 rpm, and maintained at 
37±0.5°C through-out the study. After a selected time interval, the formulation is 
withdrawn, blotted to remove excess water, and weighed. Swelling 
characteristics of the tablets expressed in terms of water uptake (WU) are 
calculated as (equation 1): 
 
In-vitro dissolution studies in swelling and expanding systems are usually carried 
out by a modified dissolution method, as in the case of FDDS. 
1.1.9.4 Floating drug delivery systems 
1.1.9.4.1 In-vitro floating time determination 
Floating time is determined by using the USP disintegration apparatus containing 
900mL of 0.1 N HCl solution as a testing medium maintained at 37±0.5ºC. The 
time required to float different dosage forms is noted as floating (or buoyancy) lag 
time, and floating duration of the dosage form is determined by visual 
observation. 
1.1.9.4.2 In-vitro dissolution study 
Dissolution tests are performed using USP dissolution apparatus. Samples are 
withdrawn periodically from the dissolution medium; replenished with the same 
volume of fresh medium at sampling time points. Recent methodology as 
described in the USP XXIII states “the dosage unit is allowed to sink to the 
bottom of the vessel before rotation of the blade is started. A small, loose piece 
of nonreactive material such as not more than a few turns of a wire helix may be 
attached to the dosage units that would otherwise float”. However, standard 
dissolution methods based on the USP or British Pharmacopoeia (BP) have been 
shown to be poor predictors of in-vitro performance for floating dosage forms. 
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Pillay and Fassihi investigated the application of a helical wire sinker to the 
swellable floating system containing theophylline (a sparingly water-soluble 
drug). They observed that the procedure tends to inhibit the three-dimensional 
swelling process of the dosage form, and consequently drug release from the 
formulation was suppressed. Based on their observations, the researchers 
proposed an alternative method in which the floatable delivery system was fully 
submerged under a ring/mesh assembly. The results showed a significant 
increase in drug release (20%). In addition, the proposed method was found to 
provide reproducible hydrodynamic conditions and consistent release profiles. 
However, in the case of a swellable floating system, which contained diltiazem (a 
highly water-soluble drug), the researchers did not find any difference in release 
between the proposed method and the USP method. These findings led to the 
conclusion that drug release from swellable floating systems depends on full 
surface exposure, unhindered swelling, and the drug solubility in water. 
1.1.9.4.3Physiological parameters 
Age, sex, posture, food, bioadhesion, health of subject and GIT condition 22,26. 
1.1.9.4.4 Galenic parameter 
Diametrical size, flexibility and density of matrices 26. 
1.1.9.4.5 Geometric parameter 
Shape 
1.1.9.4.6 Control parameter 
Floating time, specific gravity, dissolution, content uniformity, hardness and 
friability  26. 
1.1.9.4.7 Specific gravity 
Specific Gravity of the floating system can be determined by the displacement 
method using benzene as a displacing medium 18. 
1.1.9.4.8 Resultant weight 
The in-vitro measuring apparatus has been conceived to determine the real 
floating capabilities of buoyant dosage forms as a function of time. It operates by 
fource equivalent to the fource F required to keep the object totally submerged in 
the fluid. This fource determines the resultant weight of the object when 
Chapter 1.1 
                                             Introduction to stomach specific drug delivery system 
J.R.Chavda                                                                                           PhD. Thesis 20 
immersed and may be used to quantify its floating or nonfloating capabilities. The 
magnitude and direction of the fource and the resultant weight corresponds to the 
Victoria sum of buoyancy (Fbuoy) and gravity (Fgrav) forces acting on the objects as 
shown in the equations: 
F  = Fbuoy – F grav 
                 F  = dfgV – dfgV = (df-ds) gv 
  F  = (df – M/V) gV 
 
In which the F is total vertical fource (resultant weight of the object), g is the 
acceleration due to gravity, df is the fluid density, ds is the object density is the 
object mass and V is the volume of the object 25. 
1.1.10 Types of floating dosage forms 
• New floating bilayer compressed matrices 
• New multiple unit oral floating dosage form 
• Sustained release intrsgastric floating granules 
• Floatable asymmetric configuration drug delivery system 
• Floating non compressed sustained release tablets 
• Microballoons 
1.1.10.1 New floating bilayer compressed matrices 27 
One of the tablet layers mainly contains the carbon dioxide generating blend and 
a hydrodynamic polymer. The carbon dioxide being entrapped in the gasified 
hydrocolloid as liberated by the action of the gastric medium produces the 
upward motion of the tablet and maintains its buoyancy. The outer layer is 
hydrophilic matrix and contained the dug which is release in the prolong and 
controlled way. 
Advantages 
• Double layer matrix tablet shows a more homogenous behavior with 
regard to erosion   and is less sensitive to the GI peristaltism and the 
formulation of the matrix dosage form with two distinct layers allows the 
separate regulation of the floating capabilities and the drug release 
kinetics. 
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• Consequently this type of sustained release matrix could be 
advantageously used for conveying drugs which are sufficiently stable and 
soluble in acidic media, better reabsorbed in the proximal or middle 
portion of the GI tract, requiring a sustained release period to improve the 
bioavalability of poorly soluble products in non acid media or aiming to 
produce a local and specific effect in the stomach.  
1.1.10.2 New multiple unit oral floating dosage forms 28 
The Gastric Emptying Time in the humans is in fed state from 1-6 hrs has been 
reported. Accordingly when a sustained release dosage form was administered 
orally, sufficient bioavalability and prolongation of the effective plasma level 
occasionally could not be obtained especially for drug having a limited absorption 
site in the intestinal tract. Recently some studies have been reported 
prolongation of GET (Gastric Emptying Time) of certain preparations, such as the 
floating dosage systems and bioadhesive systems. 
However, as most of the floating dosage systems were single unit preparations, it 
was possible that a single unit type might be transited in to the small intestine in 
a short time, irrespective floating ability. A Multiple type of oral floating dosage 
systems has been prepared in order to prolong the GET of the preparation. 
The system was composed of the sustained release pills containing the drug and 
the double layer surrounding the pills. Inner layer was an effervescent layer 
containing both sodium bicarbonate and the outer layer was swellable membrane 
was devided in to two sub layers to avoid direct contact between sodium 
bicarbonate and tartaric acid in the outer one. 
Advantages 
• Preparation process of the floating dosage systems is easy and simple. 
Moreover, conventional sustained release pills, such as matrix type or 
barrier membrane type, can be used as the central seeds of the system. 
• The floating dosage system is compact before immersion n water, the 
system has higher density compared with other floating systems and is 
easy to handle. 
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1.1.10.3 Sustained release floating granules 29 
Drug granules, which remain in the stomach, comprise core- pharmaceutically 
effective ingredients coated with expansive films. Drug used was 
Dextromethorphan HCl (20%). Granules are developed based on chitosan of 
different buoyancy, both in acidic and neutral fluids, and gave the sustained 
release of prednisolone. The release rate of indomethacine from chitosan 
granules was compared with that of conventional commercial indomethacine 
capsules. Furthermore, enhancing the mixing ratio of drug and chitosan can 
control the release rate. 
In case of conventional capsule, the plasma concentration reach the maximum 
level one-hour after administration, while in case of granules with a 1:2 mixing of 
drug and chitosan, the chitosan produced a sustained plateau level of the drug. 
1.1.10.4 New self-correcting floatable asymmetric configuration drug 
delivery systems 30 
Apart from encountered difficulties in pulsatile delivery system design, the most 
challenging controlled drug delivery in the last two decades among 
pharmaceutical scientists has been design of the systems that would provide 
zero order kinetics for total drug release with no lag time or burst effect over a 
prolong period. 
Features 
• The system is design in such a manner that it floats, thus being likely to 
prolong gastric residence time in-vivo, resulting in longer total transit time 
within the GIT environment with maximum absorptive capacity and 
consequently greater bioavalability.  
• These particular characteristics would be applicable to drugs, which have 
pH dependent solubilities, a narrow window of absorption and are 
absorbed by active transport from either the proximal or distal portion of 
the small intestine. 
• Complete dissolution of the whole system. 
• Oral drug release. 
• Absences of both burst and lag time. 
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• Ease of manufacturing because direct compression technology in this 
case. 
Advantages 
• One major advantage of these asymmetric configuration delivery systems 
is that the duration of the drug release and the release pattern could be 
easily toilered by adjusting the amount or composition of each layer, which 
offers a greater degree of flexibility to formulation scientists. 
• The absence of the real burst effect which is usually seen with matrix type 
delivery system is highly significant. 
• Drug release from these systems may not be affected by changes in pH of 
the GIT and in-vivo situation. 
• One feature of these swelling hydrophilic matrices is their low density and 
the ease with which the system can be easily trapped, adding to floating 
behavior after exposure to dissolution medium delay gastric emptying of 
stomach. 
• Zero order kinetic is achievable. 
• Drug is totally released but always in a controlled manner. 
1.1.10.5 Floating noncompressed sustained release tablets 31 
Sustained release noncompressed tablets having a network of multitude air holes 
and passage there in a density of less than one and capable of floating on gastric 
juice in-vivo comprises a matrix containing 
• Gelling agents (0.5-0.4%) 
• Inert oil (10-20%) 
• Therapeutic agent (50-75%) 
• Water up to 100% 
Example by an adding an agar solution to a theophyllin oil mixture at 70 °C with 
vigorous stirring to get O/W emulsion, which was poured into a tablet mould, 
allowed to cool and gel removed from the mould and air dried. The average 
diameter of the tablet was 0.70 mm. 
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1.1.10.6 Microballoons  
Multiple units floating system which can be distributed widely through out the GIT 
providing a possibility of achieving a longer lasting and more reliable release of 
drugs, has been brought. To achieve this goal a novel method to prepare floating 
microspheres loaded with drug was developed as a modification of the emulsion 
solvent diffusion method for the preparation of the polymeric microsponge for a 
controlled drug delivery system. This microsphere was termed as “microballoons” 
due to its characteristic internal hollow structure and excellent floatability in-vitro. 
The method of preparation of the microballoons is described earlier in the 
article12 32. 
   Parameters mainly affect the microballoons preparations 
1. Temperature 
2. Concentration of PVA in aqueous solution 
3. Agitation speed 
4. Ethanol dichloromethane ratio 
Advantages 33 
• More predictive drug release kinetic 
• Less chances of localized mucosal damage 
• Larger margin of safety against dosage form failure.e.g.air compartment 
multiple unit system for gastric retention 
1.1.11 Advantages of stomach specific drug delivery systems 23, 34 
1. The bioavailability of therapeutic agents can be significantly enhanced 
especially for those which get metabolized in the upper GIT by this 
gastroretentive drug delivery approach in comparison to the administration 
of nongastroretentive drug delivery. There are several different factors 
related to absorption and transit of the drug in the gastrointestinal tract 
(GIT) that act concomitantly to influence the magnitude of drug absorption.  
2. For drugs with relatively short half life, sustained release may result in a 
flip- flop pharmacokinetics and also enable reduced frequency of dosing 
with improved patient compliance. 
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3. They also have an advantage over their conventional system as it can be 
used to overcome the adversities of the gastric retention time (GRT) as 
well as the gastric emptying time (GET). As these systems are expected 
to remain buoyant on the gastric fluid without affecting the intrinsic rate of 
employing because their bulk density is lower than that of the gastric 
fluids. 
4. Gastroretentive drug delivery can produce prolong and sustain release of 
drugs from dosage forms which avail local therapy in the stomach and 
small intestine. Hence they are useful in the treatment of disorders related 
to stomach and small intestine.  
5. The controlled, slow delivery of drug form gastroretentive dosage form 
provides sufficient local action at the diseased site, thus minimizing or 
eliminating systemic exposure of drugs. This site-specific drug delivery 
reduces undesirable effects of side effects.  
6. Gastroretentive dosage forms minimize the fluctuation of drug 
concentrations and effects. Therefore, concentration dependent adverse 
effects that are associated with peak concentrations can be presented. 
This feature is of special importance for drug with a narrow therapeutic 
index. 
7. Gastroretentive drug delivery can minimize the counter activity of the body 
leading to higher drug efficiency. 
8. Reduction of fluctuation in drug concentration makes it possible to obtain 
improved selectivity in receptor activation.  
9. The sustained mode of drug release from Gastroretentive doses form 
enables extension of the time over a critical concentration and thus 
enhances the pharmacological effects and improves the chemical 
outcomes. 
1.1.12 Limitations/disadvantages  
• These systems require a high level of fluid in the stomach for drug delivery 
to float and work efficiently-coat, water. 
• Not suitable for drugs that have solubility or stability problem in GIT. 
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• Drugs such as nifedipine which is well absorbed along the entire GIT and 
which undergoes first pass metabolism, may not be desirable. 
• Drugs which are irritant to Gastric mucosa is also not desirable or 
suitable1. 
• The drug substances that are unstable in the acidic environment of the 
stomach are not suitable candidates to be incorporated in the systems 1. 
• The dosage form should be administered with a full glass of water (200-
250 mL) 3. 
• These systems do not offer significant advantages over the conventional 
dosage forms for drugs, which are absorbed through out the 
gastrointestinal tract. 
1.1.13 Application of floating drug delivery system 5 
• Recent study indicated that the administration of Diltiazem floating tablets 
twice a day might be more effective compared to normal tablets in 
controlling the Blood pressure of hypertensive patients. 
• Modapar® HBS containing l-dopa and Benserazide, here the drug was 
absorbed over a period of 6-8 hrs and maintained substantial plasma 
concentration for Parkinsonian patients. Cytotech®- containing 
Misoprostol, a synthetic prostaglandin –EL analogue, for prevention of 
gastric ulcer caused by non-steroidal anti-inflammatory drugs (NSAIDS). 
• As it provides high concentration of drug within gastric mucosa, it is used 
to eradicate H.pylori (a causative organism for chronic gastritis and peptic 
ulcers). 
• 5-fluorouracil has been successfully evaluated in the patients with 
stomach neoplasm. 
• Developing HBS dosage form for tacrin provide better delivery systems 
and reduced its GI side effects. 
• Treatment of gastric and duodenal ulcer. 
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1.1.14 Future potential 
• Floating dosage form offers various future potential as evident from 
several recent publications. The reduced fluctuations in the plasma level 
of drug results from delayed gastric emptying. 
•  Drugs that have poor bioavailibility because of their limited absorption to 
the upper gastrointestinal tract can be delivered efficiently thereby 
maximizing their absorption and improving their absolute bioavalability. 
• Buoyant delivery system considered as a beneficial strategy for the 
treatment of gastric and duodenal cancers. 
• The floating concept can also be utilized in the development of various 
anti-reflux formulations. 
• Developing a controlled release system for the drugs, which are potential 
to treat the Parkinson’s disease. 
• To explore the eradication of Halico-bector pylori by using the narrow 
spectrum antibodies. 
 
Table 1.1.2: Drugs explored in stomach specific dosage forms13, 35 
Types of dosage forms Drugs explored in stomach specific dosage forms 
Microspheres Aspirin, Griseofulvin, P-nitro aniline, Ibuprofen, 
Terfenadine, Tranilast 
Granules Diclofenac Sodium, Indomethacin, Prednisolone 
Films Cinnarizine 
Powders Several Basic Drugs 
Capsules 
 
Chlordiazepoxide HCl, Diazepam, Furocemide, l-dopa 
and Benserazide, Misoprostol, Propranolol HCl 
Tablets/Pills 
 
Acetaminophen, Aspirin, Amoxycillin, Ampicillin, 
Atenolol, Chlorpheniramine maleate, Cinnarizine, 5-
Fluorouracil, Isosorbide mononitrate, Diltiazem, 
Isosorbide dinitrate, Piretenide, Quinidine, Varapamil 
HCl, Riboflavin, Sotalol, Theophylline 
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Table 1.1.3: Commercial stomach specific floating formulations 3,36-38 
Name Type and drug Remarks 
MadoparHBS 
(PropalHBS) 
Floating capsule, Levodopa 
and benserazide 
Floating CR capsules 
Valrelease 34 Floating capsule, Diazepam Floating Capsules 
Topalkan 
 
Floating Antacid, aluminum 
and magnesium mixture 
Effervescent floating liquid 
alginate preparation 
Amalgate 
Float Coat 35 
Floating antacid 
Floating gel 
Floating dosage form 
Conviron Ferrous sulphate Colloidal gel forming FDDS 
Cifran OD Ciprofloxacine (1 gm) Gas generating floating form 
Cytotech Misoprostol (100 mcg/200 
mcg) 
Bilayer floating capsule 
Liquid 
Gaviscone 
Mixture of alginate Suppress gastro esophageal 
reflux and alleviate the heart 
burn 
 
 
1.1.15 Stability studies 
The success of an effective formulation can be evaluated only through stability 
studies. The purpose of stability testing is to obtain a stable product, which 
assures its safety and efficacy up to the end of shelf life at defined storage 
conditions and pack profile. The stability studies of different GRDDS are usually 
carried out as per the International Conference on Harmonisation guidelines. 
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1.2 Introduction to polymers 
1.2.1 Introduction to chitosan 
Chitosan are biodegradable, high molecular weight cationic polysaccharides. 
Industrially they are produced from chitin, the world’s second most abundant 
biopolymer, by deactivation process involving alkaline hydrolysis. The term 
chitosan refers to a family of polymers, individually characterized by their ratio of 
acetylated to deactivated units and molecular weight, both parameters being 
equally responsible for the properties of the polymer. Chitosan has been used for 
a range of applications as diverse as for water purification, as a food ingredient 
and as a pharmaceutical excipient. Braconnot1 first described chitin in 1811. A 
good deal of fundamental research on chitin occurred in the next century and a 
half but most of the information available today had been obtained since 1950. 
Chitin is the major polysaccharide of the shells of crustacean and exoskeletons 
of insects. It is also found in the cell walls of many fungi, yeast and algae. 
Chitosan was discovered by Rouget1 in 1859 and was prepared by Hope Seylar 
1
. Chitosan is deactivated chitin derivative. It is found naturally in fungal cell walls 
but can also be produced by alkaline treatment of chitin. 
1.2.1.1 Preparation of chitosan 2  
Chitin is treated for 1 or 2 hrs in 47% sodium hydroxide solution in nickel crucible 
at 60 oC under nitrogen atmosphere. The chitosan obtained by alkali treatment is 
washed to neutrality, the deactivation being about 80% or less by the first alkali 
treatment. The chitosan after washing in water is treated again in the alkaline 
solution twice or more to obtain chitosan which has the deactivation of 90-05 % 
for even further deactivation, thread like chitosan is again subjected to alkali 
treatment. 
1.2.1.2 Structure and properties of chitosan 2 
Chitosan is (1-4)-2-amino-2-deoxy-B-D glucon. It has similar structural 
characteristics as that of glucosaminoglycans. It is tough, biodegradable and 
nontoxic. 
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Chitin, poly-B-(1-4) linked N acetyl –D- glucosamine is a highly hydrophobic 
material that is insoluble in water and most ordinary solvents. This property of 
chitin restricts it use to application that do not require solubilization of the 
polymer. Considering chitosan as a weak base, a certain minimum amount of 
acid is required to transform the glucosamine units into the positively charged, 
water soluble form. At neutral ph most chitosan molecules will lose their charge 
and precipitate from solution. Chitosan is soluble in dilute organic acids like 
formic, acetic, propionic, oxalic, malonic, succinic, adipic, lactic, pyruvic, malic, 
tartaric and citric. 
Chitosan is also soluble in dilute nitric and hydrochloric acids, marginally soluble 
in 0.5% phosphoric acid and insoluble in sulfuric acid at room temperature. 
Formic acid is the best solvent, overall good solutions being obtained in aqueous 
systems containing 0.2 to 100% of this acid. Acetic acid has been selected as the 
standard solvent for solution property measurement. Chitosan readily dissolves is 
3:1 glycerol water when the mixture contains 1% acetic acid, resulting in clear 
colorless and very viscous solution. 
Solutions of Chitosan in 10% w/v aqueous oxalic acid show thermo reversible gel 
property. A solution containing more than 7 % chitosan will gel in less than a day 
and 3% solution will gel in about 3 weeks. The chitosan films were cross-linked 
by glutaraldehyde vapors in a closed chamber for 24 hrs at ambient temperature. 
This process was done to retard the chitosan degradation rate. The decrease in 
degradation rate of cross linked chitosan was probably due to the retarded 
hydrolysis of Schiff’s bases induced by the glutaraldehyde cross linked of 
chitosan’s amino groups. 
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Chitosan a linear polyelectrolyte at acidic pH, is soluble in variety of acids and 
interacts with polyanionic counterions. It forms gels with a number of multivalent 
anions and also with glutaraldehyde. It has a high charge density i.e. one charge 
per glucosamine unit. Since many minerals carry negative charges, the positive 
charge of chitosan interacts strongly with negative surfaces. Chitosan is a linear 
polyamine where amino groups are readily available for chemical reactions and 
salt formation with acids. The important characteristics of chitosan are its 
molecular weight, viscosity, deacetylation degree (DA) crystallinity index, number 
of monomeric units (n), water retention value, pka and energy of hydration. 
1.2.1.3 Pharmaceutical requirements of chitosan 
Particle size < 30 µm, density between 1.35 and 1.40 g/cc, ph 6.5-7.5, insoluble 
in water, and partially soluble in acids. Chitosan can also be characterized in 
terms of its quality, intrinsic properties and physical forms. The quality 
characteristics of chitosan are levels of heavy metals and proteins, pyrogenicity 
and degree of deacetylation are the intrinsic properties.  
1.2.1.4 Biological and chemical properties of chitosan 
Biocompatibility (e.g. Nontoxic, biodegradable, natural), bioactivity, wound 
healing acceleration, reduced blood cholesterol levels, and immune system 
stimulant effect. Biomedical properties biological activity and biodegradation of 
chitosan are stated by Knapczyk et al 3. Muzzarell4 gives the chemical behavior 
of chitosan and modified chitosan. Sanford5 summarized the chemical and 
biological properties of chitosan that relate to applications. Tables 1.2.1 and 
1.2.2. 
Table 1.2.1: Chemical properties of chitosan 5 
Cationic polyamine 
High charge density at pH < 6.5 
Adheres to negatively charged surfaces 
Forms gels with poly anions 
High molecular weight linear polyelectrolyte 
Viscosity, high to low 
Chelates certain transitional metal 
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Amiable to chemical modification reactive amino / hydroxyl groups 
Table 1.2.2: Biological properties of chitosan 5 
Biocompatibility 
Natural Polymer 
Biodegradable to normal body constituents 
Safe and non – toxic 
Haemostatic 
Bacteriostatic 
Fungistatic 
Spermicidal 
Anticarcinogen 
Anticholesteremic 
 
1.2.1.5 Mucoadhesive properties of chitosan 
Lehr et al.6 first evaluated mucoadhesive properties of chitosan. A number of 
characteristics are necessary for mucoadhesion (a) strong hydrogen bonding 
groups (-OH, -COOH), (b) strong anionic charges, (c) high molecular weight, (d) 
sufficient chain flexibility, and (e) surface energy properties favoring spreading on 
to mucus. However, chitosan is a poly-cationic polymer and does not have any 
anionic charge. Instead, a positively charged hydrogel is formed in acidic 
environment that could develop additional molecular attractive forces by 
electrostatic interactions with negatively charged mucosal surfaces or the 
negatively charged sialic acid groups of the mucus network. High molecular 
weight chitosan gave the best mucoadhesive properties. 
1.2.1.6 Toxicological studies of chitosan 
In-vivo toxicity tests indicated that chitosan is non toxic, inert and sterilized films 
was free of pyrogens. LD 50 and oral toxicity levels of chitosan were estimated in 
both rats and mice. Lack of cute oral toxicity to chitosan was noticed as 
evidenced by an oral LD 50, 10g/ kg in mice. Acute systemic toxicity tests in mice 
did not show any significant toxic effects of chitosan.  
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1.2.1.7 Preparation of chitosan microspheres 1 
Chitosan microspheres can prepare by following methods. 
1.2.1.7.1 Ionotropic gelation  
In this method, chitosan solutions in acetic acid are prepared and extruded drop 
wise through a needle into different concentrations of aqueous solutions of 
magnetically stirred tripolyphosphate. The beads are removed from the counter 
ion solution by filtration, washed with distilled water, dried by an air jet and further 
air dried at ambient temperature.    
1.2.1.7.2 Extrusion- spheromization 
In this method ingredients are mixed with chitosan and the wet mass is passed 
through an extruder. The cylindrical extrudate obtained is immediately processed 
in a spheronizer. The beads are collected and dried in a hot air oven at 40 oC for 
12 hrs. 
1.2.1.7.3 Solvent evaporation technique 
Chitosan dissolved in an aqueous acetic acid solution. The solution is added to 
toluene and sonicated to form a w/o emulsion. Glutaraldehyde solution in toluene 
is added to the emulsion and stirred at room temperature to give cross-linked 
microspheres. The suspension is centrifuged. Following evaporation of the 
solvent, the microspheres are separated, washed with distilled water and dried. 
Li et al. 7 modified the solvent evaporation method and named it “Dry-in-Oil” 
method. Here system is warmed to 50 oC and the pressure is reduced. When the 
solvent is evaporated completely the microspheres are separated, washed with 
sodium hydroxide solution, distilled water and diethyl ether and dried.    
1.2.1.7.4 Multiple emulsion method 
Multiphase emulsions are also prepared by the solvent evaporation technique by 
a three step emulsification process.  
Aqueous drug solution and oil phase containing emulsion stabilizers are 
combined to give water-in-oil emulsion (step 1).  
Later the w/o emulsion is dispersed in the polymer solution (step 2).  
The solvent is evaporated under reduced pressure (step 3). 
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1.2.1.7.5 Spray drying method 
Chitosan microspheres are prepared by using a spray drier apparatus. 
Microspheres have been prepared from solutions of different concentrations of 
chitosan in glacial acetic acid/water/acetone.  
1.2.1.7.6 Precipitation / coacervation method 
Berthold et al 8 prepared chitosan microspheres by a novel precipitation method 
using sodium sulphate as precipitant. In this method chitosan is dissolved in 
acetic acid containing polysorbate 80. A solution of sodium sulphate is added 
dropwise during stirring and ultrasonication. The formation of microspheres is 
indicted by turbidity. The formed microspheres are purified by centrifugation and 
resuspended in dematerialized water. This method avoided the use of organic 
solvents and glutaraldehyde for preparation of chitosan microparticles with high 
loading capacity and sustained release effect. 
Chitosan microparticles can also be prepared by complex coacervation. Sodium 
alginate, sodium carboxymethylcellulose, kappa-carregeenan and sodium poly-
acrylic acid are used in the complex coacervation procedure with chitosan. Here 
the microparticles are formed by interionic interaction between oppositely 
charged polymers. Formulation of coacervate capsules of chitosan-alginate and 
chitosan- kappa-carregeenan is carried out by extruding either an aqueous 
solution of kappa-carregeenan in a solution of sodium alginate through a hand-
operated syringe into potassium chloride or calcium chloride solution. The 
counterion solution consisted of chitin. The obtained capsules were agitated to 
harden in the counterion solution before washing and drying.   
1.2.1.7.7 Coating by chitosan  
In this method, previously formed microparticles are coated with chitosan. HAS 
microspheres are prepared and added to various concentrations of chitosan-
acetic acid solutions and mixed; the chitosan treated microspheres are filtered 
and dried.  
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1.2.2 Introduction to alginate 
Alginate is a naturally occurring biopolymer that is finding increasing applications 
in the biotechnology industry. Alginate has been used successfully for many 
years in the food and beverage industry as a thickening agent, a gelling agent 
and a colloidal stabilizer. Alginate also has several unique properties that have 
enabled it to be used as a matrix for the entrapment and/or delivery of a variety 
of proteins and cells. These properties include: (i) a relatively inert aqueous 
environment within the matrix; (ii) a mild room temperature encapsulation 
process free of organic solvents; (iii) a high gel porosity which allows for high 
diffusion rates of macromolecules; (iv) the ability to control this porosity with 
simple coating procedures and (v) dissolution and biodegradation of the system 
under normal physiological conditions.  
1.2.2.1 Sources of alginate 
Commercial alginates are extracted primarily from three species of brown algae 
(kelp). These include Laminaria hyperborea, Ascophyllum nodosum, and 
Macrocystis pyrifera. Other sources include Laminaria japonica, Eclonia maxima, 
Lesonia negrescens and Sargassum species 9. In all of these algae, alginate is 
the primary polysaccharide present and it may comprise up to 40% of the dry 
weight 10.  
1.2.2.2 Extraction and preparation 
To commercially prepare alginates, the algae is mechanically harvested and 
dried before further processing except for M. pyrifera which is processed when 
wet. Alginate is then extracted from dried and milled algal material after treatment 
with dilute mineral acid to remove or degrade associated neutral 
homopolysaccharides such as laminarin and fucoidin. Concurrently, the alkaline 
earth cations are exchanged for H+. The alginate is then converted from the 
insoluble protonated form to the soluble sodium salt by addition of sodium 
carbonate at a pH below 10. After extraction, the alginate can be further purified 
and then converted to either a salt or acid 10.  
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1.2.2.3 Chemical structure 
 
    
 
 
 
 
1.2.2.4 Microbead preparation 
There are three widely-known methods used to prepare alginate microbeads that 
are less than 0.2 mm in diameter; atomization, emulsification and coacervation. 
The most commonly used technique is an atomization or spraying method using 
an extrusion device with a small orifice. A general overview of alginate microbead 
preparation is as follows. Solutions containing the alginate and protein, as 
described above in the preparation of large beads, are well mixed and loaded 
into a syringe mounted on a syringe pump. The mixture of alginate and protein 
solution is then delivered through an atomization device with a defined diameter 
(~1 mm) orifice at the tip. Much smaller diameter orifices can be used but may 
run the risk of orifice clogging/plugging by the high viscosity alginate solution. 
The sizes of these beads can be controlled by either the pressure of the infusing 
nitrogen gas, the flow-rate of the syringe pump or the distance between the 
orifice and the surface of the cross-linking solution. Fine droplets of sodium 
alginate and protein solution will form the microbeads when cross-linked with the 
divalent solution. Outer coatings of poly-L-lysine and alginate can then be 
performed. The second method of microbead preparation involves protein 
encapsulation by an oil-in-water emulsification technique. Complex coacervation 
of oppositely charged polyelectrolytes has been commonly used as a method for 
preparing microbeads. Complex coacervation between alginic acid, gelatin11, 
chitosan12, and albumin13 has been reported. In the alginate–chitosan system, 
the complex is formed by spraying a sodium alginate solution into the chitosan 
solution. The resultant alginate–chitosan microbeads are mechanically strong 
and stable over a wide pH range. With the alginate–albumin system, 
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coacervation is found to be limited compared to other polypeptide–
polysaccharide systems due to the high viscosity of the albumin–alginic acid 
complex and a propensity to precipitate. The optimum conditions for maximum 
coacervate yield are a pH of 3.9, an ionic strength of 1 mM and a 0.15% w/v total 
polyion concentration. 
1.2.2.5 Physical properties 
The functional and physical properties of cation cross-linked alginate beads are 
dependent on the composition, sequential structure, and molecular size of the 
polymers. The flexibility of the alginate polymers in solution increases in the order 
MG>MM>GG (G=α-L-guluronic acid; M= β-D-mannuronic acid). Beads with the 
lowest shrinkage, highest mechanical strength, highest porosity, and best 
stability towards monovalent cations are made from alginate with an α-Lguluronic 
acid content greater than 70% and an average length of the α-L-guluronic acid 
blocks higher than 15. These polymers are called "high G" alginates and for 
molecular weights higher than 2.4×105, the gel strength is independent of the 
molecular weight. For lower molecular weight alginates however, there is a 
certain critical molecular weight below which the gel forming properties of 
alginates are reduced. While a gel made from a high α-L-guluronic acid alginate 
may be rigid and brittle, gels produced from alginates with a low α-L-guluronic 
acid content are more elastic. Alginate forms stable gels over the temperature 
range of 0-100°C, although the modulus of rigidity of the gels decreases with an 
increase in temperature. The gels can be prepared in either hot or cold water.  
1.2.2.6 Chemical reactivity 
Although the microenvironment in an alginate bead can be relatively inert to 
protein drugs and cells (alginate beads typically contain up to 95% water) a 
positively charged protein can potentially compete with calcium ions for available 
carboxylic acid sites on the alginate. This has been observed with small drugs by 
several investigators14-15 and has been shown to result in protein inactivation in 
the case of the protein transforming growth factor-beta (TGF- β
 1).  
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1.2.2.7 Porosity and macromolecular diffusion 
Proteins encapsulated in alginate matrices are released by two mechanisms: (i) 
diffusion of the protein through the pores of the polymer network and (ii) 
degradation of the polymer network. Analysis of calcium alginate gels 
microbeads by electron microscopy has shown that the pore size ranges from 5 
to 200 nm in diameter 16. In a different approach the porosity was determined by 
packing alginate beads in a column and recording the exclusion volumes for 
macromolecular standards 17. A cut off value of 12–16 nm was determined which 
is smaller than the pore size distribution obtained by electron microscopy. 
Diffusion of small molecules such as glucose and ethanol is unaffected by the 
alginate matrix while diffusion of larger proteins from the gels has been shown to 
be dependent on their molecular weight. The diffusion of several proteins from 
alginate beads has been reported including immunoglobulin G (IgG)18-19, 
fibrinogen18 and insulin. Increasing the concentration of alginate in the beads 
decreases the rate of diffusion of the proteins from the gel.  
1.2.2.8 Chemical stability/degradation 
Degradation of a Ca2+ cross-linked alginate gel can occur by removal of the Ca2+ 
ions. This can be accomplished by the use of a chelating agent such as ethylene 
glycol-bis (β -aminoethyl ether)-N,N,N′,N′-tetraocetic acid (EGTA), lactate, citrate 
and phosphate or by a high concentration of ions such as Na+ or Mg2+ . As Ca2+ 
ions are removed, the cross-linking in the gel decreases and the gels are 
destabilized. This can lead to leakage of entrapped material and solubilization of 
the high molecular weight alginate polymers. Alginate gels will also degrade and 
precipitate in a 0.1 M phosphate buffer solution and will completely dissolve in 
0.1 M sodium citrate at pH 7.8. If Ca2+ is used in the cross-linking solution and 
phosphate is used as the dissolution medium, the dissolution medium will turn 
turbid due to the Ca2+ dissociating from the polymer network and forming calcium 
phosphate precipitate.  
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1.2.2.9 Biological properties 
1.2.2.9.1 Immunogenicity 20 
There are many factors involved in determining the successful application of 
polymers as drug delivery carriers in humans, with polymer biocompatibility 
or/and immunogenicity being two of the more important issues. There are 
numerous reports addressing the fibrotic reaction of implanted alginates. 
Alginates can be readily purchased in several different grades namely, ultra pure, 
food or research grade.  
1.2.2.9.2 Bioadhesion 
Alginate possesses, among other features, a bioadhesive property which could 
serve as a potential advantage in mucosal drug delivery. The term bioadhesion 
can be generally defined as the adhesion or contact between two surfaces, with 
one being a biological substratum21. If one of the surfaces involved is a mucosal 
layer, the term mucoadhesion is then used 22. Studies have shown that polymers 
with charge density can serve as good mucoadhesive agents 23-26. Peppas and 
colleagues believed that mucoadhesion is achieved by chain penetration across 
a polymer–mucosa interface 27-28. It has been reported that polyanion polymers 
are more effective bioadhesives than polycation polymers or nonionic polymers. 
Alginate, with its carboxyl end groups, is classified as an anionic mucoadhesive 
polymer. Alginate mucoadhesion studies, conducted by Chickering et al., were 
performed with a tensile testing apparatus in which the adhesive forces between 
different polymers and living intestinal epithelium were evaluated 24-25. The 
intestinal epithelium used in these experiments was from excised rat jejunum. In 
brief, individual polymer beads were placed on an inverted jejunum. The force 
required to detach the beads from the jejunum's surface was recorded and 
compared with the values obtained from other types of polymer beads. These 
studies showed that alginate has the highest mucoadhesive strength when 
compared to polymers such as polystyrene, chitosan, carboxymethylcellulose 
and poly(lactic acid). Mucoadhesive drug delivery systems work by increasing 
the drug residence time at the site of activity or resorption. This mucoadhesive 
feature of alginate may aid in its utility as a potential delivery vehicle for drugs to 
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mucosal tissues such as the gastrointestinal tract or the nasopharynx. The 
adherence of these microbeads to the mucosal tissues localizes the drug and 
delays the protein transit time, therefore potentially improving the overall drug 
effectiveness and bioavailability. 
1.2.2.10 Microsphere and liposome encapsulation 
Alginate gels have been used to encapsulate other delivery systems including 
microspheres and liposomes. Ethylcellulose microspheres were dispersed into 
an aqueous solution of sodium alginate which was subsequently dropped into a 
CaCl2 solution 29. The authors suggested that the beads could potentially be 
useful as an oral delivery system for micro-or nanoparticles. Liposomes that 
contained the model proteins BSA or horse-radish peroxidase were incorporated 
into alginate spheres with a diameter of 500-800 µm 30-31. Prior to their 
entrapment, the liposomes were coated with either phospholipase C, D, or A2. 
The alginate microbeads that contained the liposomes remain stable at 10°C. 
Upon heating to 37°C, release of the protein is triggered by the enzymatic 
degradation of the phospholipids by the phospholipases. By selecting the 
appropriate phospholipase the duration of protein release could be controlled.  
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1.2.3 Introduction to hydroxypropyl methyl cellulose 32 
1.2.3.1 Nonproprietary names 
BP/USP: Hypromellose 
PhEur: Hypromellosum 
1.2.3.2 Synonyms 
Methyl hydroxypropyl cellulose, propylene glycol ether of methyl cellulose, methyl 
cellulose propylene glycol ether, methocel, HPMC. 
1.2.3.3 Chemical names 
 Cellulose, 2-hydroxy propyl methyl ether. 
1.2.3.4 Structural formula 
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1.2.3.5 Functional category 
Suspending and /or viscosity increasing agent, tablet binder, coating agent, 
Viscosity increasing agent, adhesive anhydrous ointment ingredient, film former, 
emulsion stabilizer, rate-controlling polymer for sustain release. 
1.2.3.6 Method of manufacture 
A purified form of cellulose fibers obtained from cotton linters or wood pulp, are 
treated with caustic (sodium hydroxide) solution. The alkali cellulose thus 
obtained is in turn treated with methyl chloride and propylene oxide to provide 
methylhydroxypropyl ethers of cellulose. The fibrous reaction product is then 
purified and ground to a fine, uniform powder or granules. 
1.2.3.7 Description 
An odorless, tasteless, white or creamy-white fibrous or granular powder. 
1.2.3.8 Applications in pharmaceutical formulation or technology 33-34 
Hypromellose is widely used in oral and topical pharmaceutical formulations. In 
oral products, primarily used as a tablet binder, in film-coating and as an 
extended-release tablet matrix. Concentrations between 2 % and 5 % w/w may 
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be used as a binder in either wet or dry granulation. Depending upon the 
viscosity grade, concentrations of 2-20 % w/w are used for film-forming solutions 
to film-coat tablets. Hypromellose is also used as a suspending and thickening 
agent in topical formulations, particularly ophthalmic preparations. 
Concentrations between 0.45-0.1 % w/w may be added as a thinking agent to 
vehicles for eye drops and artificial tear solutions. It is also used as an emulsifier, 
suspending agent, and stabilizing agent in topical gels and ointments. It is used 
as an adhesive in plastic bandages and wetting agent for hard contact lenses.      
1.2.3.9 Typical properties 35 
Acidity/ alkalinity: pH = 5.5-8.0 for a 1 % w/w aqueous solution. 
Autoignition temperature: 360 oC 
Density (bulk): 0.341 g/cm3 
Density (tapped): 0.557 g/cm3 
Density (true): 1.326 g/cm3 
Melting point: browns at 190-200 oC, chars at 225-230 oC, glass transition 
temperature is 170-180 oC. 
Moisture content: hypromellose absorb moisture from the atmosphere, the water 
absorbed depending upon the initial moisture content and temperature and 
relative humidity of the surrounding air. 
Specific gravity: approximately 1.3 
1.2.3.10 Solubility  
Soluble in cold water, forming a viscous colloidal solution; in soluble in alcohol, 
ether and chloroform, but soluble in mixtures of methyl alcohol and methylene 
chloride. Certain grades are soluble in aqueous acetone, mixtures of methylene 
chloride and isopropyl alcohol and other organic solvents. 
1.2.3.11 Stability and storage conditions 
Very stable in dry condition. Solutions are stable at pH 3-11. Aqueous solution is 
liable to be affected by microorganisms when used as a viscosity-increasing 
agent in ophthalmic solutions and anti-microbial agent. Hypromellose powder 
should be store in a well-closed container, cool place and dry place. 
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1.2.3.12 Incompatibilities  
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates.   
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1.2.4 Introduction to carbopol 32 
1.2.4.1 Nonproprietary name  
Carbopol-934P, Carbomer, Carbomera. 
1.2.4.2 Synonyms 
Carboxy polymethylene; carboxyvinyl polymer; acrylic acid polymer, carbopol. 
1.2.4.3 Chemical name 
Carboxy polymethylene. 
1.2.4.4 Structural formula 
C C O
H H
H C
OH
n
 
1.2.4.5 Method of manufacture  
A synthetic, high molecular weight, cross-linked polymer of acrylic acid co 
polymerized with approximately 0.75-2.0 % w/w of polyalkylsucrose. The end 
product contains 56-68% carboxylic acid groups. 
1.2.4.6 Description 
A white, fluffy, acidic, hygroscopic powder with a slight characteristic odor.  
1.2.4.7 Functional category 
Bioadhesive, suspending and/or viscosity-increasing agent, release-modifying 
agent, tablet binder. 
1.2.4.8 Typical properties 35  
Carbopol is soluble in water, alcohol and glycerin. Agents that can neutralize 
carbopol include sodium hydroxide; potassium hydroxide; sodium bicarbonate; 
borax; amino acids; polar organic amines. 
Specific gravity: 1.41 
Density (bulk): 5 g/cm3  
Density (tapped): 1.4 g/cm3 
Viscosity (0.2%): 20.5-54.5 poise and (0.5%): 305-394 poise. 
Acidity/ alkalinity: pH = 2.7-3.5 for a 0.5 % w/v aqueous dispersion, pH = 2.5-3.0 
for a 1 % w/v aqueous dispersion. 
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Glass transition temperature: 100-105 oC. 
Moisture content: normal water content is up to 2 % w/w. Carbomers are 
hydroscopic and typical equilibrium moisture content at 25 oC and 50 % relative 
humidity is 8-10 % w/w.  
1.2.4.9 Applications in pharmaceutical formulation or technology 36-39 
Carbomers are mainly used in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity-increasing agents. Formulations include creams, gels 
and ointments for use in ophthalmic, rectal and topical preparations. Carbomer 
having low residuals only of ethyl acetate, such as carbomer 971P or 974P, may 
be used in oral preparations, in suspensions, tablets or sustain release tablet 
formulation. Carbomer resins have also been investigated in the preparation of 
sustained-release matrix beads as enzyme inhibitors of intestinal proteases in 
peptide containing dosage forms, as a bioadhesive for a cervical patch and for 
intranaslly administratered microspheres and magnetic granules for site specific 
drug delivery to the esophagus. 
1.2.4.10 Stability and storage conditions 
Dry powder forms of carbopol do not support the growth of molds and fungi; 
however, microorganisms grow well in unpreserved aqueous dispersions. 
Dispersions maintain their viscosity on storage during prolonged periods at room 
temperature or elevated temperature when stored away from light or with the 
addition of an antioxidant. Store in an airtight or well-closed container. 
1.2.4.11 Incompatibilities 
Carbopol is incompatible with phenol, cationic polymers, strong acids and high 
concentrations of electrolytes, and is discolored by resorcinol. Exposure to light 
causes oxidation, which is reflected in a decrease in viscosity. 
1.2.4.12 Safety  
Acute oral doses of carbopol-934P to rats, mice and guinea pigs produce LD50 
values of 4.3, 4.6 and 2.5 g/kg, respectively. In dogs, no fatalities were noted with 
doses as high as 8g/kg. No primary irritation or any evidence of sensitivity or 
allergic reaction in humans following topical application of dispersions containing 
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carbopol-934P has been observed. Carbopol-934P in contact with the eye is very 
irritating. 
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1.3 Introduction to drugs 
 
1.3.1 Introduction to famotidine  
1.3.1.1 Therapeutic class 
Long-acting histamine H2-receptor antagonist. 
1.3.1.2 Chemical name 
3-[2-[(aminoiminomethyl) amino] -4-thiazolyl] methyl] thio]-N- (aminosulfonyl) 
propanimidamide. 
1.3.1.3 Empirical formula 
CH5N7O2S3 
1.3.1.4 Molecular weight 
337.43 
1.3.1.5 Structural formula  
1.3.1.6 Dose 
20 mg twice and 40 mg once a day. 
1.3.1.7 Description 
Famotidine is a white to pale yellow nonhygroscopic crystalline substance. It is 
very slightly soluble in water and practically insoluble in ethanol, acetone, ethyl 
acetate, ethyl ether and acetone. It is freely soluble in glacial acetic acid. 
1.3.1.8 Indications 
• Duodenal ulcer (4o mg daily by mouth twice daily for 6 to 12 weeks) 
• Benign gastric ulcer  
• Hypersecretory conditions such as Zollinger-Ellison syndrome (20 mg 
every 6 hrs) 
• Prevention of relapses of duodenal ulceration  
• Prevention of relapses of benign gastric ulcer  
• Symptomatic relief of gastro-esophageal reflux disease (40 mg twice daily 
for 6 to 12 weeks) 
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• Healing of esophageal erosion or ulceration associated with gastro-
esophageal reflux disease Prevention of relapses of symptoms and 
erosions or ulcerations associated with GERD  
1.3.1.9 Pharmaceutical precautions 
Store in a dry place below 30°C. 
1.3.1.10 Medicine classification 
Prescription Medicine. 
1.3.1.11 Stability 
Famotidine at a concentration of 2 mg per mL, diluted with glucose 5%, sodium 
chloride 0.9%, or sterile water was stable in PVP syringes stored at 4°C for 14 
days 1. It is also stable at room temperature for a 5 days as a 0.2 mg per mL. 
When stored at -20°C in polypropylene syringes it was stable for 3 weeks when 
diluted with glucose 5%, and for 8 weeks when diluted with sodium chloride 0.9% 
or sterile water. The stability of famotidine in a range of parenteral nutrition 
solutions containing amino acids, glucose lipids, electrolytes, vitamins and trace 
elements has been investigated 2-4. In the system tested famotidine was stable 
for up to 74 hrs at room temperature. 
1.3.1.12 Pharmacokoinetic parameters of famotidine 5,6 
Table 1.3.1.1 Pharmacokoinetic parameters of famotidine 
Pharmacokoinetic Parameters Values 
Bioavailibility (%) 
Time to peak plasma concentration (hrs) 
Peak plasma concentration (µg/mL) 
Half-life (hrs) 
Protein binding (%) 
Volume of distribution (L/kg) 
Elimination (%) 
-Urine unchanged (Oral, IV) 
-Metabolized 
40-45 
1-3 
0.076-0.1 
2.5-3.5 
15-20 
1.1-1.4 
25-30(Oral), 65-70 (IV) 
30-35 
25-30 
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1.3.1.13 Contraindications 
Hypersensitivity to any component of these products. Cross sensitivity in this 
class of compounds has been observed. Therefore, famotidine should not be 
administered to patients with a history of hypersensitivity to other H2-receptor 
antagonists 7,8. 
1.3.1.14 Overdosage 
There is no experience to date with overdosage. Patients with Zollinger-Ellison 
Syndrome have tolerated doses up to 800mg/day for more than a year without 
development of significant side effects. The usual measures to remove 
unabsorbed material from the gastro-intestinal tract, clinical monitoring, and 
supportive therapy should be employed. 
1.3.1.15 Adverse effects 
Famotidine has been demonstrated to be generally well tolerated. Headache, 
dizziness, constipation and diarrhea have been reported rarely. Other adverse 
experiences reported even less frequently included dry mouth, nausea and/or 
vomiting, abdominal discomfort or distension, anorexia, fatigue, rash, pruritus 
and urticaria, liver enzyme abnormalities, cholestatic jaundice, anaphylaxis, 
angioedema, arthralgia, muscle cramps, reversible psychic disturbances 
including depression, anxiety disorders, agitation, confusion and hallucinations. 
Toxic epidermal necrolysis has been reported very rarely with H2-receptor 
antagonists. In addition to the above adverse effects, A-V block has been 
reported very rarely with H2-receptor antagonists administered intravenously 9-12. 
1.3.1.16 Official preparations 
USP 23: Famotidine Tablets 12 
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1.3.2 Introduction to glipizide 
1.3.2.1 Chemical name  
1-cyclohexyl-3-[[p-(2-(5-ethylpyrazinecarcoxamido) ethyl] phenyl]sulfonyl]urea.   
1.3.2.2 Chemical formula 
 C21H27N5O4S 
1.3.2.3 Molecular weight 
 445.54 
1.3.2.4 Chemical structure 
 
1.3.2.5 Category 
 Antidiabetic 
1.3.2.6 Description 
 A white powder. 
1.3.2.7 Solubility 
Practically insoluble in water and ethanol; soluble in chloroform, 
dimethylformamide, and in dilute solution of alkali hydroxides, sparingly soluble in 
acetone. 
1.3.2.8 Pharmacokinetics 
Glipizide is completed and rapidly absorbed ensuring prompt and constant 
activity. Peak plasma concentrations are attained within 1.5 to 2.0 hrs after a 
single oral dose. The half-life of elimination ranges from 2 to 3 hrs. The drug is 
excreted in the urine as virtually inactive metabolites. When taken before each 
meal, glynase controls post-prandial hyperglycaemia without the risk of delayed 
episodes of hypoglycaemial 13.  
1.3.2.9 Mechanism of action 
The primary mode of action of glipizide in experimental animals appears to be 
the stimulation of insulin secretion from the beta cells of pancreatic islets tissue 
and is thus dependent on functioning beta cells in the pancreatic islets. In human 
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glipizide appears to lower the blood glucose acutely by stimulating the release of 
insulin from the pancreas, an effect dependent upon functioning beta cells in the 
pancreatic islet. In man stimulation of insulin secretion by glipizide in response to 
a meal is undoubtedly of major importance. Fasting insulin levels are not 
elevated even on long term glipizide administration, but the post-prandial insulin 
response continues to be enhanced after at least six months of treatment. The 
insulinotopic response to a meal occurs within 30 min after an oral dose of 
glipizide in diabetic patients, but elevated insulin levels do not persist beyond the 
time of the meal challenge. Extrapancreatic effects may play a part in the 
mechanism of action of oral sulfonylurea hypoglycemic drugs.  Beginning 2 to 3 
hrs after the administration of glipizide sustained release, plasma concentrations 
of glipizide gradually rise reaching to a maximum concentration within 3 to 8 hrs 
after dosing. With subsequent once daily dosing of glipizide sustained release, 
effective plasma concentrations are maintained throughout 24 hrs period with 
fewer peaks to trough fluctuations. In view of the time required to reach an 
optimal concentration in plasma, drug may be more effective when given 30 min 
before eating. Drug in plasma 98.3 % bound to plasma protein especially with 
albumin. Drug is metabolized in liver, and the metabolites are excreted in the 
urine. Less than 5 % drug excreted unchanged in urine 14. 
1.3.2.10 Indication and dosage 
Management of Type 2 diabetes (Non Insuline Dependent Diabetes mellitus) 
where diet control alone is not effective in controlling the hyperglycemia. Dosage 
should be adapted to patients individually, on basis of periodic tests of glycosuria 
and blood sugar. The maximum daily dose should not exceed 10 mg.  
1.3.2.11 Contraindications 
Like other sulfonylurea, glipizide is contraindicated in: Insulin dependent diabetes 
mellitus, diabetic-keto-acidosis, diabetic coma, pregnancy, subjects with severely 
impaired kidney or liver function, adrenal insufficiency and cases of confirmed 
individual hypersensitivity to the drug. In latent diabetes or prediabetic states, the 
use of sulfonylurea is not advisable.  
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1.3.2.12 Interaction 
The hypoglycemic actions of sulfonylurea may be potentiated by certain drugs 
including nonsteriodal anti-inflammatory drugs and other drugs that are highly 
protein bound salicylates, sulphonamides, and chloramphenicol. When such 
drugs are administered to a patient receiving Glipizide, the patient should be 
observed for hypoglycemia.  
1.3.2.13 Side effect 
Hypoglycemia, gastrointestinal disturbances, allergic reactions including 
erythema urticaria.  
1.3.2.14 Precaution 
Patients should be instructed to closely follow their physician’s prescription as 
regards diet, dosage and schedule for taking the drug, and should be taught to 
recognize promptly the early symptoms of hypoglycemia, that generally are 
headache, irritability, sleep disorders, tremor and heavy sweating, so they can 
contact a doctor in good time. 
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1.3.2 Introduction to amoxicillin 
1.3.2.1 Chemical name  
2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-
oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 
1.3.2.2 Chemical formula 
C16H19N3O5S 
1.3.2.3 Molecular weight 
365.40 
1.3.2.4 Chemical structure 
 
1.3.2.5 Category 
Anti-Bacterial Agents 
1.3.2.6 Description 
A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its 
resistance to gastric acid permits higher serum levels with oral administration. 
1.3.2.7 Solubility in water 
3430 mg/L 
1.3.2.8 Indication 
For the treatment of infections of the ear, nose, and throat, the genitourinary 
tract, the skin and skin structure, and the lower respiratory tract due to 
susceptible (only b-lactamase-negative) strains of Streptococcus spp. (a- and b-
hemolytic strains only), S. pneumoniae, Staphylococcus spp., H. influenzae, E. 
coli, P. mirabilis, or E. faecalis. Also for the treatment of acute, uncomplicated 
gonorrhea (ano-genital and urethral infections) due to N. gonorrhoeae (males 
and females). 
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1.3.2.9 Pharmacology 
Amoxicillin is a moderate-spectrum antibiotic active against a wide range of 
Gram-positive, and a limited range of Gram-negative organisms. It is usually the 
drug of choice within the class because it is better absorbed, following oral 
administration, than other beta-lactam antibiotics. Amoxicillin is susceptible to 
degradation by β-lactamase-producing bacteria, and so may be given with 
clavulanic acid to increase its susceptability. The incidence of β-lactamase-
producing resistant organisms, including E. coli, appears to be increasing. 
Amoxicillin is sometimes combined with clavulanic acid, a β-lactamase inhibitor, 
to increase the spectrum of action against Gram-negative organisms, and to 
overcome bacterial antibiotic resistance mediated through β-lactamase 
production. 
1.3.2.10 Mechanism of action 
Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the 
bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-
terminal domain by opening the lactam ring. This inactivation of the enzyme 
prevents the formation of a cross-link of two linear peptidoglycan strands, 
inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then 
mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible 
that amoxicllin interferes with an autolysin inhibitor. 
1.3.2.11 Absorption 
Rapidly absorbed after oral administration. 
1.3.2.12 Toxicity 
Serious toxicity is unlikely following large doses of amoxicillin. Acute ingestion of 
large doses of amoxicillin may cause nausea, vomiting, diarrhea and abdominal 
pain. Acute oliguric renal failure and hematuria may occur following large doses. 
1.3.2.13 Side effect 
All medicines may cause side effects, but many people have no, or minor side 
effects. Check with your doctor if any of these most common side effects persist 
or become bothersome when using amoxicillin: 
Diarrhea; nausea; vomiting. 
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Seek medical attention right away if any of these severe side effects occur when 
using amoxicillin:  
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the 
chest; swelling of the mouth, face, lips, or tongue); bloody stools; confusion; dark 
urine; fever, chills, or persistent sore throat; red, swollen, blistered, or peeling 
skin; seizures; severe diarrhea; stomach pain or cramps; unusual bruising or 
bleeding; vaginal discharge or irritation; yellowing of the skin or eyes. 
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2.1 Review of work done on stomach specific drug delivery systems 
 
Sheth et al [1] developed sustained release hydrodynamically balanced capsules 
which, upon contact with gastric fluid acquired and maintained a bulk density of 
less than one and remained buoyant in the fluid and remained so until 
substantially all of the active ingredients are released. The percent 
Chordiazepoxide release from capsules in to simulated gastric fluid (pH 1.2) after 
1,2,3.7 hrs was 39,61,…100 % respectively. 
Du Quing et al [2]  formulated multiple unit floating sustained release granules of 
aminophyllin and evaluated. They have reported that increasing quantity of cetyl 
alcohol and octadecanol could increases the granules floating capability in- vitro. 
Increased concentration of ethyl cellulose delayed the drug release rate. 
Stochwell et al [3]  formulated and evaluated a floating gel system. Buoyancy 
was achieved by carbon dioxide gas and its subsequent entrappement in to gel 
network. Sodium alginate, which undergoes gelation in acidic conditions and in 
the presence of calcium, was used. It was evaluated in-vitro as sustained release 
floating gel system. 
Igani et al [4]   formulated dosage form with specific density less than one in the 
form of double layer sustained release compressed hydrophilic matrix to achieve 
a reproducible floatation of a tablet. Carbon dioxide was trapped in to gelled 
hydrocolloids. The gastric retention of HBS dosage form was found to be 
significantly more than that of the non-floating dosage form. 
Shimpi S et al [5]  prepared Gelucire 43/01 for the design of multi-unit floating 
systems of a highly water-soluble drug diltiazem HCl. Diltiazem HCl-Gelucire 
43/01 granules were prepared by melt granulation technique. The granules were 
evaluated for in-vitro and in-vivo floating ability, surface topography, and in-vitro 
drug release. Aging effect on storage was evaluated using scanning electron 
microscopy, hot stage polarizing microscopy (HSPM), differential scanning 
calorimetry (DSC), and in-vitro drug release. Granules were retained in stomach 
at least for 6 hrs. Approximately 65% to 80% drug was released over 6 hrs with 
initial fast release from the surface. Surface topography, HSPM, DSC study of 
the aged samples showed phase transformation of Gelucire. The phase 
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transformation also caused significant increase in drug release. In conclusion, 
hydrophobic lipid, Gelucire 43/01, can be considered as an effective carrier for 
design of a multi-unit floating drug delivery system of highly water-soluble drugs 
such as diltiazem HCl. 
Zia et al [6] optimized Sotalol floating and bioadhesive extended release tablet 
formulation which posses a unique combination of flotation and bioadhesion for 
prolong residence in the stomach. A new factor factorial design was employed to 
optimize the tablet formulation contaoining 240 mg Sotalol HCl, the ratio of 
NaCMC to HPMC and the ratio of EC to Crosspovidone.The dependent variable 
was dissolution, bioadhesive capability, tablet disintegration and required 
compression fource for producing 6 kg hardness tablets. 
Tossounian et al [7] investigated the in-vivo and in-vitro characterization of 
hydrodynamically balanced dosage forms. In-vivo visualization was done by 
using blood level time profiles for diazepam and chlordiazepoxide HBS dosage 
forms. 
Ichiwaka et al [8]  prepared floating granules containing 20% Dextromethorphan 
HCl, coated with sodium bicarbonate –HPC-Ethyl alcohol mixture and a vinyl 
acetate, shellac, HPMC phthalate, acetylmonoglyceride, calcium stearate and 
ethanol mixture. The granules floated in acetate buffer solution in 14-15 min after 
immersion. 
Sangekar et al [9] investigated the effect of food and specific gravity on the 
gastric retention time of floating and non-floating tablet formulations using gama 
scintigraphy in humans. No correlation was found between gastric residence time 
and specific gravity of the dosage form. 
Nakamichi K et al [10] prepared a floating dosage form composed of nicardipine 
hydrochloride (NH) and hydroxypropylmethylcellulose acetate succinate (enteric 
polymer) was prepared using a twin-screw extruder. By adjusting the position of 
the high-pressure screw elements in the immediate vicinity of die outlet, and by 
controlling the barrel temperature, he was able to prepare a puffed dosage form 
with very small and uniform pores. It was found that the porosity and pore 
diameter could be controlled by the varying amount of calcium phosphate 
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dihydrate. In the shaking test, the puffed dosage form was found to have 
excellent floating ability and mechanical strength in acid solution (JP First Fluid, 
pH 1.2). The dissolution profile of NH was controlled by the amount of wheat 
starch. In the dissolution test using JP Second Fluid (pH 6.8), rapid dissolution of 
NH and loss of buoyancy were observed 
Fabregas et al [11]  formulated long acting antacid compositions with floating 
properties. It contained a substance soluble in water at neutral pH. The 
formulation resulted in gastric regularization for epigastric pain and nausea. 
Mazer et al [12] observed intragastric behavior and absorption kinetic of normal 
and floating modified release capsule of iseradipine under fasted and fed 
conditions. Presence or absence of food rather than buoyancy was the principal 
determinant of the gastric residence time of the capsule. The drug release and 
absorption were more by the intragastric interaction with the lipid phase of the 
meal. 
Inouye,Y et al [13]  prepared buoyant sustained release granules of Prednisolone 
using ‘H’ or ‘L’ grades of chitosan. The granules were immediately buoyant in 
both acidic and neutral fluids. Sustained drug absorption from these preparations 
was noticed in beagle dogs. 
Kawashima et al [14] prepared hollow microspheres (microballoons) loaded with 
drug in their outer polymer shell by a novel emulsion solvent diffusion method. 
The ehanol: dichloromethane solution of drug (ibuprofen) and an acrylic polymer 
were poured that were thermally controlled at 40°C.The gas phase generated in 
the dispersed polymer droplet by the evaporation of the dichloromethane formed 
and the internal cavity in the microballoons of the polymer. The flowability and 
packability of the resultant microballons were characterized as an entire property 
and the drug release rate were drastically reduced depending on the polymer 
concentration at pH 6.8. 
Franz et al [15] prepared sustained release bilayer buoyant floating dosage form 
containing Misoprostol, one layer is a drug release layer and other is buoyant or 
floating layer. The dosage form provided extended gastric retention so that the 
entire drug is released in the stomach over an extended period. The floating layer 
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included a polymer i.e.HPMC, which has a property of gelling and which on 
contact with gastric fluids, hydrates and forms a gelatinous barrier. This dosage 
form is buoyant on gastric fluid for up to approximately 13 hrs. 
Desai et al [16]  developed a noncompressed controlled release floating tablets of 
Thyophylline using agar and minaral oil. Tablets were made by dispersing a 
drug /minaral oil mixture in warm agar solution, the resultant mixture was poured 
in to tablet moulds which on cooling and air-drying formed a floatable CR tablets. 
The light mineral oil was essential for the floating property of the tablet since 
relatively high amount of drug (75%) and low amount of agar (2%) were used into 
formulation. 
Baumgartener et al [17] prepared floating matrix tablets with high dose of freely 
soluble drugs. Tablets containing HPMC, drug and different additives are 
compressed. Tablet composition and mechanical strength have greater influence 
on the floating properties and drug release. With the incorporation of gas 
generating agent, besides optimum floating time of 30 sec and duration of 
floating > 8 hr, the drug release was also increased. 
Whitehead et al [18] prepared floating alginate beads from alginate solution 
containing either dissolved or suspending Amoxycillin.The beads were produce 
by a drop-wise addition of the alginate into calcium chloride solution, followed by 
removal of the gel beads and freeze drying. Drug release study shows that the 
beads prepared with the drug in solution provided some sustained release 
characters and these were improved by the addition of amylase. The beads 
retained their buoyancy were amylase and amoxicilline were incorporated. 
Nur Abubakr O et al [19]  prepared captopril floating and/or bio adhesive tablets 
using two grades of HPMC (400 and 15000 cps.).He compared two conventional 
tablets; release from floating tablets was apparently prolonged. A 24 hrs 
controlled release dosage form for captopril was achieved. Tablet hardness was 
found determining factor with regard to buoyancy of the tablets. 
Shoufeng et al [20] illustrated statistical experimental design and data analysis 
using response surface methodology. A central composite box-Wilson design for 
the controls release of calcium was used with three formulation variables like 
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HPMC loading, Citric acid loading and magnesium stearate loading. Sustained 
release floating delivery of calcium with increased bioavalability was achieved. 
Farouk et al [21] developed a programmable controlled release drug delivery 
system. The device in the form of a non digestible oral capsule was design to 
utilized an automatically operated geometric obstruction that keeps the device 
floating in the stomach and prevent it from passing through the remainder of the 
GIT. Different viscosity grades of HPMC were used as a model eroding matrices. 
Zero-order release could be maintained for period ranging between 5 to 20 days 
before the geometric obstruction was triggered off. 
Talwar et al [22] prepared gastroretentive oral drug delivery system structurally 
comprised of highly porous matrix having a drug, gas generating component, 
sugar, release controlling agent and optionally spheronising agents. The 
pharmaceutical formulation either in the form of pellets, beads, granules or 
capsules was retained in the stomach while selectively delivering the drug at 
gastric level or upper part of small intestine for extended period of time. 
Joseph et al [23] prepared a floating type dosage form (FDF) of piroxicam in 
hollow polycarbonate (PC) microspheres capable of floating on simulated gastric 
and intestinal fluids was prepared by a solvent evaporation technique. 
Incorporation efficiencies of over 95% were achieved for the encapsulation. In- 
vitro release of piroxicam from PC microspheres into simulated gastric fluid at 
37°C showed no significant burst effect. The amount released increased with 
time for about 8 h after which very little was found to be released up to 24 hrs. In 
intestinal fluid, the release was faster and continuous and at high drug pay loads, 
the cumulative release reached above 90% in about 8 hrs. In-vivo evaluation of 
different dosage forms of piroxicam such as free drug, drug-encapsulated 
microspheres and microspheres along with a loading dose of free drug in rabbits 
showed multiple peaking in the plasma concentration-time curve suggesting 
enterohepatic recirculation of the drug.  
Patel et al [24] developed freeze dried chitosan polyethylene oxide hydrogel for 
the site-specific antibiotic release in the stomach. The freeze dried PEO matrix 
swollen extensively as compared to air-dried hydrogels. The freeze dried 
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chitosan PEO could be useful for localized delivery of antibiotic in the acidic 
environment of the gastric fluid. 
Atybi et al [25] studied bicarbonate loaded bicarbonate ion exchange resin beads 
coated with semipermeable membrane. The beads exhibited prolong gastric 
recidence due to floating. In, addition to bicarbonate, a model drug theophyllin 
has also been loaded on to the resin. This system gives a controlled release of 
drug by coating and has potential application as a control release gastric 
retentive system. 
Yang [26] developed an asymmetric three-layered tablet. The outer layer 
consisted of gas generating system. The other outer layer was similar but devoid 
of gas generating element. The function of these layers was to provide the 
necessary buoyancy and control the passage of the fluid in to the drug containing 
layer. Zero-order release of theophylline in-vitro was possible for 16 hrs with 
buoyancy maintained through out the period.  
Timmerman et al [27] optimized floating and non floating hydrophilic matrix 
capsule in-vitro with regard to their buoyancy or non buoyancy capabilities and 
their diametric sine evaluation with time. The GRT prolongation is obtained with 
floating dosage form compared to non floating dosage forms. 
Sheth et al [28] published a patent for hydrodynamically balance system. This unit 
consisting of capsule formulation consisting drug, hydrocilloid and other 
excipients. After emersion in other fluid, the capsule dissolves and hydrocolloid 
forms a hydrated boundary layer. That gives the formulation floating properties. 
The drug is subsequently released through this layer is by diffusion. 
Wei et al [29] formulated a new kind of two-layer floating tablet for gastric retention 
(TFTGR) with cisapride as a model drug was developed. The in-vitro drug 
release was determined, and the resultant buoyancy and the time-buoyancy 
curve were plotted. Because of the sodium bicarbonate added to the floating 
layer, when immersed in simulated gastric fluid the tablet expands and raises to 
the surface, where the drug is gradually released. The drug release of this kind of 
two-layer dosage was controlled by the amount of HPMC in the drug-loading 
layer. Generally the more HPMC, the slower the drug releases. Because 
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cisapride has graeter solubility in SGF than SIF, in  vitro drug dissolution in SGF 
is faster than in SIF. 
Soppimath et al [30] prepared hollow microspheres of cellulose acetate loaded 
with four cardiovascular drugs (Nifedipine, Nicardipine HCl, Varapamil HCl and 
Dypiridamole) were prepared by a novel solvent diffusion-evaporation method. 
The O/W emulsion prepared in an aqueous solution of 0.05% poly (vinyl alcohol) 
medium with ethyl acetate, a water-soluble and less toxic solvent, was used as a 
dispersing solvent. The yield of the microspheres was up to 80%. The 
microspheres had smooth surfaces, with free floating and good packing 
properties. Scanning Electron Microscopy (SEM) confirmed their hollow 
structures, with sizes in the range of 350-489 mm. The microspheres were 
tended to float over the gastric media of more than 12 hrs.  
Jayvadan et al [31] formulated and systematically evaluate in-vitro and in-vivo 
performances of mucoadhesive microspheres of glipizide. Glipizide microspheres 
containing chitosan were prepared by simple emulsification phase separation 
technique using glutaraldehyde as a cross-linking agent. Results of preliminary 
trials indicate that volume of cross-linking agent, time for cross-linking, polymer-
to-drug ratio, and speed of rotation affected characteristics of microspheres. 
Microspheres were discrete, spherical, and free flowing. The microspheres 
exhibited good mucoadhesive property in the in-vitro wash-off test and also 
showed a high percentage drug entrapment efficiency. A 32 full factorial design 
was employed to study the effect of independent variables, polymer-to-drug ratio 
(X 1), and stirring speed (X 2) on dependent variables percentage mucoadhesion, 
t80, drug entrapment efficiency, and swelling index. The best batch exhibited a 
high drug entrapment efficiency of 75% and a swelling index of 1.42; percentage 
mucoadhesion after 1 hr was 78%. The drug release was also sustained for more 
than 12 hrs. The polymer-to-drug ratio had a more significant effect on the 
dependent variables. In-vivo testing of the mucoadhesive microspheres to albino 
Wistar rats demonstrated significant hypoglycemic effect of glipizide. 
Jayvadan et al [32]    formulated and systematically evaluate in-vitro and in-vivo 
performances of mucoadhesive amoxicillin microspheres for the potential use of 
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treating gastric and duodenal ulcers, which were associated with Helicobacter 
pylori. Amoxicillin mucoadhesive microspheres containing chitosan as 
mucoadhesive polymer were prepared by simple emulsification phase separation 
technique using glutaraldehyde as a cross-linking agent. Results of preliminary 
trials indicate that volume of cross-linking agent, time for cross-linking, polymer-
to-drug ratio, and speed of rotation affected characteristics of microspheres. 
Microspheres were discrete, spherical, free flowing and also showed high 
percentage drug entrapment efficiency. In-vitro mucoadhesive test showed that 
amoxicillin mucoadhesive microspheres adhered more strongly to gastric 
mucous layer and could retain in gastrointestinal tract for an extended period of 
time. A 32 full factorial design was employed to study the effect of independent 
variables, polymer-to-drug ratio (X1), and stirring speed (X2) on dependent 
variables i.e. percentage mucoadhesion, t80, drug entrapment efficiency, particle 
size and swelling index. The best batch exhibited a high drug entrapment 
efficiency of 70 % and a swelling index of 1.39; percentage mucoadhesion after 
one h was 79 %. The drug release was also sustained for more than 12 h. The 
polymer-to-drug ratio had a more significant effect on the dependent variables. 
The morphological characteristics of the mucoadhesive microspheres were 
studied using scanning electron microscopy. In-vitro release test showed that 
amoxicillin released slightly faster in pH 1.0 hydrochloric acid than in pH 7.8 
phosphate buffer. In-vivo H. pylori clearance tests were also carried out by 
administering amoxicillin mucoadhesive microspheres and powder, to H. pylori 
infectious Wistar rats under fed conditions at single dose or multiple dose(s) in 
oral administration. The results showed that amoxicillin mucoadhesive 
microspheres had a better clearance effect than amoxicillin powder. In 
conclusion, the prolonged gastrointestinal residence time and enhanced 
amoxicillin stability resulting from the mucoadhesive microspheres of amoxicillin 
might make contribution complete eradication of H. pylori. 
Myung-Kwan Chun et al [33] prepared mucoadhesive microspheres to increase 
gastric residence time using an interpolymer complexation of poly(acrylic acid) 
(PAA) with poly(vinyl pyrrolidone) (PVP) and a solvent diffusion method. The 
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complexation between poly(acrylic acid) and poly(vinyl pyrrolidone) as a result of 
hydrogen bonding was confirmed by the shift in the carbonyl absorption bands of 
poly(acrylic acid) using FT-IR. A mixture of ethanol/water was used as the 
internal phase, corn oil was used as the external phase of emulsion, and span 80 
was used as the surfactant. Spherical microspheres were prepared and the 
inside of the microspheres was completely filled. The optimum solvent ratio of the 
internal phase (ethanol/water) was 8/2 and 7/3, and the particle size increased as 
the content of water was increased. The mean particle size increased with the 
increase in polymer concentration. The adhesive force of microspheres was 
equivalent to that of Carbopol. The release rate of acetaminophen from the 
complex microspheres was slower than the PVP microspheres at pH 2.0 and 6.8. 
B. Y. Choi et al [34] prepared floating beads from a sodium alginate solution 
containing CaCO3 or NaHCO3 as gas-forming agents. The solution was dropped 
to 1% CaCl2 solution containing 10% acetic acid for CO2 gas and gel formation. 
The effects of gas-forming agents on bead size and floating properties were 
investigated. As gas-forming agents increased, the size and floating properties 
increased. Bead porosity and volume average pore size, as well as the surface 
and cross-sectional morphology of the beads were examined with Mercury 
porosimetry and Scanning Electron Microscopy. NaHCO3 significantly increased 
porosity and pore diameter than CaCO3. Incorporation of CaCO3 into alginate 
solution resulted in smoother beads than those produced with NaHCO3. Gel 
strength analysis indicated that bead strength decreased with increasing gas-
forming agent from 9 to 4 N. Beads incorporating CaCO3 exhibited significantly 
increased gel strength over control and NaHCO3-containing samples. Release 
characteristics of riboflavin as a model drug were studied in-vitro. Release rate of 
riboflavin increased proportionally with addition of NaHCO3. However, increasing 
weight ratios of CaCO3 did not appreciably accelerate drug release. The results 
of these studies indicate that CaCO3 is superior to NaHCO3 as a gas forming 
agent in alginate bead preparations. The enhanced buoyancy and sustained 
release properties of CaCO3-containing beads make them an excellent candidate 
for floating drug dosage systems (FDDS). 
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Colombo et al [35] prepared swellable matrices by compression of a powdered 
mixture of a hydrophilic polymer and a drug. Their success is linked to the 
established tabletting technology of manufacturing. Swellable matrix DDS must 
be differentiated from true swelling-controlled delivery systems. This review 
focuses on hydrophilic swellable matrix tablets as controlled DDS. Gel-layer 
behaviour, front movement and release are described to show the dependence 
of the release kinetics on the swelling behaviour of the system. In-vivo behaviour 
of matrix systems is also considered. 
Alvaro et al [36] developed and characterized the delivery properties of swellable 
drug-polyelectrolyte matrices (SDPM). Solid complexes (C–D)X of carbomer (C) 
neutralized with different proportions of model basic drugs (D), in which D is 
atenolol, lidocaine, and metoclopramide, and X = 25, 50, 75 and 100 mol of D per 
100 equivalents of carboxylic groups of C, were prepared and characterized by 
DSC-TG, IR, and X-ray diffraction studies. Mechanistic studies with hydrophilic 
and hydrophobic basic drugs were conducted to explore the drug release 
patterns of SDPM. Besides, release and up-take studies were carried out in 
water and NaCl solution to examine the influence of ionic effects. The authors 
concluded that drugs can be loaded in a high proportion on to the polymer and 
therefore the resulting material could be diluted with other polymers to modulate 
delivery properties of SDPM. Matrices of atenolol and lidocaine exhibited robust 
delivery properties with regard to change in proportion of loading D. 
J. A. Raval and J. K. Patel [37] investigated the effects of formulation and 
processing parameters on a floating matrix controlled drug delivery system 
consisting of a poly (styrene-divinyl benzene) copolymer low density powder, a 
matrix-forming polymer(s), drug, and diluents (optional). The tablets were 
prepared by the direct compression technique, using hydrophilic matrix polymers 
HPMC K4M, HPMC K15M, HPMC K100M, sodium alginate, psyllum, sesbania 
gum, guar gum, and gum acacia, with or without low density copolymer. Tablets 
were physically characterized and evaluated for in-vitro release characteristics 
for 8 h in 0.1 mol/l HCl at 37°C. The effect of the addition of low density 
copolymer and the drug release pattern were also studied. The release rate was 
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modified by varying the type of matrix-forming polymer, the tablet geometry 
(radius), and the addition of water-soluble or water-insoluble diluents. At the 
same time, different concentrations of low-density copolymer were taken to 
examine any differences in the floating lag-time of the formulation. The in-vitro 
release mechanism was evaluated by kinetic modeling. The similarity factor, 
floating lag-time, and t50 and t90 were used as parameters for selection of the 
best batch. The tablet eroded/swelled upon contact with the release medium, and 
the relative importance of drug diffusion, polymer swelling and tablet erosion on 
the resulting release patterns varied significantly with the type of matrix forming 
polymer. The highly porous copolymer provided a low density and, thus, 
excellent in-vitro floating behavior of the tablets at a concentration of 15% (w/w). 
It was established that floating behavior of the low-density drug delivery systems 
could be successfully combined with accurate control and prolongation of the 
drug release patterns. 
Anand Kumar [38] studied preparation and evaluation of floating microspheres 
with cimetidine as model drug for prolongation of gastric residence time. The 
microspheres were prepared by the solvent evaporation method using polymers 
hydroxypropylmethyl cellulose and ethyl cellulose. The shape and surface 
morphology of prepared microspheres were characterized by optical and 
scanning electron microscopy, respectively. In-vitro drug release studies were 
performed and drug release kinetics was evaluated using the linear regression 
method. Effects of the stirring rate during preparation, polymer concentration, 
solvent composition and dissolution medium on the size of microspheres and 
drug release were also observed. The prepared microspheres exhibited 
prolonged drug release (8 hrs) and remained buoyant for > 10 hrs. The mean 
particle size increased and the drug release rate decreased at higher polymer 
concentration. No significant effect of the stirring rate during preparation on drug 
release was observed. In-vitro studies demonstrated diffusion-controlled drug 
release from the microspheres. 
Whitehead et al [39] prepared floating dosage forms of Amoxicillin based on 
alginate to exhibit prolong gastric residence time. A freeze-dried calcium alginate 
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multiple unit floating dosage form that demonstrated favorable in-vitro floating 
characteristics was developed.                                                                                                                                                                         
Ganguly S et al [40]developed a novel chitosan-glyceryl monooleate (GMO) in 
situ gel system for sustained drug delivery & targeting was developed. The 
delivery system consisted of 3 % (w/v) chitosan & 3 % (w/v) glyceryl monooleate  
in 0.33M citric acid. In situ gel was formed at a biological pH and in-vitro release 
studies were conducted in Sorensen’s phosphate buffer (pH 7.4). 
Characterization of the gel included the effect of cross-linker, determination of 
diffusion coefficient and water uptake by thermogravimetric analysis (TGA). 
Incorporation of a cross-linker (glutaraldehyde) retarded the rate and extent of 
drug release.  Drug release from the gel followed a matrix diffusion controlled 
mechanism.  
Kubo W et al [41] developed oral sustained delivery of paracetamol from in situ-
gelling gellan and sodium alginate formulations. The potential for the oral 
sustained delivery of paracetamol of two formulations with in situ gelling 
properties was evaluated. In-vitro studies demonstrated diffusion-controlled 
release of paracetamol from the gels over a period of six hrs. The bioavailability 
of paracetamol from the gels formed in situ in the stomachs of rabbits following 
oral administration of the liquid formulations was similar to that of a commercially 
available suspension containing an identical dose of paracetamol. 
Dairaku M et al [42] developed insitu gel using pectin.Gels formed in situ following 
oral administration of dilute aqueous solutions of pectin (1.0 and 1.5 %, w/v) 
containing calcium ions in complexed form to rats was evaluated as vehicles for 
the sustained release of the expectorant drug ambroxol hydrochloride. A 
bioavailability of approximately 64 % of that of a commercially available 
formulation was achieved from gels containing an identical dose of ambroxol 
formed in situ in the stomachs of rats, with appreciably lower peak plasma levels, 
diffusion controlled and sustained release of drug over a period of at least six hrs. 
The influence of added sorbitol (17 %, w/v) on the rheological and drug release 
properties of the formulations has been examined. 
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Fujiwara  et al [43] studied in situ gel from in-vitro and in-vivo release of 
paracetamol and ambroxol the influence of different polyhydric alcohols like 
xylitol, mannitol and sorbitol in different concentration of in situ gelling pectin 
formulations was examined. 2 % (w/v) pectin gels containing 10 % (w/v) sorbitol 
showed a sustained release of paracetamol and bioavailabilities of approximately 
90 % was seen. Sustained release of ambroxol with pectin concentrations of 1.5 
and 1 % (w/v) and a sorbitol concentration of 10 % (w/v) was seen. 
Peterson et al [44] developed insitu gelling alginates formulations as an 
alternative to incorporation of various excipients N4- alkoxy carbonyl cytosine 
derivatives possessing various physicochemical properties and cytosine 
regeneration rates was being examined to modify release rate and kinetics from 
in situ gelling alginate formulations. Release rate constants and square root of 
solubility showed a linear relationship for suspension. A zero order release of 
parent cytosine was observed from in situ gelling suspension and diffusion 
coefficients calculated was observed to be similar for suspension and solution.10 
Itoh K et al [45]compared the gelation and drug release characteristics of 
formulations of pectin with high (31%) and low (9%) degrees of methoxylation 
over a wide pH range (pH 1.2-5.0). Gelation of formulations of pectin with a 
degree of esterification of 9% (DE9) was observed over the pH range 2.5-5.0 in 
the presence of 1.6mM Ca (++), but was incomplete in formulations of pectin with 
a degree of esterification of 31% (DE31). A sustained release of ambroxol was 
observed following oral administration of pectin DE9 formulations to gastric-
acidity controlled rabbits at pH 5.5-5.7 and visual observation of the stomach 
contents of these rabbits confirmed in situ gelation of these formulations. 
Kunihiko Itoh et al [46] studied the influence of a variation of gastric pH & 
addition of a taste masking agent on gelation of pectin solutions and on in-
vitro/in-vivo release of acetaminophen from gels. Increase of pH above 2.5 and 
addition of 10% (w/v) D-sorbitol significantly affected ability of 1.5% (w/v) pectin 
solutions to form coherent gels in-vitro. Gelation of sorbitol-free formulations was 
observed at pH 1.2 and in-vitro release of acetaminophen from gel followed 
diffusion-controlled kinetics; in-vitro gelation was incomplete at pH 3.0 resulting in 
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poor sustained release characteristics. While D-sorbitol inhibited in-vitro gelation 
& noted poor sustained release properties.  
Oi H et al [47] developed a thermosensitive in situ gelling and mucoadhesive 
ophthalmic drug delivery system containing puerarin based on poloxamer 
analogs (21% (w/v) poloxamer 407/5% (w/v) poloxamer 188) and carbopol (0.1% 
(w/v) or 0.2% (w/v) carbopol 1342P NF). The combined solutions would convert 
to firm gels under physiological condition and attach to the ocular mucosal 
surface for a relative long time. In-vitro release studies demonstrated diffusion-
controlled release of puerarin from the combined solutions over a period of 8 hrs. 
In-vivo evaluation indicated the combined solutions had better ability to retain 
drug than poloxamer analogs or carbopol alone. 
Kashyap et al [48] developed biodegradable glucose-sensitive in situ gelling 
system based on chitosan for pulsatile delivery of insulin was developed. The 
sols/gels were thoroughly characterized for swelling properties, rheology, texture 
analysis and water content. Insulin load onto the gels was optimized and was 
found to affect the rheological behavior of these gels, the final preparation used 
for in-vitro contained 1IU/200mul of the sol. These gels released the entrapped 
insulin in a pulsatile manner in response to the glucose concentration in-vitro. 
The formulations also evaluated for their in-vivo efficacy in streptozotocin-
induced diabetic rats at a dose of 3IU/kg. 
Escobar-Chavez JJ et al [49] developed insitu gel by using Pluronic F-127 PF-
127The use of high viscosity hydromiscible vehicles such as hydrophilic gels, is 
one of various approaches for controlled drug delivery, and represents an 
important area of pharmaceutical research and development. Of these systems, 
PF-127 provides the pharmacist with an excellent drug delivery system for a 
number of routes of administration and is compatible with many different 
substances. Gels containing penetration enhancers have proven to be especially 
popular for administering anti-inflammatory medications since they are relatively 
easy to prepare & very efficacious. 
Voorspoels et al [50]  studied treatment of bacterial vaginosis with a single 
application of 100 mg metronidazole in a bioadhesive vaginal tablet was found to 
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be a valid alternative. Further research in relation to tablet shaping and optimal 
dose finding might increase the cure rate. 
Smart  [51] developed in-vitro method for the assessment of the adhesive force 
[i.e. the force required to break an adhesive bond] between a disc of test material 
and a model mucous membrane. This system showed reasonable reproducibility 
and produced data in agreement with previous studies. Some factors influencing 
the adhesive force were assessed and only increasing the rate of application of 
the tensile force was found to have a significant effect. Some putative mucosa- 
adhesive formulations were evaluated and some buccal tablets found to have 
minimal adhesive properties. It was concluded that only a small force is required 
to retain a dosage form within the buccal cavity. The stability of the adhesive 
bond was assessed for the two most adhesive materials {poly [acrylic acids] 
carbopol-934P and EX55} by subjecting to a continuous stress for 8 hrs prior to 
measuring the adhesive force. The carbopol EX55 [polycarbophil] formed the 
most stable adhesive bond which remained intact for 8 hrs.  
Han-Gon et al [52]  studied the release and bioavailability of omeprazole 
delivered by buccal adhesive tablets composed of sodium alginate, 
hydroxypropyl methylcellulose [HPMC], magnesium oxide and cross-carmellose 
sodium. Cross-carmellose sodium enhanced the release of omeprazole from the 
tablets. The tablet was composed of omeprazole, sodium alginate, HPMC, 
magnesium-oxide, cross-carmellose sodium [20:24:6:50:10 mg]. It may be 
attached to the human cheek without collapse and it enhanced the stability of 
omeprazole in human saliva for at least 4 hrs giving a fast release of omeprazole.  
Results demonstrate that the omeprazole buccal adhesive tablet would be useful 
to deliver omeprazole which degrades very rapidly in acidic aqueous medium 
and undergoes hepatic first-pass metabolism after oral administration.  
Codd et al [53] developed two novel antifungal bioadhesive lozenges. Both were 
two-layered with an upper modified-release drug containing layer and a lower 
bioadhesive layer composed of drum-dried waxy maize starch and carbopol-
980P to facilitate application to the oral mucosa. The first type of lozenge 
contained miconazole nitrate as a spray-dried form containing acacia and 
Chapter 2 
                                                                                                Review of work done 
J.R.Chavda                                                                                           PhD. Thesis 81 
cremophor-RH40 to increase the dissolution of the poorly soluble azole, plus 
flavorings. The second type also contained chlorhexidine acetate in the drug 
layer, as both drugs had been reported to act synergistically. In comparison to a 
proprietary oral gel formulation, the new bioadhesive lozenges produced much 
more uniform and effective salivary levels of miconazole nitrate over a prolonged 
period. 
Prudat-Christiaens et al [54] studied the bioadhesive systems are new delivery 
systems used to reduce bioavailability problems resulting from a too short stay of 
the pharmaceutical form at the activity or absorption site. Aminophylline 
bioadhesive tablets were made by wet granulation with different polymers: 
Carbomers-934P, 974P, EX55, sodium carmellose, hypromellose and 
hydroxypropyl cellulose [HPC]. Wet granulation is a limiting factor for 
bioadhesion. The combination of polyacrylic acids with hypromellose or sodium 
carmellose increases bioadhesion and decreases drug release. Carbomer-974P 
alone had a lower adhesion than carbomer-934P. Combinations of  carbomer-
934P/hypromellose-100 gave the best adhesion properties and slow release 
dissolution.  
Hosny et al [55] prepared polycarbophil containing diclofenac sodium tablets 
using two different size of granules. The granules were obtained by evaporation 
under reduced pressure of polycarbophil particles loaded with alcoholic solution 
of the drug. The in-vitro release of these bioadhesive containing tablets was 
evaluated together with that of Ciba-Geigy commercially available enteric coated 
tablets ‘Voltaren’ in simulated gastric fluid for 2 hrs followed by another 2 hrs in 
simulated intestinal fluid.  
Bouckaert et al [56] studied the use of a bioadhesive buccal tablet containing 
miconazole nitrate has been shown to be effective in the treatment of oral 
candidosis and the influence of the application site on the buccal levels of 
miconazole nitrate. The tmax the adhesion time and T>MIC were significantly higher 
[P < 0.05] when the gingiva was chosen as the application site in comparison 
with the cheek. The Cmax, tmax and AUC were not significantly different. The 
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gingiva is the application site of choice in irradiated patients even with a 
decreased salivary flow.  
Mumtaz et al [57] prepared bioadhesive buccal tablets from different ratios of 
poly[acrylic acid-2,5-dimethyl-1,5-hexadiene] [PADH] and HPMC with and 
without triamcinolone acetonide [TAA] has been investigated in the buccal 
cavities of healthy human volunteers. The results indicate that tablets with a 
higher ratio of PADH swell faster, causing the disintegration of the tablets and 
consequently give rise to more rapid release of drug. The inclusion of higher 
percentages of HPMC provides more prolonged release of drug through its 
properties of gelling and slow dissolution. However, adhesion of the tablet was 
reduced in the excessive flow of saliva and there was also a tendency for the 
tablet to be dislodged from the mucosa. The tablet with a PADH/HPMC ratio of 
50:50 seems to provide a suitable compromise for good bioadhesion and 
prolonged release of drug. 
Woolfson et al [58] prepared novel bioadhesive cervical patch drug delivery 
containing 5-fluorouracil for the treatment of cervical intraepithelial neoplasia 
[CIN]. The patch was of bilaminar design; with a drug-loaded bioadhesive film 
cast from a gel containing 2% [w/w] carbopol-981P plasticized with 1% [w/w] 
glycerin. The casting solvent was ethanol/water 30:70, chosen to give a non-   
fissuring film with an even particle size distribution. Bioadhesive strength was 
independent of drug loading in the bioadhesive matrix over the range 
investigated but was influenced by both the plasticizer concentration in the 
casting gel and the thickness of the final film. Release of 5-fluorouracil from the 
bioadhesive layer into an aqueous sink was rapid but was controlled down to an 
undetectable level through the backing layer.  
Miyazaki et al [59] prepared oral mucosal bioadhesive tablets of diltiazem by 
directly compressing the drug with a mixture of chitosan and sodium alginate. In-
vitro adhesion studies indicated adhesion properties comparable to those of a 
commercial formulation. In-vitro release of diltiazem was rapid and could be 
modified by changing the mixing ratio of chitosan and sodium alginate; increasing 
the chitosan content in the tablets and/or the viscosity grade of the alginate 
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resulted in a decrease in the in-vitro release rate. The bioavailability of diltiazem 
was 69.6% from tablets with a 1:4 chitosan/alginate weight ratio when 
administered sublingually to rabbits compared with 30.4% by oral administration.  
Needleman et al [60] examined the factors important to prolonged adhesion 
[adhesion time] in organ culture under standardized conditions. A wide variety of 
bioadhesive were tested in the model and the effect of mucin was also examined. 
Whilst many gels adhered for 1–5 hrs, others [chitosan and eudispert] showed no 
retention loss over 4 days. Histologically, chitosan also showed excellent tissue 
wetting properties. For most materials, however, mucin significantly reduced 
adhesion times [P < 0.05]. In conclusion, the absence of mucin, the control of gel 
hydration and swelling, and wetting characteristics were identified as key factors 
for prolonged adhesion.  
Wen-Gang et al [61] prepared direct compressed disc systems containing either 
10, 15 or 20 mg of propranolol hydrochloride [PL] with a mixture of 
hydroxypropylcellulose and poly[acrylic acid]. The release data were fitted to the 
simple power equation and it was found that the release characteristics of PL 
from these systems were not affected by the amounts of the drug loaded and 
followed behavior conforming to a non-Fickian mechanism of release. The 
adhesive bond strength of the systems to the porcine buccal mucosa was 
evaluated by the tensile strength test and the result showed no significant 
difference in adhesive bond strength to the porcine buccal mucosa among the 
three PL-containing discs and drug free discs. 
Naffie et al [62] investigated different types of mucoadhesive polymers, intended 
for buccal tablet formulation, for their comparative mucoadhesive force, swelling 
behavior, residence time and surface pH. The selected polymers were carbopols 
[CP-934 and CP-940], polycarbophil [PC], sodiumcarboxymethylcellulose 
[NaCMC] and pectin representing the anionic type, while chitosan as cationic 
polymer and hydroxypropylmethyl cellulose [HPMC] as a non-ionic polymer. 
Results revealed that polyacrylic acid derivatives [PAA] showed the highest 
bioadhesion force, prolonged residence time and high surface acidity. NaCMC 
and chitosan ensured promising bioadhesive characteristics, while HPMC and 
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pectin exhibited weaker bioadhesion. Different polymer combinations as well as 
formulations were evaluated to improve the mucoadhesive performance of the 
tablets. Bioadhesive tablet formulations containing either 5% CP934, 65% HPMC 
and 30% spray-dried lactose or 2% PC, 68% HPMC and 30% mannitol showed 
optimum mucoadhesion and suitable residence time. NaCMC, when formulated 
individually, exhibited promising bioadhesion, acceptable swelling, convenient 
residence time and surface pH. In-vivo trials of these formulations proved non-
irritative and prolonged residence of the mucoadhesive tablets on human buccal 
mucosa for 8 to 13 hrs. 
Naffie et al [63] studied from the previous work [Part-I62], mucoadhesive formulae 
containing 5% CP/65% HPMC/30% lactose and 2% PC/68% HPMC/30% 
mannitol as well as formulae based on sodium carboxymethylcellulose [NaCMC] 
were selected. Medicated tablets were prepared using diltiazem hydrochloride 
and metclopramide hydrochloride in two different doses [30 and 60 mg]. The 
effect of drug and dose on the mucoadhesive properties and in-vitro drug release 
was evaluated. All formulae produced extended drug release [over 8 to 12 hrs]. 
Doubling the dose significantly reduced the bioadhesion strength [p < 0.05] with a 
slight improvement in drug release rate. The formulation of bilayer tablets 
containing drug-free layer and medicated layer enhanced the drug release 
without affecting the bioadhesive performance. The bilayer tablet formulated with 
2% PC/68% HPMC/30% mannitol was selected for studying the in-vivo 
metoclopramide release in four healthy volunteers. The tablet ensured controlled 
drug release for 12 hrs, in addition, good correlation [r = 0.9398] was observed 
between in-vitro and in-vivo data. Storage at 40°C and 75% relative humidity for 
6 months didn't influence the mucoadhesive performance, however, an enhanced 
released rate was observed. 
Shan-chul et al [64] developed the new local anesthetic formulations with a 
suitable bioadhesive property, hydroxypropylmethylcellulose based gel was 
formulated. The effects of permeation enhancers on the permeation rate of drug 
through skin were studied using various enhancers, such as the glycols, the 
nonionic surfactants, and the bile salts. Among the enhancers used, 
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polyoxyethylene 2-oleyl ether showed the highest enhancing effects on drug 
permeation through skin. The analgesic activity was examined using a tail-flick 
analgesimeter. 
Chowdary et al [65] prepared mucoadhesive tablets with nifedipine alone and its 
inclusion complexes with β-cyclodextrin and the mucoadhesive polymers sodium 
carboxy methyl cellulose and carbopol were investigated with a view to the 
design of oral controlled release tablets of nifedipine.  
Raghuraman et al [66] prepared propranolol hydrochloride buccal films using 
three different polymers in various proportions and combinations. The 
physiochemical parameters like weight variation, thickness, folding endurance, 
drug content, percentage moisture absorption and percentage moisture loss 
were evaluated.    
Perioli et al [67] prepared mucoadhesive tablets using different mixture of 
cellulose and polyacrylic derivatives in order to obtain new formulations 
containing metronidazole for periodontal disease treatment. 
Patil et al [68] prepared mucoadhesive buccal patches of diclofenac sodium. 
Patches were fabricated by casting technique with different polymer 
combinations. 
Khurana et al [69] prepared mucoadhesive films of miconazole nitrate for the 
treatment of oral candidosis. Films were fabricated by casting technique with 
different polymer combinations and were evaluated for their in-vitro bioadhesive 
performance and release characteristics. 
Nafee et al [70] prepared mucoadhesive patches containing 10 mg miconazole 
nitrate with ionic polymers, sodiumcarboxymethylcellulose and chitosan or non-
ionic polymers polyvinyl alcohol, hydroxyethylcellulose and hydroxypropylmethyl 
cellulose.  
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3.1 Materials used in the present investigation  
 
Amoxicillin (powder) : Zydus Cadila, Ahmedabad. 
Chitosan (degree of 
deacetylation of 85%; 
intrinsic viscosity, 1390 mL/g 
in 0.30 M acetic acid and 
viscometric molecular 
weight, 4.08 × 105 Da)              
: Central Institute of Fisheries Technology,           
  Cochin. 
Skirrow’s medium : Himedia Ltd. Mumbai, India. 
Petroleum ether 80:20             : S. D. Fine Chemicals Ltd., Mumbai. 
Liquid paraffin                        : Loba Chemie Pvt. Ltd., Mumbai. 
Citric acid  : Merck, Germany. 
Hydrochloride acid                 : Qualigen Chemicals, India. 
Acetic acid                              : S. D. Fine Chemicals Ltd., Mumbai. 
Glipizide : USV Ltd., Daman, India. 
Sodium bicarbonate  : Merck, Germany. 
Famotidine   : Torrent Pharmaceuticals Pvt. Ltd Chhatral,  
  India. 
Sodium hydroxide : Loba Chemie Pvt. Ltd., Mumbai, India. 
Alginate  
Sodium citrate 
: Sigma Chemicals Ltd, New Delhi, India. 
: Sigma Chemicals Ltd, New Delhi, India. 
Calcium chloride   : Muby Chemicals, Mumbai, India. 
Carbopol-934P (CP)  
(CP, molecular weight [MW] 
3 × 106 Da) 
: Noveon® Mumbai, India. 
Hydroxypropyl methyl 
cellulose-K4M (HPMC) 
: Zydus Research Center, Ahmedabad, India. 
Polymethacrylic acid (PMA) : Zydus Cadila. Ahmedabad, India. 
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3.2 Instruments used in the present investigation 
 
UV Spectrophotometer : Shimadzu UV-1601 UV/Vis double beam    
  Spectrophotometer (Kyoto, Japan). 
Stirrer : Propeller Stirrer (Remi, Mumbai, India). 
Dissolution test 
apparatus 
: Dissolution test apparatus-TDT-06T (Electrolab,  
  Mumbai, India). 
Microscope : Optical microscope (Labomed CX RIII, Ambala,  
  India). 
Scanning electron 
microscope 
: Scanning electron microscope (JSM 5610 LV  
  SEM, JEOL, Datum Ltd, Tokyo, Japan). 
pH meter 
Sigma plot version 10.0  
 
 
Tablet compression 
machine      
 
: Systronic, 335 pH meter. 
: Sigma plot software, Jangel Scientific Software,  
  San Rafael, CA. 
: Multipunch tablet compression machine  
  (Cadmach Machinery Co. Pvt. Ltd., Ahmedabad,  
  India). 
Tablet-disintegrating 
tester 
: USP tablet-disintegrating tester. 
 
: Modified analytical balance.  Balance 
Thermogravimetric 
Analyzer  
: TGA-50, Shimadzu, Kyoto, Japan. 
Brookfield viscometer  : Model no RVT 81990 
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3.3 Animals 
 
Six-week-old mixed sexes specific pathogen free Wistar rats (Body weight 
200-250 gm) were gifted from Torrent Research Center (Ahmedabad, India) 
and maintained under standard laboratory conditions (room temperature, 
23°±2°C; relative humidity, 55±5%; 12/12 hrs light/dark cycle) with free access 
to a commercial rodent diet and tap water. 
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4.1 Aim of present investigation  
Microsphere carrier systems made from the naturally occurring biodegradable 
polymers have attracted considerable attention for several years in sustained 
drug delivery. Recently, dosage forms that can precisely control the release rates 
and target drugs to a specific body site have made an enormous impact in the 
formulation and development of novel drug delivery systems. Microspheres form 
an important part of such novel drug delivery systems 1-3. They have varied 
applications and are prepared using assorted polymers 4. However, the success 
of these microspheres is limited owing to their short residence time at the site of 
absorption. It would, therefore, be advantageous to have means for providing an 
intimate contact of the drug delivery system with the absorbing membranes 5-8. 
This can be achieved by coupling mucoadhesion characteristics to microspheres 
and developing mucoadhesive microspheres. Mucoadhesive microspheres have 
advantages such as efficient absorption and enhanced bioavailability of drugs 
owing to a high surface-to-volume ratio, a much more intimate contact with the 
mucus layer, and specific targeting of drugs to the absorption site 9-12. Carbopol-
934P (acrylic acid homopolymer) is anionic polymer that has been used in 
mucoadhesive systems by a several researchers 13-17. Carbopol-934P was 
selected as a polymer in the preparation of mucoadhesive microspheres because 
of its good mucoadhesive and biodegradable properties and ethyl cellulose as 
carrier polymer for microspheres.  
In a relatively short time span, Helicobacter pylori (H. pylori) have become 
recognized as a major gastric pathogen with worldwide distribution. H. pylori are 
a spiral-shaped bacterium found in the stomach, which (along with acid 
secretion) damages stomach and duodenal tissue, causing inflammation and 
peptic ulcers. H. pylori, a prevalent human-specific pathogen, is a causative 
agent in chronic active gastritis18, gastric and duodenal ulcers19, and gastric 
adenocarcinoma20, one of the most common forms of cancer in humans. 
Epidemiological, laboratory, and interventional human studies strongly suggest 
that H. pylori play a pathogenic role in the development of adenocarcinoma of the 
distal stomach 21. The mechanisms by which H. pylori may cause gastroduodenal 
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disease and contribute to gastric carcinogenesis are still hypothetical. However, 
the production of specific virulence factors by the bacterium, the inflammatory 
response of the host, and the association with environmental contributors may all 
be responsible 22. 
Treatment regimens for H. pylori infection have been evolving since the early 
1990s, when monotherapy was first recommended. Antimicrobial therapy for this 
infection is a complex issue, and the following drugs are currently used in 
combination regimens: proton-pump inhibitors and/or bismuth, metronidazole, 
clarithromycin, and amoxicillin 23. Tetracycline is used in the rescue therapy 24. 
Although optimal first-line treatment is associated with high cure rates, the rising 
prevalence of resistance to the antibiotic component of current eradication 
regimens increasingly threatens to compromise the efficacy of these regimens. 
Strains resistant to metronidazole 25 and clarithromycin 26 have been well 
documented, while resistance to amoxicillin 27 and tetracycline was mainly 
reported in Asia 28. Therapeutic regimens directed against H. pylori infection will 
continue to evolve. What is required is a simpler and more efficacious strategy 
for the treatment of H. pylori infection. H. pylori is susceptible to many antibiotics 
in-vitro but has proved difficult to eradicate (to root out) in-vivo. 
Amoxicillin (α-amino-hydroxybenzylpenicillin) is a semi-synthetic, orally 
absorbed, board-spectrum antibiotic. It is now widely used in the standard 
eradication treatment of gastric and duodenal ulcers, which are associated with 
H. pylori infection combined with a second antibiotics and an acid-suppressing 
agent 29-31. These tripe therapies are proved to be effective in clinical application. 
However, some other reports and clinical trials indicate that the therapies cannot 
bring out compete eradication of H. pylori and suggest that the therapeutic effect 
needs more investigation 32-33. One reason for the incomplete eradication of H. 
pylori is probably due to short residence time of dosage form in the stomach so 
that effective antimicrobial concentration cannot be achieved in gastric mucous 
layer or epithelial cell surfaces where H. pylori exist 34-35. The other may be the 
degradation of amoxicillin in gastric acid 36-37. Therefore, some researchers had 
prepared and reported new amoxicillin formulations such as float tablets, 
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mucoadhesive tablets, pH-sensitive excipients composition microspheres, etc., 
which were able to reside in the gastrointestinal tract for an extended period of 
time for a more effective H. pylori eradication 38-39. In our previous investigation 
on H. pylori clearance effect showed that there was tendency for a more effective 
H. pylori activity of mucoadhesive amoxicillin microspheres prepared using 
chitosan as mucoadhesive microspheres 40.   
In context of the above principles, a strong need was felt to develop a dosage 
form that delivered amoxicillin in the stomach and would increase the efficiency 
of the drug, providing sustains action. Thus, an attempt was made in the present 
investigation to use carbopol-934P as mucoadhesive polymer and ethyl cellulose 
as carrier polymer and prepare mucoadhesive amoxicillin microspheres. The 
microspheres were characterized by in-vitro and iv-vivo tests and factorial design 
was used to optimize the variables.        
 
It is our intention to develop mucoadhesive microspheres that:  
1. Adhere to the stomach mucosa for prolonged period of time. 
2. Provide an increased gastric residence time resulting in prolonged drug 
delivery in gastrointestinal tract. 
3. Delivers a drug at a controlled rate over a period of time, which is same 
as or less than the residency period of the delivery system in the 
gastrointestinal tract.  
4. Shows better in-vivo performances than conventional dosage forms.  
In context to above intention, following criteria were aimed to achieve:  
1. Microspheres should be discrete, spherical and free flowing. 
2. Mucoadhesion time of microspheres should be more than 8 hrs. 
3. Drug entrapment should be more than 50 %. 
4. More than 90 % of drug should be released within 10 hrs.  
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4.2 Experimental 
4.2.1 Preparation of standard calibration curve of amoxicillin   
Amoxicillin (10 mg) was dissolved in 0.1 N HCl and volume was made up to 100 
mL in 100 mL volumetric flask. This solution (100 mcg/mL) was further diluted 
with 0.1 N HCl to obtain solution of 5 to 40 mcg/mL. Absorbance of each solution 
was measured at 228 nm using Shimadzu UV-1601 UV/Vis double beam 
spectrophotometer and 0.1 N HCl as reference standard. The standard curve 
was generated for the entire range from 5 to 40 mcg /mL. The results of standard 
curve preparation are shown in the Table 4.1 and Figure 4.1.  
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Table 4.1: Standard calibration curve of amoxicillin in 0.1 N HCl 
Sr. 
No. 
Concentration 
(µg/mL) 
Absorbance Average 
Absorbance 
Calculated 
absorbance 1 2 3 
1 0 0 0 0 0 -0.0012 
2 5 0.110 0.109 0.111 0.110 0.1073 
3 10 0.227 0.228 0.226 0.227 0.2158 
4 15 0.316 0.314 0.312 0.314 0.3243 
5 20 0.419 0.419 0.419 0.419 0.4328 
6 25 0.531 0.530 0.529 0.530 0.5413 
7 30 0.660 0.659 0.659 0.659 0.6498 
8 35 0.770 0.770 0.770 0.770 0.7583 
9 40 0.860 0.859 0.861 0.860 0.8668 
Correlation Co-efficient : 0.9988 
Absorbance= 0.0217x - 0.0012 
 
 
 
Figure 4.1: Standard calibration curve of amoxicillin in 0.1 N HCl 
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4.2.2 Preparation of mucoadhesive amoxicillin microspheres 
Mucoadhesive microspheres of amoxicillin were prepared containing carbopol-
934P as mucoadhesive polymer and ethyl cellulose as carrier polymer by 
emulsion-solvent evaporation technique. Briefly, ethyl cellulose (1500 mg) was 
dissolved in 200 mL of ethanol. Each five hundred milligrams of amoxicillin and 
carbopol-934P were dispersed in the polymer solution of ethyl cellulose under 
stirring. In preliminary trail batches the drug-to-polymer-to-polymer (amoxicillin-
ethyl cellulose-carbopol-934P) ratio was kept constant at 1:3:1.  The resultant 
mixture was extruded through a syringe (gauge No. 20) in 500 mL of liquid 
paraffin (mixture of heavy and light, 1:1 ratio) containing 2.0 % v/v Span 80 and 
stirring was carried out using a propeller stirrer (Remi, Mumbai, India) at 1000 
rpm. Stirring was continued for three hrs. The amount of emulsifying agent and 
time for stirring were varied in preliminary trial batches from 1 to 3 % v/v and 1 to 
3 hrs respectively. In factorial design batches J1 to J9, 2.0 % v/v Span 80 was 
used as an emulsifying agent and time for stirring was kept to 3 hrs. The drug-to-
polymer-to-polymer ratio and stirring speed were varied in batches J1 to J9 as 
shown in Table 4.2. All other variables were similar as per in preliminary trial 
batches. Microspheres thus, obtained were filtered and washed several times 
with petroleum ether (80:20) to remove traces of oil. The microspheres were then 
dried at room temperature (25oC and 60 % RH) for 24 hrs. The effect of 
formulation variables on characteristics of the microspheres of factorial design 
batches is summarized in Table 4.2. 
4.2.3 Optimization of microspheres formulation using 32 full factorial design 
A statistical model incorporating interactive and polynomial terms was utilized to 
evaluate the responses.  
 
       Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X12 + b22 X22                                      [4.1] 
 
Where, Y is the dependent variable, b0 is the arithmetic mean response of the 
nine runs, and bi is the estimated coefficient for the factor Xi. The main effects (X1 
and X2) represent the average result of changing one factor at a time from its low 
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to high value. The interaction terms (X1X2) show how the response changes 
when two factors are simultaneously changed. The polynomial terms (X12 and 
X22) are included to investigate non-linearity. On the basis of the preliminary trials 
a 32 full factorial design was employed to study the effect of independent 
variables i.e. drug-to-polymer-to-polymer (X1) and the stirring speed (X2) on 
dependent variables % mucoadhesion, drug entrapment efficiency, particle size 
and the time required for 80% drug dissolution (t80).   
4.2.4 Drug entrapment efficiency 
Two hundred milligrams of accurately weighed microspheres were crushed in a 
glass mortar-pestle and the powdered microspheres were suspended in 10 mL 
phosphate buffer (pH 7.8). After 24 hrs the solution was filtered and the filtrate 
was analysed for the drug content. The drug entrapment efficiency was 
calculated using the following formula: Practical drug content/Theoretical drug 
content × 100. The drug entrapment efficiency for batches J1 to J9 is reported in 
Table 4.2. 
4.2.5 Particle size of microspheres 
The particle size of the microspheres was determined by using optical 
microscopy method 41. Approximately 300 microspheres were counted for particle 
size using a calibrated optical microscope (Labomed CX RIII, Ambala, India). 
The particle size of microspheres of batches J1 to J9 is reported in Table 4.2.  
4.2.6 In-vitro wash-off test for microspheres 
The mucoadhesive properties of the microspheres were evaluated by in-vitro 
wash-off test as reported by Lehr et al 42. A 1x1 cm piece of rat stomach mucosa 
was tied onto a glass slide (-3 inch-by-1inch-) using thread. Microspheres were 
spread (~50) onto the wet rinsed tissue specimen and the prepared slide was 
hung onto one of the groves of a USP tablet disintegrating test apparatus with 
continuous oxygen supply. The disintegrating test apparatus was operated 
whereby the tissue specimen was given regular up and down movements in the 
beaker of the disintegration apparatus, which contained the gastric fluid (pH 1.2). 
At the end of 30 min, 1 hr and at hourly intervals upto 12 hrs, the number of 
microspheres still adhering onto the tissue was counted. The results of in-vitro 
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wash-off test after 1, 5 and 10 hrs of batches J1 to J9 are shown in Table 4.2. 
Also results of in-vitro wash-off test of amoxicillin loaded carbopol-934P 
mucoadhesive microspheres of batch J4 is shown in Figure 4.2. 
4.2.7 Scanning electron microscopy 
Scanning electron photomicrographs of drug-loaded carbopol-934P 
mucoadhesive microspheres were taken. A small amount of microspheres was 
spread on glass stub. Afterwards, the stub containing the sample was placed in 
the scanning electron microscope (JSM 5610 LV SEM, JEOL, Datum Ltd, Tokyo, 
Japan) chamber. Scanning electron photomicrograph was taken at the 
acceleration voltage of 20 KV, chamber pressure of 0.6 mm Hg, at different 
magnification. The photomicrograph of batch J4 is depicted in Figure 4.3.  
The photomicrograph of in-vitro wash-off test results after 2 hrs and 8 hrs are 
depicted in Figure 4.4 and Figure 4.5, respectively. 
4.2.8 Drug release study 
The drug release study was carried out using USP XXIV basket apparatus 
(Electrolab, TDT-06T, India) at 37°C±0.5°C and at 100 rpm using 900 mL of 
phosphate buffer (pH 7.8) as a dissolution medium (n=5) as per USP XXVI 
dissolution test prescribed for amoxicillin tablets. Microspheres equivalent to 100 
mg of amoxicillin were used for the test. Five milliliters of sample solution was 
withdrawn at predetermined time intervals, filtered through a 0.45 µm membrane 
filter, diluted suitably, and analyzed spectrophotometrically. An equal amount of 
fresh dissolution medium was replaced immediately after withdrawal of the test 
sample. Percentage drug dissolved at different time intervals was calculated 
using the Lambert-Beer’s equation. The t80 was calculated using the Weibull 
equation43. The average values of t80 for batches J1 to J9 are mentioned in Table 
4.2. The percentage drug release of batch J4 in pH 1.2 and pH 7.8 is shown in 
Table 4.3 and Figure 4.6.  
4.2.9 Data fitting  
An attempt was made to fit the dissolution data into the Hixon-Crowell 43 model 
represented:  
m = [(100) * (1/3) – k * t] 3                                                                                             [4.2] 
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Where, k is Hixon-Crowell constant [mass/ (time)] 1/3. In this model the % drug 
unreleased versus cube root of time is linear. 
The data was treated with the Korsmeyer-Peppas model 44 to characterize the 
mechanism of drug release: 
 
          Mt / M∝ = Kptn                                                                                   [4.3] 
 
Mt/M∝ represents the fraction of drug released at time t and Kp is the kinetic 
constant characterizing the polymeric system and n stands for the diffusion 
exponent. 
The dissolution data was also analyzed using the Weibull equation43 to determine 
the kinetics of drug release from different batches of mucoadhesive 
microspheres: 
m = 1- exp [-(t-ti ) b/a]                                                                  [4.4] 
 
Where, ‘a’ is the scale parameter which defines the time scale of the process, ‘ti’ 
is location parameter which represents the lag period before the actual onset of 
dissolution process (in most cases ti = 0) and ‘b’ is the shape parameter. In this 
model the plot of log of time vs- In (1-m) is linear. 
The results of F-statistics were used for the selection of the most appropriate 
model. Results of F-statistics and summary of results of regression analysis are 
shown in Tables 4.4 and 4.5, respectively. 
The curve fitting, simulation and plotting was performed in Excel (Microsoft 
Software Inc., USA) and Sigma plot® version 10.0 (Sigma plot soft ware, Jangel 
Scientific Software, San Rafael, CA). The effects of independent variables on the 
response parameters were visualized from the contour plots. Numerical 
optimization using the desirability approach was employed to locate the optimal 
settings of the formulation variables so as to obtain the desired response 45. An 
optimized formulation was developed by setting constraints on the dependent 
and independent variables. The formulation developed was evaluated for the 
responses and the experimental values obtained were compared with those 
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predicted by the mathematical models generated. Counter plot showing the effect 
of drug-polymer-polymer ratio (X1) and stirring speed (X2) on: % mucoadhesion, 
particle size, drug entrapment efficiency and t80 in Figure 4.7.  
4.2.10 In-vivo clearance of H. pylori 
The H. pylori infected animal model was established according to Qian’s method 
(China Patent, CN 1304729A). Briefly, 0.3 mL of broth containing 109 CFU/mL of 
H. pylori, isolated from patients with gastritis and gastric ulcer, was inoculated 
into the stomachs of 6-week-old male Wistar rats. Then, the rats were fed for 4 
weeks. H. pylori infection in rat was detected using the “golden standard” culture, 
W-S stain and rapid urease test etc. The rapid urease test was carried out by 
collecting and transferring the bacterial colonies into small tubes containing 0.5 
mL of mixture of phosphate buffer, urea (2% w/v) and phenol red (0.03% v/v). If 
the solution color turned into red in several minutes, the urease test was 
regarded to be positive, which indicated presence of H. pylori. While if the 
solution color did not turn red in several minutes, the urease test was regarded to 
be negative, this indicated absence of H. pylori. 
4.2.10.1 Single-dosage administration  
To determine the dose for H. pylori clearance, mucoadhesive amoxicillin 
microspheres and amoxicillin powder were orally administered to the H. pylori 
infected rats at the dosages of 4.0, 7.5 and 15 mg/kg (n=2). Physiological saline 
was given to rats as control (n=2). One day after administration of drug to the H. 
pylori infectious rats, they were killed, and their stomachs were removed and cut. 
Then, the gastric tissue was daubed on the modified Skirrow’s medium. The 
plates were incubated for 3 days at 37 oC under microaerobic conditions. H. 
pylori clearance effect was judged by both bacterial colony counts and rapid 
urease test. The rapid urease test was carried out by collecting and transferring 
the bacterial colonies into small tubes containing 0.5 mL of mixture of phosphate 
buffer, urea (2% w/v) and phenol red (0.03% v/v). If the solution color turned into 
red in several minutes, the urease test was regarded to be positive, which 
indicated for H. pylori detection. H .pylori clearance effect of amoxicillin at 
different doses in different formulations (n=2) are shown in Tables 4.6 and 4.7. 
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4.2.10.2 Multidose administration  
To determine whether the mucoadhesive amoxicillin microspheres could 
completely eradicate H. pylori, a multidose administration therapy was carried 
out. Briefly, amoxicillin was orally administrated twice a day for three days at a 
dose of 3.5 mg/kg in the form of either amoxicillin mucoadhesive microspheres or 
powder (n=2). Physiological saline was given to rat as control (n=2). One day 
after administration the H. pylori infectious rats were killed, and their stomachs 
were removed and cut. Then, the gastric tissue was daubed on the modified 
Skirrow’s medium. H. pylori clearance effect was studied using the same method 
as described for single doge administration. H .pylori clearance effect of 
amoxicillin at different doses in different formulations is shown in Figure 4.8.   
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Table 4.2: Amoxicillin mucoadhesive microspheres batches using 32 full 
factorial design layout 
Batch 
code 
Variable 
levels in 
coded from 
In-vitro wash-off 
test  (% 
mucoadhesion 
after ) 
Drug 
entrapment 
efficiency 
(%) 
Particle 
size  
(µm) 
t80 
(min) 
X1 X2 
1 h 5 h 10 h 
J1 -1 -1 57 50 45 26 99 592 
J2 -1 0 55 49 44 21 93 645 
J3 -1 1 40 35 29 20 86 727 
J4 0 -1 80 72 60 56 109 502 
J5 0 0 77 70 55 52 101 542 
J6 0 1 71 65 50 41 94 582 
J7 1 -1 90 80 72 47 112 299 
J8 1 0 81 75 64 41 110 308 
J9 1 1 73 64 50 34 99 340 
Translation of coded levels in actual units 
Variables level Low (-1) Medium  (0) High (+1) 
Drug-to-polymer-to polymer ratio (X1) 
(amoxicillin-ethyl cellulose-carbopol-
934P) 
Stirring speed (X2) rpm 
1:3:0.5 
 
 
800 
1:3:1 
 
 
1000 
1:3:1.5 
 
 
1200 
All the batches were prepared using 2 % v/v Span 80 and stirring time of 3 hrs 
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Figure 4.2: % mucoadhesion of amoxicillin loaded carbopol-934P 
mucoadhesive microspheres (batch J4) after 1, 5, 10 and 12 hrs 
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Figure 4.3: Scanning electron photomicrograph of amoxicillin loaded 
carbopol-934P mucoadhesive microspheres (batch J4) 
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Figure 4.4: In-vitro wash-off test of amoxicillin loaded carbopol-934P 
mucoadhesive microspheres (batch J4) on rat stomach after 2 hrs 
 
 
 
 
 
Figure 4.5: In-vitro wash-off test of amoxicillin loaded carbopol-934P 
mucoadhesive microspheres (batch J4) on rat stomach after 8 hrs 
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Table 4.3: In-vitro dissolution of amoxicillin from 
mucoadhesive microspheres of batch J4  
Time(min) pH=1.2 pH=7.8 
0 0 0 
30 17±4 11±3 
60 27±3 23±4 
120 41±3 35±3 
180 51±4 42±4 
240 56±3 50±3 
300 65±3 59±3 
360 70±4 66±4 
420 75±3 69±2 
480 78±2 72±5 
540 90±2 80±3 
600 94±5 90±4 
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Figure 4.6:  In-vitro dissolution of amoxicillin from mucoadhesive 
microspheres of batch J4 (-♦- pH=1.2 and -■- pH=7.8) 
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Table  4.4: Results of models fitting of batch J4 
Time 
(min) 
Cumulative 
percent 
release 
Hixon-Crowell Korsemeyer and 
Peppas 
Weibull 
Calculated  
cumulative 
percent 
release 
Residual 
square 
Calculated  
cumulative 
percent 
release 
Residual 
square 
Calculated  
cumulative 
percent 
release 
Residual 
square 
0 0 -6.86 47.00 - - - - 
60 11.0 10.57 4.51 14.01 1.71 11.69 1.01 
120 35.0 26.00 0.48 25.45 0.02 25.98 0.45 
180 42.1 39.54 1.29 36.09 5.35 39.61 1.45 
240 50.2 51.32 0.77 46.23 35.64 51.70 0.25 
300 60.2 61.46 0.43 56.02 22.80 61.98 1.38 
360 66.1 70.08 8.30 65.55 2.72 70.48 10.73 
420 69.9 77.31 10.32 74.85 0.56 77.34 10.53 
480 72.3 83.27 5.63 83.97 9.45 82.80 3.60 
540 80.4 88.09 3.19 92.94 44.07 87.07 0.58 
600 90.2 91.87 12.43 101.77 40.51 90.36 25.39 
SSR 94.41 162.88 55.43 
F-value 10.49 20.36 6.92 
Correlation 
Coefficient 
0.9889 0.9935 0.9931 
R-Square 0.9780 0.9871 0.9863 
Slope 0.0046 0.8611 1.2745 
Intercept -0.1038 -2.38 -3.17 
 
 
Chapter 4                       
Stomach specific amoxicillin mucoadhesive microspheres 
J.R.Chavda                                              113                                       PhD. Thesis 
 
 
 
Figure 4.7: Counter plot showing the effect of drug-polymer-polymer 
ratio(X1) and stirring speed (X2) on: % mucoadhesion (a), particle size (b), 
drug entrapment efficiency (c) and t80 (d) 
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Table 4.5: Summary of results of regression analysis 
Coefficient b0 b1 b2 b11 b22 b12 R2 
% Mucoadhesion 77.66 15.33 -7.16 0 -10.0 -2.5 0.9803 
Drug entrapment 
efficiency 
50.11 9.16 -5.66 -1.75 
 
-18.16 
 
-0.66 
 
0.9954 
Particle size 102.33 7.16 -6.83 0 -1.5 -1.5 0.9824 
t80 536.22 -169.5 42.66 -23.5 -56.83 8.66 0.9994 
 
 
Table 4.6: H .pylori clearance effect of amoxicillin at different doses in 
different formulations (n=2)   
Colony counts Doses (mg/kg) 
4 7.5 15 
Amoxicillin 
mucoadhesive 
microspheres 
20 26 
 
8 6 2 2 
(23±4.24)* (7.0±1.41)* (2±0)* 
Amoxicillin powder 72 84 25 33 5 30 
(78±8.48)* (29±5.65)* (18.0±16.97)* 
Physiological saline 98 90 99 85 105 80 
(94±5.65)* (92±9.89)* (92.5±17.67)* 
* Figure showed mean ± S.D. 
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Table 4.7: In-vivo clearance of H .pylori after the administration of amoxicillin 
powder, mucoadhesive amoxicillin microspheres and physiological saline (n=2)   
 
H .pylori 
Condition  
Mucoadhesive amoxicillin 
microspheres  
Amoxicillin 
powder 
Physiological 
saline 
1 2 1 2 1 2 
-/- -/- +/+ +/+ +/+ +/+ 
Negative (-) means neither bacterial colony was found nor rapid urease test was 
positive (+) means either bacterial colony was found or rapid urease test was positive  
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Figure 4.8:  H .pylori clearance effect of amoxicillin at different doses in 
different formulations 
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4.3 Results and discussion 
4.3.1 Preliminary trials 
The mucoadhesive microspheres of amoxicillin using carbopol-934P and ethyl 
cellulose were prepared by emulsion-solvent evaporation technique. Carbopol-
934P was selected as a polymer for the preparation of mucoadhesive 
microspheres owing to its biodegradable and mucoadhesive properties. Ethyl 
cellulose was used as carrier polymer.  Different concentrations of span 80 from 
1% v/v to 3% v/v were used as emulsifying agent. Significant effect of 
concentration of span 80 was observed on percentage mucoadhesion, particles 
size and drug entrapment efficiency. Results showed that increase in the 
concentration of span 80 increase the particles size and percentage 
mucoadhesion but decrease the drug entrapment efficiency. At 1% v/v, 
percentage mucoadhesion, particles size and drug entrapment efficiency were 
66%, 80 µm and 65 %, respectively but irregular shape of microspheres was 
observed. While at 3% v/v, percentage mucoadhesion, particles size and drug 
entrapment efficiency were 82%, 210 µm and 38% respectively; spherical shape 
of microspheres was observed but particles were coalesced. Therefore, 2 % v/v 
of concentrations of span 80 was used for further study.  
One of the important factors related to microspheres as reported by Lee et al 46 is 
the viscosity of the polymer solution. Polymers concentrations of 0.5%, 1%, and 
2% w/v were selected for preliminary trials. Flake formation was observed when 
ethyl cellulose and carbopol-934P concentration was used at a level of 0.5% w/v, 
whereas maximum sphericity was observed at the 1% w/v level. Non spherical 
microspheres were found when polymer concentration was used at the 2% w/v 
level. Therefore, 1% w/v of ethyl cellulose and carbopol-934P each, in ethanol 
was found to be the optimum concentration for the polymer solution. A 1:1 
mixture of heavy and light liquid paraffin was found to be suitable as a dispersion 
medium.  
Preliminary trial batches were prepared to study the effect of the time for stirring 
and stirring speed on the percentage mucoadhesion, drug entrapment efficiency, 
and characteristics of the microspheres. Increase in the time for stirring from 1 to 
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3 hrs, showed increase in percentages of mucoadhesion but decrease in drug 
entrapment efficiency and particles size. Thus, 3 hrs of stirring time was selected 
for further study. Since stirring speed has significant effect on percentage 
mucoadhesion, drug entrapment efficiency and particles size, it was selected as 
one an important factor for further study.  
On the basis of the preliminary trials a 32 full factorial design was employed to 
study the effect of independent variables (i.e, drug-to-polymer-to-polymer ratio 
[X1] and the stirring speed [X2]) on dependent variables percentage 
mucoadhesion, drug entrapment efficiency, particle size and t80. The results 
depicted in Table 4.2 clearly indicate that all the dependent variables are strongly 
dependent on the selected independent variables as they show a wide variation 
among the 9 batches (J1 to J9). The fitted equations (full models) relating the 
responses (ie, percentage mucoadhesion, drug entrapment efficiency, particle 
size and t80) to the transformed factor are shown in Table 4.5. The polynomial 
equations can be used to draw conclusions after considering the magnitude of 
coefficient and the mathematical sign it carries (ie, positive or negative). The high 
values of correlation coefficient (Table 4.5) for the dependent variables indicate a 
good fit. The equations may be used to obtain estimates of the response since 
small error of variance was noticed in the replicates. 
4.3.2 Factorial equation for % mucoadhesion 
The in-vitro mucoadhesiveness test showed that the percentage of 
mucoadhesive microspheres remaining on the stomach mucosa (Table 4.2). 
Figure 4.2 showed that even after 12 hrs, 52 % microspheres were adhered to 
gastric mucous layer. The mucoadhesive microspheres of all the batches of the 
factorial design were spherical (Figure 4.3, batch J4) and free flowing.  
The linear model generated for % mucoadhesion was found to be significant with 
an F-value of   29.96 (p<0.0001) and R2 value of 0.9803: 
 
% mucoadhesion = 77.66+ 15.33X1 – 7.16X2 -2.5X1X2 -10 X22                        [4.5] 
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The counter plot (Figure 4.7a) shows that the in-vitro wash-off test for % 
mucoadhesion of microspheres increased from 40 to 57 and 73 to 90 at lower 
and higher levels of drug-to-polymer-to-polymer ratio, respectively, as stirring 
speed decreased. Results of equation indicate that the effect of X1 (drug-to-
polymer-to-polymer) is more significant than X2 (stirring speed). Moreover, 
stirring speed had a negative effect on the percentage mucoadhesion (ie, as the 
stirring speed increased, the percentage mucoadhesion decreased). This finding 
may be attributed to the change in particle size that affects mucoadhesion. As 
the drug -to-polymer-to-polymer ratio increases, the % mucoadhesion also 
increases; because more amounts of polymer results in higher amount of free –
COOH groups 17, which are responsible for binding with sialic acid groups in 
mucus membrane and thus results in increase in mucoadhesive properties of 
microspheres. In-vitro mucoadhesive test showed that amoxicillin mucoadhesive 
microspheres a-dhered more strongly to gastric mucous layer and could retain in 
gastrointestinal tract for an extended period of time (Figures 4.4 and 4.5). Figure 
4.5 showed that even after 8 hrs, some of microspheres were adhered to gastric 
mucous layer. All factorial batches showed more than 50 % mucoadhesion even 
after 10 hrs.  
4.3.3 Factorial equation for particle size  
The linear model generated for particle size was found to be significant with an 
F-value of   33.6 (p<0.0001) and R2 value of 0.9824: 
 
 Particle size = 102.33+ 7.16X1 – 6.83X2 -1.5X1X2 -1.5 X22                             [4.6] 
 
The counter plot (Figure 4.7b) shows that the particle size of microspheres 
increased from 86.0 to 99.0 µm and 99.0 to 112 µm at lower and higher levels of 
drug-to-polymer-to-polymer ratio, respectively, as stirring speed decreased. 
Results indicate that the effect of X1 (drug-to-polymer-to-polymer) is more 
significant than X2 (stirring speed). Means, as the stirring speed increased, the 
particle sizes decreased that directly affect the percentage mucoadhesion.  
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Thus, we can conclude that the amount of polymer (carbopol-934P) and stirring 
speed directly affects the percentage mucoadhesion and particles size. 
4.3.4 Factorial equation for drug entrapment efficiency 
The drug entrapment efficiency and t80 are important variables for assessing the 
drug loading capacity of microspheres and their drug release profile, thus 
suggesting the amount of drug availability at site. These parameters are 
dependent on the process of preparation, physicochemical properties of drug, 
and formulation variables. The linear model generated for drug entrapment 
efficiency was found to be significant with an F-value of 40.70 (p<0.0001) and R2 
value of 0.9954: 
 
Drug entrapment efficiency = 50.11+9.16X1 -5.66X2 -0.66X1X2 -1.75X12-18.16X22                                                                                          
 [4.7] 
 
The counter plot (Figure 4.7c) shows that the % drug entrapment efficiency of 
microspheres increased from 20.0 to 26.0 and 34.0 to 47.0 at lower and higher 
levels of drug-to-polymer-to-polymer ratio, respectively, as stirring speed 
decreased. But at medium level of drug-to-polymer-to-polymer ratio, as stirring 
speed decreased, % drug entrapment efficiency of microspheres showed 
increase from 47.0 to 52.0. Results of equation indicate that the effect of X1 (drug 
-to-polymer-to-polymer) is more significant than X2 (stirring speed). Moreover, the 
stirring speed had a negative effect on the percentage drug entrapment efficiency 
(ie, as the stirring speed increased, the particle size decreased, and thus drug 
entrapment efficiency decreased). 
4.3.5 Factorial equation for t80 
The linear model generated for t80 was found to be significant with an F-value of 
115.91 (p<0.0001) and R2 value of 0.9994: 
 
  t80 = 536.22 – 169.5X1+ 42.66X2 -23.5X1X2 -56.83X12 -8.66 X22                    [4.8] 
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The counter plot (Figure 4.7d) shows that the % drug released in-vitro from 
microspheres decreased from 727 to 592 min and 340 to 299 min at lower and 
higher levels of drug-to-polymer-to-polymer ratio, respectively, as stirring speed 
decreased. Results depicted in Table 4.5 indicate that the % drug released in- 
vitro is highly dependent on the drug-to-polymer-to-polymer and stirring speed. 
The drug-to-polymer-to-polymer ratio has a negative effect on t80, while stirring 
speed has a positive effect on t80, because as the particle size decreases the 
drug release decreases.  
A numerical optimization technique using the desirability approach was employed 
to develop a new formulation with the desired responses. Constraints like 
maximizing % mucoadhesion, drug entrapment efficiency, particle size and 
release at the end of 12 hrs in addition to minimizing the t80 were set as goals to 
locate the optimum settings of independent variables in the new formulation. The 
optimized microsphere formulation (J10) was developed using 1:3:1.25 drug-to-
polymer-to-polymer ratio and 950 rpm stirring speed. The optimized formulation 
was evaluated for % mucoadhesion, drug entrapment efficiency, particle size and 
drug release. The results of experimentally observed responses and those 
predicted by mathematical models along with the percentage prediction errors 
were compared. The prediction error for the response parameters ranged 
between 0.50 and 2.15% with the value of absolute error of 1.36 ± 0.70%. The 
low values of error indicate the high prognostic ability of factorial equation and 
counter plot methodology. The drug release from the optimized formulation was 
found to low t80 (410 min) thus, we selected batch J4 for further study, which 
exhibited a high t80 of 502 min and seems to be a promising candidate for 
achieving drug release upto 12 hrs. The drug release profile of batch J4 is shown 
in Figure 4.6. The figure reveals that drug release rate slowed after 4 hrs. The 
study focus was the preparation of mucoadhesive microspheres, thus the 
microspheres of batch J4 were also evaluated in simulated gastric fluid USP (pH 
1.2). In-vitro release test showed that amoxicillin released faster in pH 1.2 
hydrochloric acid than in pH 7.8 phosphate buffer but the results indicated that no 
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significant difference was observed between dissolution profiles at pH 7.8 and pH 
1.2 as the ƒ2 (similarity factor) value was 63.48. 
The results of curve fitting of best batch into different mathematical models are 
given in Table 4.4. The mechanism of drug release from the microspheres was 
found to be diffusion controlled because plots of percent cumulative drug release 
vs. square root of time were found to be linear with the regression coefficient (R2) 
values ranging from 0.9780 to 0.9871 for the best batch. Results of F-statistics 
are shown in Table 4.4. The release profile fitted to Weibull equation F value was 
found 6.92. The value of correlation coefficient was found to be 0.9931. The 
values of slope and intercept were found to be 1.27 and –3.17 respectively. 
While release profile fitted to Korsmeyer-Peppas equation, F value was found 
20.36. The value of correlation coefficient was found to be 0.9935. The values of 
slope and intercept were found to be 0.8611 and –2.38 respectively; and release 
profile fitted to Hixon-Crowell equation, F value was found 10.49. The value of 
correlation coefficient was found to be 0.9889. The values of slope and intercept 
were found to be 0.0046 and –0.1038 respectively. The results of F-statistics 
were used for the selection of the most appropriate model, thus we concluded 
that the release profile fitted best to Weibull equation (F =6.92). 
4.3.6 In-vivo study 
At present, most studies of mucoadhesive formulations loading amoxicillin for 
anti- H. pylori focused on prolonging the gastric retarding time. The stability of 
amoxicillin in acidic medium was neglected. In fact, lots of antibiotics, such as 
erythromycin, clarithromycin, were reported with strong in-vitro H. pylori 
clearance effect but with poor in-vivo results. Ogwal and Xide 47 suggested that 
one of the reasons was due to their instability in acidic medium. Amoxicillin was 
also reported to be unstable in mediums with pH below 2 48-50. Amoxicillin can be 
quickly absorbed after its conventional dosage forms are orally administered. 
Therefore, its residence time in the stomach is expected to be short 34, which 
might cover up its shortcoming of being unstable in acidic medium. But for the 
mucoadhesive microspheres, which would stay in the stomach for a much longer 
time, the stability of amoxicillin should be seriously considered. In this study, we 
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found that, amoxicillin microspheres were more stable in pH 1.2 HCl than 
amoxicillin powder.        
From the result of the in-vivo H. pylori clearance test, we observed that, with the 
increase of amoxicillin’s doses, the H. pylori clearance effect was enhanced in 
mucoadhesive amoxicillin microspheres formulation. In the single dosage 
administration test, it was found that the total colony counts decreased markedly 
with the increase of the amoxicillin dose in both groups. Means, 4 mg/kg dose of 
amoxicillin mucoadhesive microspheres administrated colony counts were 
23±4.24, and on increase in the doses to 7.5 and 15 mg/kg colony counts were 
7.0±1.41 and 2±0, respectively. On administrating Amoxicillin powder 4 mg/kg 
dose colony counts were 78±8.48, and on increase in the doses to 7.5 and 15 
mg/kg colony counts were 29±5.65 and 18.0±16.97, respectively. While in case 
of Physiological saline 4 mg/kg dose administrated colony counts were 94±5.65, 
and than increases the doses 7.5 and 15 mg/kg colony counts were 92±9.89 and 
92.5±17.67, respectively. Physiological saline did not show any decrease in 
colony count. But the ratio of colony counts between amoxicillin powder and 
mucoadhesive microspheres increased rapidly from 3.39 at 4 mg/kg to 9.0 at 15 
mg/kg. (Table 4.6, Figure 4.8). This phenomenon indicated that with the increase 
in dose, mucoadhesive amoxicillin microspheres showed more effective 
clearance of H. pylori than that in case of amoxicillin powder. We inferred that 
this might be due to the lack of repetition of drug administration. Therefore, 
another multidose administration regimen was tried. The results showed that, at 
the dose of 3.5 mg/kg, when amoxicillin microspheres, powder or physiological 
saline was administrated, respectively, to the H. pylori infectious rat twice a day 
for three consecutive days (Table 4.7). Neither H. pylori colony was found nor 
was urease test positive in rats whom mucoadhesive amoxicillin microspheres 
were administrated. We conclude that the mucoadhesive amoxicillin 
microspheres showed a more complete H. pylori clearance effect. 
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4.4 Conclusion 
Amoxicillin mucoadhesive microspheres containing carbopol-934P as 
mucoadhesive polymer and ethyl cellulose as carrier polymer, were prepared by 
emulsion-solvent evaporation technique. The results of a 32 full factorial design 
revealed that the drug-to-polymer-to-polymer (amoxicillin-ethyl cellulose-
carbopol-934P) and stirring speed significantly affected the dependent variables 
% mucoadhesion, drug entrapment efficiency, particle size and t80.The 
microspheres of the best batch (J4) exhibited a high % mucoadhesion of 80% 
after 1 hr, 56 % drug entrapment efficiency and mean particles size of 109 µm. 
The t80 of 502 min indicates that the mucoadhesive microspheres of amoxicillin 
could sustain the release of the drug for more than 10 hrs. The investigation on 
H. pylori clearance effect showed that there was a tendency for a more effective 
H. pylori activity of mucoadhesive amoxicillin microspheres compare to 
amoxicillin powder and physiological saline, which might indicate a potential use 
of mucoadhesive amoxicillin microspheres in treating H. pylori infection. 
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5.1 Aim of present investigation 
Famotidine is a histamine H2-receptor antagonist. It is widely prescribed in 
gastric ulcers, duodenal ulcers, Zollinger-Ellison syndrome and 
gastroesophageal reflux disease. In the management of benign gastric and 
duodenal ulceration the dose is 40 mg daily by mouth at bedtime, for 4 to 8 
weeks. In gastroesophageal reflux disease the recommended dose is 20 mg by 
mouth twice daily for 6 to 12 weeks; where gastroesophageal reflux disease is 
associated with esophageal ulceration, the recommended dosage is 40 mg twice 
daily for a similar period. For the short term symptomatic relief of heartburn or 
non-ulcer dyspepsia a dose of 10 mg up to twice daily is suggested. In the 
Zollinger-Ellision syndrome the initial dose by mouth is 20 mg every 6 hrs, 
increased as necessary; dose up to 80 mg daily have been employed 1. Its low 
bioavailability (40-45%) and short biological half-life (2.5-4.0 hrs) following oral 
administration favors development of a sustained release formulation. 
The gastroretentive drug delivery systems can be retained in the stomach and 
contribute in improving the oral sustained delivery of drugs that have an 
absorption window in a particular region of the gastrointestinal tract. These 
systems help in continuously releasing the drug before it reaches the absorption 
window, thus ensuring optimal bioavailability 2. It has been reported that the oral 
treatment of gastric disorders with an H2 receptor antagonist like famotidine or 
ranitidine used in combination with antacids promotes local delivery of these 
drugs to the receptor of parietal cell wall. Local delivery also increases the 
stomach wall receptor site bioavailability and increases efficacy of drugs to 
reduce acid secretion. Hence this principle may be applied for improving 
systemic as well as local delivery of famotidine, which would efficiently reduce 
gastric acid secretion 3. 
There are a number of approaches that can be used to prolong gastric retention 
time, like these include floating drug delivery systems, also known as 
hydrodynamically balanced systems, swelling and expanding systems, polymeric 
bioadhesive systems, modified-shape systems, high-density systems, and other 
delayed gastric emptying devices 4-10. A floating drug delivery system, being less 
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dense than gastric juice due to the incorporation of at least one porous structural 
element was described 11. Recently, research has been done using famotidine as 
an effervescent type drug delivery system 12. Also, a new type of multiparticulate 
floating drug delivery system consisting of a highly porous carrier material (foam 
powder), drug and polymer: low density microparticles have been proposed 13-14.  
In situ gel, or in-vivo gel, environment sensitive gel is a new dosage form which 
has been used in stomach-specific drug delivery recently. Oral administration of 
in situ gels as low viscosity solution and upon contact with the simulated gastric 
fluid, the polymer changes conformation producing a gel, so it cannot only 
prolong the contact time between the drug and the absorptive sites at the 
stomach, but also release drug slowly and continuously15-16. The alginate based 
in situ gelling liquid formulation containing calcium ion in complexed form gets 
converted into gel when reaches to acidic environment of stomach and make the 
formulation to float for prolong period of time. The optimum quantity of sodium 
citrate was added to the above formulation to maintain its fluidity at room 
temperature before administration. The proposed alginate based floating in situ 
gelling systems of famotidine (FIGF), would have the advantage of ease of 
administration, as being a liquid, and is more patient compliance. 
 
It is our intention to develop floating in situ gelling systems of famotidine that:  
1. Formation of gel in gastric fluid and float to the stomach for prolonged 
period of time. 
2. Provide an increased gastric residence time resulting in prolonged drug 
delivery in gastrointestinal tract. 
3. Delivers a drug at a controlled rate over a period of time, which is same 
as or less than the residency period of the delivery system in the 
gastrointestinal tract.  
4. Shows better in-vivo performances than conventional dosage forms.  
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In context to above intention, following criteria were aimed to achieve:  
1. The proposed alginate based floating in situ gelling systems of famotidine 
(FIGF), would have the advantage of ease of administration, as being a 
liquid, and is more patient compliance. 
2. Floating time of in situ gel should be more than 8 hrs. 
3. Drug entrapment should be more than 50 %. 
4. More than 90 % of drug should be released within 10 hrs.  
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5.2 Experimental 
5.2.1 Estimation of famotidine  
A solution of Famotidine was prepared in 0.1 N HCl and Phosphate buffer pH 4.5 
and UV spectrum was taken using Shimadzu UV-1601 UV/Vis double beam 
Spectrophotometer (Kyoto, Japan), The UV maxima of Famotidine was found to 
be 265 nm in 0.1 N HCl and also same in Phosphate buffer pH 4.5 
5.2.1.1 Preparation of standard curve of famotidine in 0.1 N HCl 
Famotidine (10 mg) was dissolve in 0.1 N HCl and volume is made up to 100 mL 
in volumetric flask.1 mL of stock solution (100 µg/mL) was further diluted with 0.1 
N HCl to obtained solution of 10 µg/mL to 25 µg/mL. Absorbance of each solution 
was measured at 265 nm using Shimadzu UV-1601 UV/Vis double beam 
Spectrophotometer (Kyoto, Japan) and 0.1 N HCl as a reference standard. The 
standard curve was generated for entire range from 10 to 25 µg/mL. The 
experiment was performed in triplicate and based on average absorbance; the 
equation for the best line was generated. The results of standard curve 
preparation are shown in Figure 5.1. 
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Table 5.1: Standard curve of famotidine in 0.1 N HCl 
Sr. 
No. 
Concentration 
(µg/mL) 
Absorbance Average 
Absorbance 
Calculated 
Absorbance 1 2 3 
1 5 0.180 0.182 0.181 0.181 0.184 
2 10 0.356 0.360 0.358 0.358 0.354 
3 15 0.523 0.523 0.521 0.521 0.531 
4 20 0.702 0.710 0.706 0.706 0.714 
5 25 0.884 0.892 0.889 0.889 0.890 
Correlation Coefficient = 0.9995 
Absorption = 0.0353x  + 0.0018 
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Figure 5.1: Standard curve of famotidine in 0.1 N HCl 
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5.2.1.2 Preparation of standard curve of famotidine in phosphate buffer (pH 
4.5) 
Famotidine (10 mg) was dissolve in phosphate buffer (pH 4.5) and volume is 
made up to 100 mL in volumetric flask. 1 mL of stock solution (100 µg/mL) was 
further diluted with phosphate buffer (pH 4.5) to obtained solution of 10 µg/mL to 
25 µg/mL. Absorbance of each solution was measured at 265 nm using 
Shimadzu UV-1601 UV/Vis double beam Spectrophotometer (Kyoto, Japan) and 
phosphate buffer (pH 4.5) as a reference standard. The standard curve was 
generated for entire range from 10 to 25 µg/mL. The experiment was performed 
in triplicate and based on average absorbance; the equation for the best line was 
generated .The results of standard curve preparation are shown in Figure 5.2. 
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Table 5.2: Standard curve of famotidine in phosphate buffer (pH 4.5) 
Sr. 
No. 
Concentration 
(µg/mL) 
Absorbance Average 
Absorbance 
Calculated 
Absorbance 1 2 3 
1 5 0.188 0.191 0.190 0.190 0.186 
2 10 0.331 0.339 0.335 0.335 0.341 
3 15 0.499 0.504 0.504 0.502 0.497 
4 20 0.654 0.646 0.650 0.650 0.651 
5 25 0.803 0.813 0.808 0.808 0.806 
Correlation Coefficient = 0.9996 
Absorption = 0.031x  + 0.0317 
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Figure 5.2: Preparation of standard curve of famotidine in phosphate buffer 
(pH 4.5) 
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5.2.2 Preparation of in situ gelling solution 
Sodium alginate solutions of concentrations 0.25, 0.5, 1.0 and 1.5 % (w/v) were 
prepared by adding the alginate to ultrapure water containing 0.25% (w/v) 
sodium citrate and 0.075% (w/v) calcium chloride and heating to 60 °C while 
stirring. Famotidine (40 mg) was then dissolved in 10 mL of 0.1N hydrochloride 
acid solution (pH 1.2) and added in the resulting solution after cooling to below 
40 °C. The solution was neutralized by 0.1N sodium hydroxide. A 1% (w/v) 
control solution (for use in the in vitro release experiments) was prepared by 
dissolving famotidine in a 0.6% (w/v) aqueous solution of sodium alginate. A 1% 
(w/v) solution of famotidine was prepared in ultrapure water. The resulting 
alginate in situ gel solution containing famotidine was checked for viscosity and 
gelling property (Figure 5.3) and finally stored in amber color narrow mouth 
bottles until further use. In the preliminary batches J1 to J12 the concentration of 
calcium chloride and sodium citrate were kept constant at 0.075 and 0.25 % w/v, 
respectively. The concentration of the alginate was varied in batches J1 to J12 
from 0.25 to1.5 % w/v. The effect of formulation variables on characteristics of 
the sodium alginate based in situ gel of famotidine are summarized in Tables 
5.2.3 and 5.2.4. In factorial design batches F1 to F9, the concentration sodium 
alginate (X1) and the concentration of calcium chloride (X2) were varied from 0.5 
to 1.5 % w/v and 0.05 to 0.1 % w/v respectively, as shown in Table 5.4.   
5.2.3 Optimization by using 32 full factorial design 
On the basis of the preliminary trials in the present study a 32 full factorial design 
was employed to study the effect of independent variables, i.e. concentration of 
sodium alginate (X1) and the concentration of calcium chloride (X2) on dependent 
variables; drug content, viscosity, % drug released at 4 hrs (Q50) and 8 hrs (Q80). 
A statistical model (see equation) incorporating interactive and polynomial terms 
was utilized to evaluate the responses.  
 
 Y = b0 + b1X1+b2X2 + b12X1X2 + b11X12 + b22X22                                     [5.1] 
 
Chapter 5                       
Floating in situ gel stomach-specific drug delivery of famotidine 
J.R.Chavda                                               137                                      PhD. Thesis 
 
Where, Y is the dependent variables, b0 is the arithmetic mean response of the 
nine runs, and b1 is the estimated coefficient for the factor X1. The main effects 
(X1 and X2) represent the average result of changing one factor at a time from its 
low to high value. The interaction terms (X1X2) show how the response changes 
when two factors are simultaneously changed. The polynomial terms (X12 and 
X22) are included to investigate non-linearity. The polynomial equation can be 
used to draw conclusions after considering the magnitude of coefficient and the 
mathematical sign it carries, i.e. positive or negative. The high values of 
correlation coefficient for the dependent variables indicate a good fit. The 
equation may be used to obtain estimate of the response because small error of 
variance was noticed in the replicates. 
5.2.4 Physical appearance and pH   
All the prepared alginate based in situ solutions of famotidine were checked for 
their clarity and the time required for gel formation. The pH was measured of in 
situ solutions of famotidine using a calibrated digital pH meter at 25°C. All 
measurements of pH were made in triplicate and the results are given in Table 
5.3. 
5.2.5 In vitro gelation study and viscosity measurement of in situ gels 
Famotidine in situ solution (5 mL) and artificial simulated gastric fluid (100 mL) 
were mixed (1:20, v/v) and gelation was observed by visual examination. The 
viscosity of the sodium alginate solution either in solution or in gel made with 
artificial simulated gastric fluid were determined with a Brookfield viscometer 
(Model no RVT 81990) using a 20 mL aliquot of the sample. Measurements were 
performed using suitable spindle number at 6, 12, 30, 60 rpm, and the 
temperature was maintained at 25±1°C. The viscosity was read directly from the 
viscometer display. Gelation was also checked in collected gastric juice from the 
rats. All measurements were made in triplicate and the results are given in 
Tables 5.3 and 5.4. 
5.2.6 Determination of drug content 
The amount of famotidine in each sample was determined by spectrophotometer 
(UV-1601, Shimadzu Co Ltd., Kyoto, Japan). The UV absorbance of the sample 
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was determined at a wavelength of 265 nm. The drug content for batches J1 to 
J12 and F1 to F9 are depicted in Tables 5.3, 5.4 and Figure 5.4. 
5.2.7 Measurement of in vitro drug release 
The release of famotidine from floating in situ gel were determined as described 
by Zatz and Woodford 17 with some modification using USP dissolution test 
apparatus (USP 24) with a paddle stirrer at 50 rpm. This speed was slow enough 
to avoid the breaking of gelled formulation and was maintaining with the mild 
agitation conditions believed to exist in-vivo. The dissolution medium used was 
500 mL of 0.1N HCL (pH 1.2), and temperature was maintained at 37 ± 0.2 °C. 
Ten mL of formulation was drawn up using disposable syringe, the needle was 
wiped clean and excess formulation was removed from the needle end. The 
syringe end was then placed into the Petri dish (4.5 mm internal diameter) and 
the syringe plunger depressed slowly to extrude 10 mL and finally Petri dish 
containing formulation was kept in the dissolution vessel containing dissolution 
medium without much disturbance. At each time interval, a precisely measured 
sample of the dissolution medium was removed and replenished with pre 
warmed (37°C) fresh medium. Samples were withdrawn at predetermined time 
intervals, filtered through a 0.45 µm membrane filter, dilute suitably and analyzed 
spectrophotometrically. The experiments were conducted in triplicate. The 
amount of drug released at 4 hrs (Q50) and 8 hrs (Q80) were calculated 18-19. The 
average value of Q50 and Q80 for batches F1 to F9 is mentioned in Tables 5.4 
and Figure 5.5. 
5.2.8 Measurement of water uptake by the gel  
The water uptake by the gel was determined using a Thermogravimetric Analyzer 
(TGA-50, Shimadzu, Kyoto, Japan). The in situ gels formed in 40 mL of 
Sorensen’s phosphate buffer were used for this study. At periodic time intervals a 
portion of the gel was carefully removed. The sample was immediately loaded 
onto a TGA pan after removal of surface water by an absorbing tissue. The 
sample was subjected to a controlled temperature program (10 °C/min). The 
weight loss (% (w/w)) on heating was measured over 30–200 °C. Water uptake 
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of in situ gels containing various cross-linker concentrations and different 
reaction times was examined over 6 hrs. All studies were carried out in triplicate. 
 
 
 
 
 
 
 
 
 
Table 5.3: Results of preliminary trial batches*  
Batch 
No. 
Concentration 
of 
Sodium 
alginate (%) 
pH Viscosity 
(cp) 
Drug 
content 
(%) 
Characteristic of 
In situ gels 
J1 0.25 7.4 90 83.25 Gel is not form 
properly  J2 0.25 7.4 92 86.22 
J3 0.25 7.3 91 84.55 
J4 0.5 7.1 150 91.92 Gel formation  
J5 0.5 7.1 153 93.80 
J6 0.5 7.2 155 92.35 
J7 1 7.0 236 97.87 Gel formation  
J8 1 6.9 238 98.98 
J9 1 7.0 235 98.25 
J10 1.5 6.8 331 96.56  
Gel formation  J11 1.5 6.7 299 98.11 
J12 1.5 6.8 332 97.12 
*All the batches were prepared using 0.075% (w/v) calcium chloride and 
0.25% (w/v) sodium citrate 
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Table 5.4: 32 full factorial design layout*  
Batch  
No. 
Variables 
levels in 
coded 
form 
Viscosity  
(cp) 
Drug 
content 
(%) 
% Drug 
release 
 (Q50) 
% Drug  
release 
 (Q80) 
X1 X2 
F1 -1 -1 98 92.12 98.18 98.18 
F2 -1 0 134 93.65 97.66 97.66 
F3 -1 +1 155 94.78 91.39 99.23 
F4 0 -1 192 95.92 75.76 98.22 
F5 0 0 236 98.72 54.81 92.40 
F6 0 +1 266 95.54 50.29 81.26 
F7 +1 -1 296 96.22 46.17 78.66 
F8 +1 0 335 97.95 43.10 75.43 
F9 +1 +1 365 95.75 37.71 71.21 
Translation of coded levels in actual units 
Variables level Low (-1) Medium (0) High (+1) 
Concentration of 
sodium alginate (X1) 
0.5% 1% 1.5% 
Concentration of  
Calcium chloride (X2) 
0.05% 0.075% 0.1% 
*All the batches contain 40 mg famotidine, viscosity measured at 150 rpm.  
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Figure 5.3: Gel formation of alginate based in situ gel in simulated gastric 
fluid (batch F5) 
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Figure 5.4: Drug content of alginate based in situ gel batches F1-F9 
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Figure 5.5: Percent drug release from in situ gel batches F1-F9 
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Table 5.5: Summary of results of regression analysis  
Coefficient B0 B1 B2 B11 B22 B12 R2 
Viscosity 236.381 102.73 34.57 1.14 -2.07 -7.57 0.9996 
Drug content (%) 98.02 1.78 0.52 -1.11 -1.87 -1.94 0.8361 
Q50 (%) 56.84 -30.47 -10.5 -5.23 12.5 5.16 0.9853 
Q80 (%) 90.11 -13.09 -5.35 0.07 -2.43 0.76 0.9416 
 
5.2.9 Stability studies 
Stability studies were carried out on gel formulation according to ICH 
(International Conference on Harmonization) guidelines. A sufficient quantity of in 
situ gel in glass bottles was stored in desiccator containing saturated solution of 
sodium chloride, which gave a relative humidity of 75±5%. The desiccator was 
placed in a hot air oven maintained at 40±2 oC and samples were withdrawn at 0, 
30, 60, and 90 days. The physical stability of gel was observed periodically the 
occurrence of turbidity or gelation. The drug content remaining and the viscosity 
of formulation were measured at predetermined time interval. The results of the 
stability study for the selected batch of alginate based in situ formulation is given 
in Figure 5.6. 
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Figure 5.6: Stability study of famotidine in situ gel 
 
5.2.10 Data fitting  
An attempt was made to fit the dissolution data in to Zero order19 release kinetics 
represented: 
 m = k * t  [5.2] 
 
Where, k is zero-order constant, m is the % drug unreleased and t is the time. 
The plot of % drug unreleased (released) versus time is the linear. 
The data was treated with the First order20 release kinetics to characterize the 
mechanism of drug release: 
 m = ea * e-bt [5.3] 
 
Where, a is the intercept and b is the slope. It assumes that the drug molecules, 
diffuses out through a gel like layer formed around the drug during the dissolution 
process. A plot of log % drug release versus time is the linear. 
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The data was treated with the Higuchi 21 model to characterize the mechanism of 
drug release: 
 m = 100 – q * square root of time [5.4] 
 
Where q is the Higuchi constant (% per square root of time). In this model, a plot 
of % drug unreleased (released) versus square root of time is linear. 
The dissolution data was also analyzed using the Krosmeyer-Peppas model 22 to 
determine the kinetic of drug release from different batches of in situ gel: 
 
  Mt/M∞ = Kptn [5.5] 
 
Where, Mt/M∞ represent the fraction of drug released at time t and Kp is the 
kinetic constant characterizing the polymeric system and n stands for the 
diffusion exponent. 
The results of F-statistics were used for the selection of the most appropriate 
model. Results of summary of results of regression analysis and data fitting are 
shown in Tables 5.5 and 5.6, respectively. The curve fitting, simulation and 
plotting was performed in Excel (Microsoft Software Inc., USA) and Sigma plot 
version 10.0 (Sigma plot software, Jangel Scientific Software, San Rafael, CA). 
The effects of independent variables on the response parameters were 
visualized from the contour plots. Numerical optimization using the desirability 
approach was employed to locate the optimal settings of the formulation 
variables so as to obtain the desired response 23. An optimized formulation was 
developed by setting constraints on the dependent and independent variables. 
The formulation developed was evaluated for the responses and the 
experimental values obtained were compared with those predicted by the 
mathematical models generated. Counter plots showing the effect of the 
concentration of sodium alginate (X1) and the concentration of calcium chloride 
(X2) on drug content, viscosity, % drug released at 4 hrs (Q50) and 8 hrs (Q80) 
appear in Figure 5.7. 
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Table 5.6: Results of models fitting of batches F1-F9 
Batch 
no. 
Regression 
Zero order 
kinetic 
First order 
kinetic 
Higuchi 
kinetic 
Krosmeyer 
peppas 
F1 0.7068 0.4951 0.8299 0.9124 
F2 0.7491 0.5110 0.8637 0.9314 
F3 0.8128 0.5550 0.9048 0.9505 
F4 0.9149 0.9300 0.9651 0.9848 
F5 0.9959 0.8790 0.9858 0.9986 
F6 0.9841 0.9679 0.9804 0.9929 
F7 0.9872 0.9731 0.9879 0.9972 
F8 0.9953 0.9680 0.9773 0.9927 
F9 0.9953 0.9797 0.9651 0.9812 
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Figure 5.7: Counter plots showing the effect of the concentration of sodium 
alginate (X1) and the concentration of calcium chloride (X2) on viscosity (a), 
drug content (b), Q50 (c) and Q80 (d) 
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5.11 In-vivo study  
In-vivo evaluation studies for optimized formulation were performed on normal 
healthy Wistar rats weighing 200-250 gm each as per pyrolus ligation method 24. 
The approval of the Institutional Animal Ethics Committee was obtained before 
starting the study. The study was conducted in accordance with standard 
intuitional guidelines. Three groups of  Wistar rats (5 in each group) that were 
fasted (with water) at least 24 hrs before experiments were used for the study 
and divided first group as control, second as control plus immediate treatment 
and third as treated (in situ famotidine gel). Wistar rats were anaesthetized with 
ether and a portion of the abdomen was opened by a small midline incision 
below the xiphoid process. The pylorus portion of the stomach was lifted and 
ligated. During this process, care was taken to avoid the traction to the pylorus or 
damage to its blood supply the stomach was closed by interrupted sutures. In 
first group after 5 hrs the animals were sacrificed and the stomachs were 
removed, cut along the greater curvature and subjected to measurement of ulcer 
index. In second group alginate based in situ gel of famotidine were administered 
orally after 5 hrs of ligation, after 20 min the animals were sacrificed and the 
stomachs were removed, cut along the greater curvature observed whether gel is 
form or not and subjected to measurement of ulcer index. And in third group the 
alginate based in situ gel of famotidine were administered orally 30 min before 
starting the experiment in 24 hrs fasted rats and after 8 hrs of animals were 
sacrificed and observed for the effect of drug by counting the ulcer index. The 
ulcer index was determined using the formula: 24-26 Ulcer index = 10/X, Where X 
= Total mucosal area/Total ulcerated area. The results of in-vivo study are 
depicted in Figures 5.8 to 5.11. 
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Figure 5.8: Group 1 as a control 
 
 
Figure 5.9: Group 2 as control + immediate treatment by alginate based in 
situ gel 
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Figure 5.10: Group 3 as treated + alginate based in situ gel  
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Figure 5.11: Ulcer index of alginate based in situ of famotidine 
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5.3 Results and Discussion  
5.3.1 Preliminary trials    
The floating in situ gels of famotidine were prepared by ion activation technique, 
dissolving varying concentrations of alginate in deionized water containing 
sodium citrate, to which varying concentrations of drug and calcium chloride was 
added. In preliminary trial batches of J1 to J12 (Table 5.3) were prepared using 
different concentration of sodium alginate to see the effect on the viscosity of the 
solution, drug content, pH and the physical properties of the gel in simulated 
gastric fluid (pH 1.2). The concentration of sodium alginate was varied from 0.25 
to 1.5 % w/v. In the batches J1 to J3 (0.25 % w/v) improper gelation was 
observed which leads the rapid flow of the formulation. Also the time required for 
gelation and drug content was very low. Batches J4 to J6 prepared using 0.5 % 
w/v of sodium alginate the gelation, time required for gelation and drug content 
were slightly better than batches J1 to J3. While in the batches J7 to J12 all the 
characteristics of the gels were good but, in the batches of J10 to J12 the 
viscosity of the solutions were very high because of the higher concentration of 
sodium alginate which was difficult to pour while it was not observed in batches 
J7 to J9. Thus, we can conclude that 1 % w/v sodium alginate was the optimum 
concentration. The concentration of sodium citrate was constant in all the 
batches (0.25 % w/v) and observed no significant effect.  
On the basis of the preliminary trials in the present study a 32 full factorial design 
was employed to study the effect of independent variables, i.e. concentration of 
sodium alginate (X1) and concentration of calcium chloride (X2) on dependent 
variables viscosity, drug content, drug released at 4 hrs (Q50) and 8 hrs (Q80). 
The results summarized in Table 5.4 clearly indicate that all the dependent 
variables are strongly dependent on the selected independent variables as they 
show a wide variation among the nine batches (F1 to F9). Fitted equations (full 
models) relating the responses i.e. viscosity, drug content, Q50 and Q80 to the 
transformed factor are shown in Table 5.5. The polynomial equation can be used 
to draw conclusions after considering the magnitude of coefficient and the 
mathematical sign it carries, i.e. positive or negative. The high values of 
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correlation coefficient (Table 5.5) for the dependent variables indicate a good fit. 
The equation may be used to obtain estimate of the response because small 
error of variance was noticed in the replicates. 
5.3.2 Factorial equation for viscosity 
 
The viscosity is an important variable because it affects the gelation of the 
solutions, the flow of the formulation and time required for the gelation. The 
viscosity is dependent on the concentrations of the polymer and calcium chloride. 
The linear model generated for viscosity was found to be significant with an F-
value of 590.35 (p<0.0001) and R2 value of 0.9993: 
 
Viscosity (cp) = 236.381+102.73X1+34.57X2+1.14X1X2 – 2.07X12 -7.57X22 [5.6] 
 
The counter plot (Figure 5.7a) shows that the viscosity of solution increased from 
98 to 155 cp and 296 to 365 cp at lower and higher levels of concentration of 
sodium alginate, respectively, as concentration of calcium chloride increased. 
The results of the equation indicate that the effect of X1 (concentration of sodium 
alginate) is more significant than X2 (concentration of calcium chloride). 
Moreover, amount of calcium chloride had a positive effect on the viscosity, i.e. 
as the volume of cross-linking agent increase, the viscosity increases. 
5.3.3 Factorial equation for drug content
 
The linear model generated for drug content was found to be significant with an 
F-value of 2.041 (p<0.0001) and R2 value of 0.8361: 
 
Drug content =98.02+1.78X1+0.52X2-1.11X1X2 – 1.87X12 -1.94X22 [5.7] 
 
The counter plot (Figure 5.7b) shows that the drug content increased from 92.12 
to 94.78 % at lower levels of concentration of sodium alginate and decreased 
from 97.75 to 96.22 % at higher levels of concentration of sodium alginate as 
concentration of calcium chloride increased. The results of the equation indicated 
that both the concentration of the X1 and X2 were responsible for the drug content 
of the in situ formulations but the effect of X1 (concentration of sodium alginate) is 
Chapter 5                       
Floating in situ gel stomach-specific drug delivery of famotidine 
J.R.Chavda                                               153                                      PhD. Thesis 
 
more significant than X2 (concentration of calcium chloride), the effect of the X2 
was very less so, it was considered non significant compared to the 
concentration of sodium alginate.  
5.3.4 Factorial equation for Q50 
The amount of drug released in an important parameter for sustained release 
action of the in situ gel of famotidine. The linear model generated for drug 
released at 4 hrs was found to be significant with an F-value of 26.97 (p<0.005) 
and R2 value of 0.9853: 
 
Q50 =56.84-30.47X1 -10.55X2+5.23X1X2 + 12.517X12 +5.16X22                                     [5.8] 
 
The counter plot (Figure 5.7c) shows that the drug release at 4 hrs (Q50) 
decreased from 98.18 to 91.39 at lower and 46.17 to 37.71 at higher levels of 
concentration of sodium alginate, respectively, as concentration of calcium 
chloride increased. The results depicted in Table 5.4 indicate that the percentage 
drug released in vitro is highly depended on the concentration of sodium alginate 
(X1) and the concentration of calcium chloride (X2).  The concentration of calcium 
chloride (X2) has a negative effect on Q50, while the concentration of sodium 
alginate had lower effect on Q50.  
5.3.5 Factorial equation for Q80  
The linear model generated for drug released at 8 hrs found to be significant with 
an F-value of 6.45 (p<0.005) and R2 value of 0.9416: 
 
Q80 =90.11-13.09X1 -5.35X2+0.07X1X2 - 2.43X12 +0.76X22                                                [5.9] 
 
The counter plot (Figure 5.7d) shows that the drug release at 8 hrs (Q80) 
increased from 98.18 to 99.23 at lower and decreased from 78.66 to 71.21 at 
higher levels of concentration of sodium alginate, respectively, as concentration 
of calcium chloride increased. The results depicted in Table 5.5 indicate that the 
percentage drug released in vitro is highly depended on the concentration of 
sodium alginate (X1) and the concentration of calcium chloride (X2).  The 
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concentration of calcium chloride (X2) has a negative effect on Q80, while the 
concentration of sodium alginate had lower effect on Q80.  
5.3.6 Release mechanism  
Release of the drug from a polymeric matrix depends on the amount of water 
associated with the system. The release of the drug may involve the penetration 
of water into the matrix and simultaneous release of the drug via diffusion or 
dissolution as governed by Ficks law 27-28. The results of curve fitting of factorial 
batches into different mathematical models are given in Table 5.6. The 
mechanism of drug release from the in situ gel was found to be diffusion 
controlled because plots of percentage cumulative drug release vs square root of 
time were found to be linear with the regression coefficient (R2) values ranging 
from 0.9124–0.9986 for the factorial batches. The release profile of batch F5 
fitted to Korsmeyer-Peppas equation, F-value was found to be 10.16. The value 
of correlation coefficient was found to be 0.9986. The values of slope and 
intercept were found to be 0.8621 and -1.42, respectively. The results of F-
statistics were used for the selection of the most appropriate model, thus it was 
concluded that the release profile fitted best to Korsmeyer-Peppas equation 
(F=10.16). 
5.3.7 Optimized batch 
A numerical optimization technique using the desirability approach was employed 
to develop a new formulation with the desired responses. Constraints like 
maximizing drug content, minimizing the viscosity and release at the end of 10 
hrs in addition to manimizing the Q50 and Q80 were to set as goals to locate the 
optimum setting of independent variables in the new formulation.  The optimized 
in situ gel formulation (J10) was developed using a 0.75 % w/v of sodium 
alginate and 0.0625 % w/v of calcium chloride. The optimized formulation was 
evaluated for percentage viscosity, drug content, Q50 and Q80. The results of 
experimentally observed responses and those predicted errors for the response 
parameters ranged between 0.46-1.95 percent, with the value of absolute error of 
1.25±0.56 %. The low value of error indicates the high prognostic ability of 
factorial equation and counter plot methodology. The drug content from the 
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optimized formulation was found to be low 96.5% and viscosity of 208 cp, thus 
batch F5 was selected for further study, which exhibited a high drug content of 
98.72 and the viscosity of 236 cp which is easy for swallowing and good ability 
for gelation immediately after oral administration.  
The water associated with the formulation at any point in time in the release 
medium was studied by TGA. The percentage of weight loss was thought to be 
due to water loss during heating. TGA was also used to study the effect of cross-
linking on water uptake by the gels. The result of the water uptake by the sodium 
alginate based in situ gel of famotidine at 8 hrs was 71.72 % and the good 
correlation coefficient (0.9983). There was a sudden increase in water uptake 
followed by a decrease. This decrease is particularly prominent for gels without 
cross-linker and has been observed in lower concentrations of cross-linker. This 
decrease in water uptake can be explained by the collapsing of gels with time. 
There was also a decrease in water uptake by the gels with cross-linker. The 
formation of cross-linked networks provided an additional barrier to water 
penetration. As the concentration of the cross-linker in the delivery system 
increased, the time taken to reach maximum water uptake increased. At a higher 
cross-linker concentration the collapsing of the gel was negligible compared to 
gels without a cross-linker. 
Based on visual identification, the in situ gel has remained as liquid for a period 
of 3 months without the occurrence of turbidity or gelation at 40±2 oC. As 
illustrated in Figure 4, the viscosity of the gel slightly changed from 236 cp at 0 
month to 241 cp at the 3rd month. The samples also were analyzed for 
famotidine content by spectrophotometer. The results showed that about 2.32 % 
content decrease was found when the in situ gel was kept at 40±2 oC for 3 
months. Since the overall degradation is <5%, a tentative shelf life of 2 years 
may be assigned to the formulation. 
5.3.8 Results of in-vivo study 
The in-vivo study was carried out by pylorus ligation method in rats to see 
whether the gel was formed or not in the stomach of the rats and also checked 
the effect of the drug by counting the ulcer index. Results of group 1 showed 
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ulcer (Figure 5.8) while results of group 2 showed gel was formed but the ulcers 
was also identified (Figure 5.9). Results of group 3 showed gel was after 5 hrs of 
the treatment and an ulcer was reduced (Figure 5.10). The gel formation was 
checked in collected gastric juice of the rats and results showed immediately 
formation of gel in gastric juice of the rats. The ulcer index of group 1, 2 and 3 
were 2.25, 2.26 and 0.5995, respectively (Figure 5.11). Thus we concluded that 
the gel formation in the stomach of the rats and significant reduction of ulcers 
were also observed. 
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5.4 Conclusion  
This study reports that oral administration of aqueous solutions of famotidine 
containing sodium alginate results in formation of in situ gel at the stomach site. 
The results of a 32 full factorial design revealed that the concentration of sodium 
alginate and concentration of calcium chloride significantly affected on the 
dependent variables like viscosity, drug content, Q50 and Q80. The in-vivo study 
demonstrated the excellent gel formation in the stomach of the rat and significant 
anti-ulcer effect of alginate based in situ gel of famotidine over longer period of 
time.  
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6.1 Aim of present investigation 
The earliest studies in the field of modified drug delivery date back to the 1950s. 
Since then, a large number of drug products, mainly in the form of tablet and 
capsule with controlled release characteristics, have been introduced. Das and 
Das predicted a minimum growth of 9% per year for this market through 20081. 
This incredible growth can be attributed to several advantages that these 
products offer, including improved patient compliance, better therapeutic 
efficiency, potential for cost saving and patentability, and opportunity for 
extending product life-cycle. 
Oral sustained-release technology provides oral delivery for 24 hr; however, in 
substances that cannot be well absorbed throughout the whole gastrointestinal 
tract, it may be disadvantageous2. Extended-release dosage forms with 
prolonged residence times in the stomach are highly desirable for drugs with 
narrow absorption windows, stability problems in the intestinal or colonic 
environments, locally acting in the stomach, and poor solubility in the intestine3. 
Recent approaches to increase the gastric residence time of drug delivery 
systems include bioadhesive devices4-6, swelling devices that increase their 
size7,8, low density devices3,8, floating systems9,10, high density systems11,12, 
magnetic systems, unfoldable and expandable systems, magnetic systems, 
superporous, biodegradable hydrogel systems13 and microparticulate systems6. 
The otherwise-excellent concept of floating system suffers from a disadvantage 
that it is effective only when the fluid level in the stomach is sufficient high; 
however, as the stomach empties and the tablet is at the pylorus, the buoyancy 
of the dosage form may be impeded14. This serious limitation can be achieved by 
coupling bioadhesion characteristics to dosage form and developing bioadhesive 
tablets. Floating and bioadhesive drug delivery systems have advantages such 
as efficient absorption and enhanced bioavailability of drugs owing to a high 
surface-to-volume ratio, a much more intimate contact with the mucus layer, and 
specific targeting of drugs to the absorption site15,16. The various buoyant 
preparations include microballoons, microspheres, granules, powders, gel, 
capsules, tablets, and laminated films13. Based on the mechanism of buoyancy, 
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two distinctly different technologies, i.e., noneffervescent and effervescent 
systems have been utilized in the development of floating systems:  
1. Noneffervescent systems that use commonly gel-forming or highly swellable 
cellulose-type hydrocolloids, polysaccharides, and matrix forming polymers such 
as polycarbonate, polyacrylate, polymethacrylate, and polystyrene13.  
2. Effervescent systems that utilize matrices prepared with swellable polymers 
such as HPMC or chitosan and effervescent compounds, e.g., sodium 
bicarbonate and citric or tartaric acid17 or matrices containing chambers of liquid 
that gasify at body temperature18.  
Matrix tablets based on hydroxypropyl methylcellulose (HPMC K4M) have been 
developed by Li et al19,20. Natural gums in combination with HPMC also have 
been evaluated for gel-forming properties10. Microparticulate systems using 
natural polymers have been evaluated for stomach specific drug delivery of 
glipizide21. Different mass transport processes may occur during drug release 
from polymer-based matrix tablets, including water imbibition into the system, 
polymer swelling, drug dissolution, drug diffusion out of tablet, and polymer 
dissolution22. 
Glipizide is a second-generation sulfonylurea that can acutely lower the blood 
glucose level in humans by stimulating the release of insulin from the pancreas 
and is typically prescribed to treat type II diabetes (non-insulin-dependent 
diabetes mellitus). Its short biological half-life (3.4 ± 0.7 hr) necessitates that it be 
administered in 2 or 3 doses of 2.5 to 10 mg per day23. Glipizide is available in a 
Gastrointestinal Therapeutic System (GITS) extended-release formulation. 
Glipizide GITS provides more stable plasma drug concentrations than the 
immediate-release formulation and the once-daily regimen may optimize patient 
compliance. In patients with type II diabetes mellitus, glipizide GITS is at least as 
effective as the immediate-release formulation of glipizide in providing glycaemic 
control, and may have a greater effect on fasting plasma glucose levels. Any 
therapeutic advantage over other antidiabetic agents remains to be established, 
but in a preliminary report (n = 40) glipizide GITS provided better glycaemic 
control and produced less fasting insulinaemia than glibenclamide (glyburide) 23. 
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Menger et al24 compared the pharmacokinetic and short-term pharmacodynamic 
profile of extended-release glipizide (GITS) given with that of immediate-release 
glipizide in patients with type II diabetes mellitus. At steady state, the mean Cmax 
after immediate-release glipizide was significantly greater than after glipizide 
GITS, and the tmax was considerably shorter. Although the mean Cmin with 
glipizide GITS was about 80% higher than with immediate-release glipizide, the 
mean AUC 0-24 was significantly lower. Despite the lower plasma concentrations 
with glipizide GITS in this short-term study, the two formulations had similar 
effects on serum concentrations of glucose, insulin, and C-peptide. The absence 
of a pronounced peak plasma concentration with the GITS formulation might 
confer advantages in terms of maintaining clinical effectiveness and reducing the 
potential to cause adverse effects. Thus, the development of controlled/extended 
release dosage forms of glipizide would clearly be advantageous. Researchers 
have formulated oral controlled-release products of glipizide by various 
techniques21,25,26 .  
 
The hypothesis for this research work is that if glipizide can be delivered in a 
controlled manner to the duodenum at a rate that does not exceed the maximum 
rate of its absorption, then the oral bioavailability of glipizide could be improved. 
Based on this hypothesis, the gastric floating and bioadhesive tablets were 
designed in such a way that they should be retained in the stomach for a 
prolonged period of time, thus maximizing the exposure of this drug to its 
absorption site. 
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6.2 Experimental 
6.2.1 Preparation of standard curve of glipizide 
Glipizide (50 mg) was dissolved in 1 mL phosphate buffer (pH 7.4) and volume 
was made upto 50 mL volumetric flask using phosphate buffer (pH 7.4). Five 
microliters of stock solution (1 mg/mL) was further diluted with phosphate buffer 
(pH 7.4) to 50 mL. This solution (100 µg/mL) was further diluted to phosphate 
buffer (pH 7.4) to obtain solutions of 5 to 50 µg/mL. Absorption of each solution 
was measured at 276 nm using Shimadzu UV-1601 UV/Vis double beam 
spectrophotometer and phosphate buffer (pH 7.4) as a reference standard. The 
method was validated for linearity, accuracy and precision. The method was 
validated for linearity, accuracy and precision. The method obeys Beer-Lambert’s 
Law in the concentration range of 5-50 µg/mL. When a standard drug solution 
was analysed repeatedly (n=5) the mean error (accuracy) and relative standard 
deviation (precision) were found to be 0.8 % and 1.3 % respectively. The results 
of standard curve preparation are shown in Table 6.1 and Figure 6.1.    
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Table 6.1: Standard curve of glipizide in phosphate buffer pH (7.4) at 276 nm  
Sr. 
No. 
Concentration 
(µ/mL) 
Absorbance Average 
Absorbance 1 2 3 
1 0 0 0 0 0 
2 5 0.120 0.122 0.121 0.121 
3 10 0.222 0.220 0.221 0.221 
4 15 0.350 0.346 0.348 0.348 
5 20 0.467 0.465 0.463 0.465 
5 25 0.544 0.544 0.543 0.544 
6 30 0.699 0.697 0.695 0.697 
7 35 0.760 0.762 0.761 0.761 
8 40 0.890 0.891 0.891 0.891 
Correlation Coefficient = 0.9979  
Average Absorption = 0.0218 x Concentration + 0.0147 
 
 
Figure 6.1: Standard curve of glipizide in phosphate buffer (pH 7.4) 
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6.2.2 Preparation of bioadhesive and floating tablets 
In the tablet formulation, HPMC/CH or CP934/PMA was used as bioadhesive 
agents. These polymers produce gel-forming matrices and, in contact with gastric 
fluid, possess sufficient structure to form a gel layer and achieve an overall 
specific gravity lower than that of gastric fluid. Citric acid and sodium bicarbonate 
were used as effervescent base to generate carbon dioxide and to enhance the 
buoyancy of the tablets. All powders except magnesium stearate were sieved 
through sieve of mesh size 20. The components of the formulation were mixed 
for 20 min in a cubic mixer. Magnesium stearate (60-mesh sieved) was added 
into powder blend as a lubricant and mixed for an additional 3 min before 
compaction process. Then 200 mg tablets containing 10 mg glipizide prepared 
via a lab press (Cadmach, India) under a pressure of 50 kg/cm2 using two flat 
face punches with a 7.9-mm diameter. The tablet formulations are shown in 
Table 6.2. 
6.2.3 Floating behavior of tablets 
The in-vitro floating behavior of the tablets was studied in 500 mL preheated 
0.1NHCl (pH 1.2, 37oC, no enzyme) and stirred at 50 rpm with a paddle (USP 
paddle method). The floating lag times (time period between placing the tablet in 
the medium and tablet floating) and floating durations of the tablets were 
determined by visual observation. The results of the in-vitro buoyancy study of 
batch JE10H20CH80 are shown in Figure 6.2. 
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Table 6.2: Ingredients in mg of floating-bioadhesive tablets of glipizide 
Formulation 
code 
Sodium 
bicarbonate 
Citric 
acid 
Hydroxypropyl 
methylcellulose 
Chitosan Polymethacrylic 
acid 
Carbopol 
P934 
JE5H100 9.5 9.5 169 0 - - 
JE5H80CH20 9.5 9.5 132 37 - - 
JE5H60CH40 9.5 9.5 113 56 - - 
JE5H40CH60 9.5 9.5 56 113 - - 
JE5H20CH80 9.5 9.5 37 132 - - 
JE5CH100 9.5 9.5 0 169 - - 
JE10H100 18.5 18.5 151 0 - - 
JE10H80CH20 18.5 18.5 121 30 - - 
JE10H60CH40 18.5 18.5 90 61 - - 
JE10H40CH60 18.5 18.5 61 90 - - 
JE10H20CH80 18.5 18.5 30 121 - - 
JE10CH100 18.5 18.5 0 151 - - 
JE10P100 18.5 18.5 - - 151 0 
JE10P80CP20 18.5 18.5 - - 121 30 
JE10P60CP40 18.5 18.5 - - 90 61 
JE10P40CP60 18.5 18.5 - - 61 90 
JE10P20CP80 18.5 18.5 - - 30 121 
JE10CP100 18.5 18.5 - - 0 151 
All tablets contain 10 mg glipizide and 2 mg magnesium stearate as lubricant 
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                    At initial time                                           After 40 sec 
          
  
                  After 45 sec                                            After 15 hr 
Figure 6.2: In-vitro buoyancy studies of batch JE10H20CH80 
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6.2.4 Measurement of bioadhesive strength of the tablets 
Bioadhesive strength of the prepared tablets was measured on a modified 
physical balance27,28. Albino rat stomach was used as the membrane and 
isotonic phosphate buffer (IPB) pH 6.6 was used as the moistening fluid. The 
stomach membrane was excised by removing the underlying tissues. It was 
washed thoroughly with isotonic phosphate buffer (IPB) pH6.6 and then tied over 
the protrusion in the Teflon block using a thread. The block was lowered into the 
glass container filled with IPB pH 6.6 at 37±2°C such that the buffer just touched 
the sides of the stomach membrane. The two sides of the balance were made 
equal, before the study, by keeping 5.0 gm weight on the right pan. The glass 
container was kept below the left hand side of the balance. The tablet was stuck 
onto the lower side of the hanging Teflon cylinder using either a little moisture or 
a double sided tape. The surface of the stomach membrane was blotted with a 
whattman filter paper and 25 µL of IPB pH 6.6 was added to the stomach 
surface. This was done in order to obtain reproducible results. The 5.0 gm weight 
from the right pan was removed. This lowered the Teflon cylinder along the patch 
over the stomach membrane with a weight of 5.0 gm. This was kept undisturbed 
for 2.0 min. Then the weights on the right hand side were slowly added in 
increments of 0.5 gm till the tablet just separated from the stomach membrane 
surface. The excess weight on the right pan, that is, total weight minus 5.0 gm 
was taken as a measure of the bioadhesive strength. The equipment was located 
in an air-conditioned room at 22oC and 60% relative humidity. 
6.2.5 Density measurements 
The apparent densities of the tablets were calculated from their volumes and 
masses in triplicate. The volumes V of the cylindrical tablets were calculated from 
their heights h and radius r (both determined with a micrometer gauge) using the 
mathematical equation for a cylinder (V = pi × r 2 × h). The tablets with ~1 g/cm3 
density or less were chosen for further studies14. 
 
 
 
Chapter 6                       
Glipizide floating-bioadhesive tablets 
J.R.Chavda                                            170                                         PhD. Thesis 
 
6.2.6 Drug release study 
The drug-release study was carried out using a USP XXIV basket apparatus 
(Electrolab, TDT-06T, India) at 37°C ± 0.5°C and at 50 rpm using 250 mL of 
phosphate buffer (pH 7.4) as a dissolution medium (n = 5) as per the USP XXVI 
dissolution test prescribed for glipizide extended-release tablets (USP, 2003). 
Floating-bioadhesive tablets of glipizide (10 mg) were used for the test. A 5-mL 
sample solution was withdrawn at predetermined time intervals, filtered through a 
0.45-micrometer membrane filter, diluted suitably, and analyzed 
spectrophotometrically. An equal amount of fresh dissolution medium was 
replaced immediately following withdrawal of the test sample. The percentage of 
drug dissolved at different time intervals was calculated using the Lambert-Beer’s 
equation (Average Absorption = 0.0218 x Concentration + 0.0147, R2 = 0.9979).  
6.2.7 Data fitting 
Dissolution efficiency (DE)29 after 8 hr of release test was used to compare the 
results of dissolution tests of different formulations: 
 
 
                                         [6.1] 
The other dissolution parameter used for comparing the different formulations 
was mean dissolution time or MDT that is calculated from the amount of drug 
released to the total cumulative drug. MDT is a measure of the rate of the 
dissolution process: the higher the MDT, the slower the release rate. The 
following equation was used to calculate the MDT from the mean dissolution 
data: 
 
                                                                                             [6.2] 
           
 
Where i is the dissolution sample number, n is the number of dissolution sample 
time, tmid is the time at the midpoint between i and i − 1, and ∆M is the additional 
amount of drug dissolved between i and i − 1 30. 
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6.3 Results 
Table 6.3 shows the results of floating time and density of tablets. As this table 
shows increasing the effervescent base of tablets from 5% to 10% significantly 
lowers the lag time of floating from about 105 sec to 45 sec. All the batches 
showed good in-vitro buoyancy. The results of the in-vitro buoyancy study of 
batch JE10H20CH80 are shown in Figure 6.2. The figure clearly indicates the 
floating lag time (45 sec) of the glipizide tablets and the floating and swelling 
tendency of the formulation. The tablet swelled radially and axially. The figure 
also indicates that the tablet remained buoyant for 15 hr, but the tablet actually 
floated throughout the entire study. The in-vitro buoyancy study was also 
conducted at an elevated pH condition (~4.5). The floating tendency remained 
unaltered at higher pH. In all studied formulations the density was ~1 or less than 
1 g/cm3.  
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Table 6.3: Physical properties of floating-bioadhesive tablets of glipizide (n=3) 
Formulation code 
 
Density 
(g/cm3) 
Floating 
lag-time (sec) 
Floating 
duration (hr) 
JE5H100 0.982 ± 0.016 105.0 ± 5.4 23.5 ± 1.0 
JE5H80CH20 1.078 ± 0.023 105.0 ± 8.2 24.0 ± 1.5 
JE5H60CH40 1.011 ± 0.043 75.4 ± 3.7 23.5 ± 1.5 
JE5H40CH60 1.103 ± 0.076 87.2 ± 11.4 24.0 ± 1.5 
JE5H20CH80 0.992 ± 0.026 84.4 ± 12.4 23.5 ± 2.0 
JE5CH100 1.102 ± 0.065 89.5 ± 4.6 24.5 ± 2.5 
JE10H100 0.970 ± 0.058 47.8 ± 5.4 24.0 ± 2.0 
JE10H80CH20 1.067 ± 0.098 49.2 ± 10.0 23.5 ± 2.5 
JE10H60CH40 1.072 ± 0.097 54.0 ± 11.1 23.5 ± 2.0 
JE10H40CH60 1.042 ± 0.145 53.1 ± 9.6 24.0 ± 2.5 
JE10H20CH80 1.045 ± 0.078 45.9 ± 3.2 23.0 ± 1.0 
JE10CH100 1.045 ± 0.098 52.5 ± 4.4 23.0 ± 1.0 
JE10P100 1.013 ± 0.058 51.7± 9.0 23.0 ± 3.0 
JE10P80CP20 1.065 ± 0.065 51.0 ± 8.9 24.5 ± 2.5 
JE10P60CP40 1.045 ± 0.043 53.2 ± 11.2 23.5 ± 2.5 
JE10P40CP60 0.995 ± 0.057 54.0 ± 8.6 23.0 ± 2.0 
JE10P20CP80 0.976 ± 0.104 45.8 ± 4.6 23.5 ± 3.0 
JE10CP100 1.042 ± 0.097 52.0 ± 10.3 24.0 ± 1.0 
 
The results of bioadhesion studies are shown in Figure 6.3. Tablets with 5% or 
10% effervescent base in a matrix of HPMC/CH and 10% effervescent base in 
matrix of CP/PMA are compared for the bioadhesion in this figure.  
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Figure 6.3: Bioadhesive strength of different floating-bioadhesive tablets of 
glipizide 
 
 
 
 
Figures 6.4 and 6.5 show the effect of different ratios of HPMC and CH in tablets 
with two different percentages of effervescent base on drug release profiles.  
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Table 6.4: Glipizide release profiles in phosphate buffer solution (pH 7.4) from floating-
bioadhesive tablets containing 5 % effervescent base and HPMC/CH bland 
Batch 
 
Time 
(hr) 
JE5H100 JE5H20CH80 JE5H80CH20 JE5H60CH40 JE5H40CH60 JE5CH100 
0 0 0 0 0 0 0 
1 14 12 5 8 10 11 
2 32 32 15 17 20 25 
3 38 35 20 24 26 30 
4 51 45 25 32 37 36 
5 59 50 30 41 45 41 
6 64 55 35 42 46 46 
7 68 61 39 45 51 54 
8 70 65 43 51 57 58 
9 72 67 47 55 58 64 
10 74 69 52 61 65 68 
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Figure 6.4: Glipizide release profiles in phosphate buffer solution (pH 7.4) 
from floating-bioadhesive tablets containing 5 % effervescent base and 
HPMC/CH bland 
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Table 6.5: Glipizide release profiles in phosphate buffer solution (pH 7.4) from floating-
bioadhesive tablets containing 10 % effervescent base and HPMC/CH bland 
Batch 
Time 
(hr) 
JE10H100 JE10H20 
CH80 
JE10H80 
CH20 
JE10H60 
CH40 
JE10H40 
CH60 
JE10 
CH100 
0 0 0 0 0 0 0 
1 21 18 10 14 14 15 
2 41 35 20 23 25 28 
3 45 40 25 26 31 34 
4 53 48 32 38 39 39 
5 60 52 34 45 49 45 
6 65 57 36 48 51 49 
7 69 61 41 49 54 55 
8 71 65 43 52 58 59 
9 72 68 52 57 59 65 
10 75 69 55 62 66 70 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6                       
Glipizide floating-bioadhesive tablets 
J.R.Chavda                                            177                                         PhD. Thesis 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11
Time (hr)
%
 
D
ru
g 
R
el
ea
se JE10H100
JE10H20CH80
JE10H80CH20
JE10H60CH40
JE10H40CH60
JE10CH100
 
 
Figure 6.5: Glipizide release profiles in phosphate buffer solution (pH 7.4) 
from floating-bioadhesive tablets containing 10 % effervescent base and 
HPMC/CH bland 
 
 
 
Figure 6.6 compares the effect of gas generating agent concentration on drug 
release rate of HPMC/CH tablets. As this figure shows tablets with higher gas-
forming agent facilitates drug release.  
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Table 6.6: Comparison between glipizide release profiles in phosphate 
buffer solution (pH 7.4) from floating-bioadhesive tablets containing 5 % 
or 10 % effervescent base and HPMC/CH bland 
Batch 
Time 
(hr) 
JE5H60CH40 JE10H60CH40 JE5CH100 JE10CH100 
0 0 0 0 0 
1 8 14 11 15 
2 17 23 25 28 
3 24 26 30 34 
4 32 38 36 39 
5 41 45 41 45 
6 42 48 46 49 
7 45 49 54 55 
8 51 52 58 59 
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Figure 6.6: Comparison between glipizide release profiles in phosphate 
buffer solution (pH 7.4) from floating-bioadhesive tablets containing 5 % or 
10 % effervescent base and HPMC/CH bland 
 
 
 
Figure 6.7 compares the different ratios of CP/PMA from a release characteristic 
point of view.  
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Table 6.7: Glipizide release profiles in phosphate buffer solution (pH 7.4) from floating-
bioadhesive tablets containing 10 % effervescent base and CP/PMA bland 
Batch 
Time (hr) 
JE10H100 JE10H20C
H80 
JE10H80C
H20 
JE10H60CH
40 
JE10H40CH
60 
JE10CH1
00 
0 0 0 0 0 0 0 
1 22 18 15 8 7 4 
2 35 31 24 16 15 12 
3 40 36 33 25 22 18 
4 50 45 41 32 30 22 
5 60 54 50 39 37 32 
6 70 62 57 45 42 36 
7 72 65 60 50 45 40 
8 73 71 65 53 48 44 
9 77 72 67 58 51 46 
10 80 75 70 60 53 48 
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Figure 6.7: Glipizide release profiles in phosphate buffer solution (pH 7.4) 
from floating-bioadhesive tablets containing 10 % effervescent base and 
CP/PMA bland 
 
In all formulations curve-fitting method was used to determine the drug release 
kinetics (Tables 6.8 and 6.9).  
Dissolution results were analyzed using the semiempirical equation: 
 
                                                                                                        [6.3]      
where Mt/M∞ represents the fraction of drug released at time t, K is the diffusional 
constant characteristic of the drug/polymer system, t is the release time, and n is 
an exponent characterizing the mechanism of release of the drugs31.  
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Table 6.8: Results of mean dissolution time (MDT), dissolution efficiency after 8 hr 
(DE8%), time required for release 50% of drug (T50%), and diffusion exponent (n) 
Formulation code 
 
N MDT (hr) DE8% T50% (hr) 
JE5H100 0.77 3.52 59.24 8.54 
JE5H80CH20 0.87 3.41 55.23 8.65 
JE5H60CH40 0.71 3.22 62.65 6.54 
JE5H40CH60 0.50 3.21 67.75 5.78 
JE5H20CH80 0.51 3.22 68.93 4.76 
JE5CH100 0.53 2.81 75.34 3.67 
JE10H100 0.58 3.08 67.23 7.98 
JE10H80CH20 0.47 2.52 76.23 8.14 
JE10H60CH40 0.46 3.08 72.31 6.76 
JE10H40CH60 0.50 2.86 78.97 6.47 
JE10H20CH80 0.52 3.42 82.12 7.83 
JE10CH100 0.52 2.52 84.22 5.84 
JE10P100 0.69 3.57 65.74 26.54 
JE10P80CP20 0.70 2.12 98.25 12.56 
JE10P60CP40 0.68 2.25 96.57 5.09 
JE10P40CP60 0.67 2.32 94.75 2.37 
JE10P20CP80 0.57 2.34 86.98 2.45 
JE10CP100 0.47 2.52 86.40 3.12 
 
A table 6.8 and 6.9 summarizes the range of values of the diffusional exponent n 
and the corresponding release mechanism. The n values are in the range of 
0.45–0.85 representing a non-Fickian or anomalous transport. This table also 
represents the release parameters i.e., MDT, DE8%, and t50%. 
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Table 6.9: Correlation coefficient of release data of floating-bioadhesive 
tablets of glipizide 
Formulation 
code 
 
r2 
Zero-order First-order Higuchi model 
JE5H100 0.9862 0.9863 0.9902 
JE5H80CH20 0.9889 0.9891 0.9972 
JE5H60CH40 0.9575 0.9765 0.9854 
JE5H40CH60 0.9467 0.9790 0.9989 
JE5H20CH80 0.9365 0.9786 0.9844 
JE5CH100 0.9116 0.9702 0.9876 
JE10H100 0.9566 0.9732 0.9878 
JE10H80CH20 0.9109 0.9542 0.9809 
JE10H60CH40 0.9045 0.9598 0.9877 
JE10H40CH60 0.8154 0.9034 0.9531 
JE10H20CH80 0.6589 0.8456 0.8794 
JE10CH100 0.6439 0.8325 0.8567 
JE10P100 0.9453 0.9532 0.9822 
JE10P80CP20 0.9452 0.9598 0.9834 
JE10P60CP40 0.8764 0.9412 0.9642 
JE10P40CP60 0.8498 0.9501 0.9608 
JE10P20CP80 0.8432 0.9523 0.9678 
JE10CP100 0.6098 0.8145 0.8324 
 
 
 
 
 
 
Chapter 6                       
Glipizide floating-bioadhesive tablets 
J.R.Chavda                                            184                                         PhD. Thesis 
 
6.4 Discussion  
Studies show that some polymers like carbopolP934, polymethacrylic acid, 
chitosan, and hydroxypropyl methylcellulose are among the floating polymers 
that show bioadhesive properties more than other polymers and have been used 
in production of bioadhesive tablets. As these polymers are well hydrated and 
can adhere to the mucosal membranes, especially if a combination of them is 
used, their properties are improved32. Bioadhesive systems are used to localize a 
delivery device within the lumen and cavity of the body to enhance the drug 
absorption process in a site-specific manner33. The approach involves the use of 
bioadhesive polymers that can adhere to the epithelial surface of the 
gastrointestinal tract. The proposed mechanism of bioadhesion is the formation 
of hydrogen and electrostatic bonding at the mucus polymer boundary34.  
Floating dosage forms are meant to remain buoyant on the gastric fluid when the 
stomach is full after a meal; however, as the stomach empties and the tablet is at 
the pylorus the buoyancy of the dosage form may be impeded35. It then becomes 
increasingly likely that the dosage form will pass through the pylorus into the 
small intestine. Thus, the buoyant ability of a floating drug delivery system in the 
stomach could be limited to only 3–4 hrs. In a bioadhesive drug delivery system, 
it is quite likely that the system becomes dislodged from the stomach mucosa 
wall when the stomach is full and semi liquid contents are churning around under 
the influence of peristaltic movement14.  
A synergism between a bioadhesive system and a floating system also has been 
explored. Chitnis et al36 synthesized a series of bioadhesive polymers that were 
cross-linked polymers of PMA and CP. Floating tablets of isosorbide mononitrate 
were prepared and then coated with these polymers. The results showed good 
bioadhesion and low densities, indicating that the coat might confer buoyancy to 
these tablets. Patel et al21 prepared chitosan microspheres using cross-linked 
method. The results showed longer glycemic effect indicating good bioadhesion 
and low densities of these microspheres.  The results of bioadhesion test (Figure 
6.3) shows that the bioadhesion was significantly higher in JE10CP100 tablets 
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than other formulations (p < 0.05) and the following order is seen: JE10P100 
<JE10H100 < JE10CH100 < JE10CP100. 
Statistical analysis of bioadhesion between two groups of tablets containing 
HPMC/CH or CP/PMA shows that tablets with 80–100% and 60% of CP have 
higher bioadhesion than tablets containing the comparable amounts of CH (p 
<0.05). However, tablets with 20–40% CH, or those with pure HPMC, have high 
bioadhesion compared with tablets with similar amounts of CP or without CP (p < 
0.05). Increasing the content of CP in a series prepared with CP/PMA increased 
the bioadhesion (p < 0.05). Chng et al37 also reported that CP polymer adheres 
to the surface mucin of the epithelial cells and this cause a longer gastrointestinal 
transit time compared with PMA polymer. This is related to the charge of CP and 
neutral nature of PMA37.  
In the design of floating-bioadhesive glipizide tablets, the floatation was 
accomplished by incorporating gas-generating salts such as sodium bicarbonate 
and citric acid into a swellable matrix. The overall make-up of this particular 
matrix is of swellable polymers. As the dissolution medium was imbibed into the 
matrix, the interaction of fluid with effervescent base resulted in the formation and 
entrapment of carbon dioxide gas within the swollen gel, thus causing floatation 
as the matrix volume expanded and its density decreased. We observed that the 
amount of gas-generating effervescent base had a significant effect on the lag 
time of the system buoyancy (Table 6.3). However, statistical analysis of duration 
of floating time in HPMC/CH and CP/PMA tablets with 10% effervescent base 
showed no change (p < 0.05) in duration of system buoyancy by changing the 
percentage or the type of polymer mixtures (Table 6.3). In other words, the 
amount of gas-generating agent is just effective on the buoyancy lag time, but as 
the gas is generated at the early times of contact of fluid medium with 
effervescent base, the swelling of polymers is controlling the duration of system 
buoyancy. 
Yang et al38 used a mixture of sodium bicarbonate and calcium carbonate to 
induce gas formation in intragastric floating tablets of tetracycline/metronidazole 
tablets. Li et al 19,20 used citric acid as gas-generating agent in floating capsules 
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of calcium carbonate. A 1:1 mixture of potassium bicarbonate: monobasic 
potassium citrate as effervescent base of verapamil floating capsules has been 
reported by Gan-Lin and Wei-Hua39. Dave et al10 used sodium bicarbonate and 
citric acid as gas-generating agent in floating tablets of ranitidine hydrochloride. 
Drug release studies were made to determine whether the release of the drug is 
slow enough, i.e., which polymer percentage is enough to sustain the release of 
the drug for at least 8 hr. As Figures 6.4 and 6.5 shows, increasing the CH 
content of tablets significantly increases the percentage of drug released at 
comparable times (p < 0.05). This is because of rapid swelling and erosion of CH 
in contact with gastric fluid. Comparison of tablets with the same formulations but 
different effervescent base concentrations (Figure 6.7) shows faster release rate 
of drug and DE8% (Table 6.8) in tablets with 10% of gas-generating agent than 
5%. This is because of greater expansion of polymer matrix, better penetration of 
liquid medium into the tablet, and faster diffusion of drug. Table 6.8 shows that 
increasing CH content of tablets reduces MDT and T50% while increasing the 
DE8% (p < 0.05). Comparison of T50% and MDT of tablets with the same ratio of 
HPMC/CH but different effervescent bases shows a decrease in these 
parameters in tablets with 10% of gas-generating agent than 5% (p < 0.05) 
(Table 6.8). 
In spite of more suitable sustained-release effect of tablets with 5% effervescent 
base (Table 6.8), but as their long lag-time of buoyancy (Table 6.3), tablets of 
JE10H60CH40 and JE10H40CH60 were chosen as optimum formulations 
(Figure 6.5 and Table 6.8). However, as there were some difficulties in flow rate 
of powder in preparation of these tablets, formulation JE10H20CH80 also seems 
optimum from floating lag time, bioadhesion, and sustained-release point of view. 
Tablets composed of a polymeric matrix build a gel layer around the tablet core 
on contact with gastric fluid, which controls the drug release. Drug release from 
HPMC matrices is controlled by diffusion through the gel layer for water-soluble 
drugs or by erosion of the outer polymer chains for poorly soluble drugs40. The 
drug characteristics are as important as those of the gel. The size, shape, and 
ionization of the drug affect its diffusion through the gel layer41.  
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In tablets prepared from acrylate series, increasing the CP content, decreases 
the MDT and T50% but increases the DE8% significantly (p <0.05) (Table 6.8). 
Considering MDT and DE8%, tablets of JE10CP80P20, JE10CP60P40, and 
JE10CP40P60 seem suitable for sustained–release of drug in the stomach 
(Table 6.8). 
Curve fitting method according to zero-order, first-order, or Higuchi model for 
analysis of drug release kinetics are shown in Table 6.9. In all cases the Higuchi 
model is dominant and shows that the passage of glipizide, the water insoluble 
drug through the hydrated gel layer around the matrix tablet, is approximately 
dependent on the square root of time and can be described in the following 
form42:  
                                                                                                             [6.4] 
 
where Qt is the amount of the released drug in time t, k is the kinetic constant, 
and t is time. To predict the mechanism of diffusional release, the following 
semiempirical equation of 
 
                                                                                                        [6.5]    
  
was used to analyze data of controlled–release of this water soluble drug from 
the studied polymer matrices43. In this equation Mt is amount of the released 
drug at time t, M∞ is the overall amount of the drug (whole dose), k is the 
constant incorporating structural and geometric characteristics of the controlled–
release device, and n is the release exponent indicative of the drug release 
mechanism. For tablets of a known geometry (in this case a slab) n = 0.5 means 
Fickian diffusion, 0.5 < n < 1.0 non-Fickian diffusion, and n = 1.0 Case II 
diffusion43. Considering the n values calculated for the studied tablets (Table 
6.8), almost in most cases a non-Fickian mechanism is dominant. The drug 
diffusion through most types of polymeric systems is often best described by 
Fickian diffusion, but other processes in addition to diffusion are important. In this 
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case the non- Fickian or anomalous diffusion shows also a relaxation of the 
polymeric chains, and influences the drug release. Release from initially dry, 
hydrophilic glassy polymers that swell in contact of water and become rubbery 
show anomalous diffusion as a result of the rearrangement of macromolecular 
chains44. The thermodynamic state of the polymer and the penetrate 
concentration are responsible for the different types of the diffusion. A third class 
of diffusion is case II diffusion, which is a special case of non-Fickian 
diffusion40,43. The results of the calculated n (Table 6.8) reveal a non-Fickian type 
of drug diffusion, which means that the process of diffusion and relaxation run at 
comparable rates. 
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6.5 Conclusion 
In the current work, a matrix floating-bioadhesive tablet incorporating an insoluble 
active substance is described. The most successful tablets with the least lag time 
of buoyancy were those prepared with 10% of effervescent base but changing 
the polymer type of mixture ratio did not change the duration of buoyancy. 
Tablets containing 20% of HPMC and 80% CH or 80% of CP and 20% of PMA 
were optimum from both the bioadhesion and prolonged drug release rate point 
of view. 
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Formulation and evaluation of stomach-specific
amoxicillin-loaded carbopol-934P mucoadhesive
microspheres for anti-Helicobacter pylori therapy
Jayvadan K. Patel1 and Jayant R. Chavda2
1S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva,
Gujarat, India, and 2B. K. Modi Government Pharmacy College, Rajkot, Gujarat, India
Abstract
The purpose of this research was to formulate and systemically evaluate in vitro and in vivo performances
of mucoadhesive amoxicillin microspheres for the potential use in the treatment of gastric and duodenal
ulcers, which were associated with Helicobacter pylori. Amoxicillin mucoadhesive microspheres containing
carbopol-934P as mucoadhesive polymer and ethyl cellulose as carrier polymer were prepared by an
emulsion-solvent evaporation technique. Results of preliminary trials indicate that quantity of emulsifying
agent, time for stirring, drug-to-polymers ratio and speed of rotation affected the characteristics of micro-
spheres. Microspheres were discrete, spherical, free flowing and showed a good percentage of drug
entrapment efficiency. An in vitro mucoadhesive test showed that amoxicillin mucoadhesive micro-
spheres adhered more strongly to the gastric mucous layer and could retain in the gastrointestinal
tract for an extended period of time. A 32 full factorial design was employed to study the effect of
independent variables, drug-to-polymer-to-polymer ratio (amoxicillin-ethyl cellulose-carbopol-934P)
(X1) and stirring speed (X2) on dependent variables, i.e. percentage mucoadhesion, drug entrapment
efficiency, particle size and t80. The best batch exhibited a high drug entrapment efficiency of 56%;
mucoadhesion percentage after 1 h was 80% and the particle size was 109 mm. A sustained drug release
was obtained for more than 12 h. The drug-to-polymer-to-polymer ratio had a more significant effect
on the dependent variables. The morphological characteristics of the mucoadhesive microspheres were
studied under a scanning electron microscope. In vitro release test showed that amoxicillin released
slightly faster in pH 1.2 hydrochloric acid than in pH7.8 phosphate buffer. In vivo H. pylori clearance
tests were also carried out by administering amoxicillin powder and mucoadhesive microspheres
to H. pylori infectious Wistar rats under fed conditions at single dose or multiple dose(s) in oral
administration. The results showed that amoxicillin mucoadhesive microspheres had a better clearance
effect than amoxicillin powder. In conclusion, the prolonged gastrointestinal residence time and
enhanced amoxicillin stability resulting from the mucoadhesive microspheres of amoxicillin might
make a contribution to H. pylori complete eradication.
Key words: Mucoadhesive; amoxicillin; microspheres; factorial design; H. pylori
Introduction
Microsphere carrier systems made from the naturally
occurring biodegradable polymers have attracted consid-
erable attention for several years in sustained drug deliv-
ery. Recently, dosage forms that can precisely control the
release rates and target drugs to a specific body site have
made an enormous impact in the formulation and devel-
opment of novel drug delivery systems. Microspheres form
an important part of such novel drug delivery systems1–3.
They have varied applications and are prepared using
assorted polymers4. However, the success of these micro-
spheres is limited, owing to their short residence time at
the site of absorption. It would, therefore, be advantageous
Address for correspondence: Dr Jayvadan K. Patel, Associate Professor and Head, Department of Pharmaceutical Technology, S. K. Patel
College of Pharmaceutical Education and Research, Ganpat University, Kherva-382711, Gujarat, India. Tel: þ91-2762-286082.
E-mail: jayvadan.patel@ganpatuniversity.ac.in
(Received 15th April 2008; accepted 28th July 2008)
ISSN 0265-2048 print/ISSN 1464-5246 online  2009 Informa UK Ltd
DOI: 10.1080/02652040802373012 http://www.informaworld.com/mnc
to have means for providing an intimate contact of the
drug delivery system with the absorbing membranes5–8.
This can be achieved by coupling mucoadhesion
characteristics to microspheres and developing mucoad-
hesive microspheres. Mucoadhesive microspheres have
advantages such as efficient absorption and enhanced
bioavailability of drugs owing to a high surface-to-
volume ratio, a much more intimate contact with the
mucus layer and specific targeting of drugs to the absorp-
tion site9–12. Carbopol-934P (acrylic acid homopolymer) is
an anionic polymer that has been used in mucoadhesive
systems by several researchers13–17. Carbopol-934P was
selected as a polymer in the preparation of mucoadhesive
microspheres because of its good mucoadhesive and bio-
degradable properties and ethyl cellulose as carrier poly-
mer for microspheres.
In a relatively short time span, Helicobacter pylori
(H. pylori) have become recognized as a major gastric
pathogen with worldwide distribution. H. pylori are a
spiral-shaped bacterium found in the stomach, which
(along with acid secretion) damages stomach and duode-
nal tissue, causing inflammation and peptic ulcers. H. pylori,
a prevalent human-specific pathogen, is a causative agent
in chronic active gastritis18, gastric and duodenal ulcers19
and gastric adenocarcinoma20, one of the most common
forms of cancer in humans. Epidemiological, laboratory
and interventional human studies strongly suggest that H.
pylori play a pathogenic role in the development of adeno-
carcinoma of the distal stomach21. The mechanisms by
which H. pylori may cause gastroduodenal disease and con-
tribute to gastric carcinogenesis are still hypothetical.
However, the production of specific virulence factors by
the bacterium, the inflammatory response of the host and
the association with environmental contributors may all be
responsible22.
Treatment regimens for H. pylori infection have been
evolving since the early 1990s, when monotherapy was
first recommended. Antimicrobial therapy for this infec-
tion is a complex issue and the following drugs are cur-
rently used in combination regimens: proton-pump
inhibitors and/or bismuth, metronidazole, clarithromycin
and amoxicillin23. Tetracycline is used in the rescue ther-
apy24. Although optimal first-line treatment is associated
with high cure rates, the rising prevalence of resistance to
the antibiotic component of current eradication regimens
increasingly threatens to compromise the efficacy of these
regimens. Strains resistant to metronidazole25 and clari-
thromycin26 have been well documented, while resistance
to amoxicillin27 and tetracycline was mainly reported in
Asia28. Therapeutic regimens directed against H. pylori
infection will continue to evolve. What is required is a
simpler and more efficacious strategy for the treatment
of H. pylori infection. H. pylori is susceptible to many
antibiotics in-vitro, but has proved difficult to eradicate
(to root out) in-vivo.
Amoxicillin (-amino-hydroxybenzylpenicillin) is a
semi-synthetic, orally absorbed, broad-spectrum antibio-
tic. It is now widely used in the standard eradication treat-
ment of gastric and duodenal ulcers, which are associated
with H. pylori infection combined with a second antibiotic
and an acid-suppressing agent29–31. These tripe therapies
have proved to be effective in clinical application.
However, some other reports and clinical trials indicate
that the therapies cannot bring out compete eradication
of H. pylori and suggest that the therapeutic effect needs
more investigation32–33. One reason for the incomplete
eradication of H. pylori is probably due to the short resi-
dence time of dosage form in the stomach so that effective
antimicrobial concentration cannot be achieved in gastric
mucous layer or epithelial cell surfaces where H. pylori
exist34–35. The other may be the degradation of amoxicillin
in gastric acid36–37. Therefore, some researchers had pre-
pared and reported new amoxicillin formulations such as
float tablets, mucoadhesive tablets, pH-sensitive excipi-
ents composition microspheres, etc., which were able to
reside in the gastrointestinal tract for an extended period
of time for a more effective H. pylori eradication38–39.
A previous investigation on H. pylori clearance effect
showed that there was a tendency for a more effective
H. pylori activity of mucoadhesive amoxicillin micro-
spheres prepared using chitosan as mucoadhesive
microspheres40.
In context of the above principles, a strong need was
felt to develop a dosage form that delivered amoxicillin in
the stomach and would increase the efficiency of the drug,
providing sustained action. Thus, an attempt was made
in the present investigation to use carbopol-934P as a
mucoadhesive polymer and ethyl cellulose as a carrier
polymer and prepare mucoadhesive amoxicillin micro-
spheres. The microspheres were characterized by in-vitro
and iv-vivo tests and factorial design was used to optimize
the variables.
Materials
Amoxicillin (powder) was obtained as a gift sample from
Zydus Cadila (Ahmedabad, India). Carbopol-934P (CP,
molecular weight [MW] 3 106 Da) was obtained as a
gift sample from Noveon (Mumbai, India). Ethyl cellu-
lose and petroleum ether 80 : 20 were procured from
Willson Lab (Mumbai, India) and S. D. Fine Chemicals
Ltd (Mumbai, India), respectively. Liquid paraffin and
span 80 were purchased from Loba Chemie Pvt Ltd
(Mumbai, India). Wistar rats (300 50 g) were obtained
as a gift sample from Zydus Cadila (Ahmedabad, India).
Skirrow’s medium was purchased from Himedia Ltd.
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(Mumbai, India). All other ingredients were of analytical
grade.
Methods
Preparation of mucoadhesive amoxicillin
microspheres
Mucoadhesive microspheres of amoxicillin were prepared
containing carbopol-934P as a mucoadhesive polymer and
ethyl cellulose as a carrier polymer by emulsion-solvent
evaporation technique. Briefly, ethyl cellulose (1500 mg)
was dissolved in 200 mL of ethanol. Each 500 mg of
amoxicillin and carbopol-934P were dispersed in the
polymer solution of ethyl cellulose under stirring. In
preliminary trail batches the drug-to-polymer-to-polymer
(amoxicillin-ethyl cellulose-carbopol-934P) ratio was kept
constant at 1 : 3 : 1. The resultant mixture was extruded
through a syringe (gauge No. 20) in 500 mL of liquid par-
affin (mixture of heavy and light, 1 : 1 ratio) containing
2.0% v/v Span 80 and stirring was carried out using a
propeller stirrer (Remi, Mumbai, India) at 1000 rpm.
Stirring was continued for 3 h. The amount of emulsifying
agent and time for stirring were varied in preliminary trial
batches from 1–3% v/v and 1–3 h, respectively. In factorial
design batches J1–J9, 2.0% v/v Span 80 was used as an
emulsifying agent and time for stirring was kept to 3 h.
The drug-to-polymer-to-polymer ratio and stirring speed
were varied in batches J1–J9, as shown in Table 1. All other
variables were similar as in preliminary trial batches.
Microspheres thus obtained were filtered and washed sev-
eral times with petroleum ether (80 : 20) to remove traces
of oil. The microspheres were then dried at room tempera-
ture (25C and 60% RH) for 24 h. The effect of formulation
variables on characteristics of the microspheres of factorial
design batches is summarized in Table 1.
Optimization of microspheres formulation using 32
full factorial design
A statistical model incorporating interactive and polyno-
mial terms was utilized to evaluate the responses.
Y ¼ b0 þ b1X1 þ b2X2 þ b12X1X2 þ b11X21 þ b22X22 ð1Þ
where Y is the dependent variable, b0 is the arithmetic
mean response of the nine runs and bi is the estimated
coefficient for the factor Xi. The main effects (X1 and X2)
represent the average result of changing one factor at a
time from its low to high value. The interaction terms
(X1X2) show how the response changes when two factors
are simultaneously changed. The polynomial terms (X21
and X22 ) are included to investigate non-linearity. On the
basis of the preliminary trials a 32 full factorial design was
employed to study the effect of independent variables, i.e.
drug-to-polymer-to-polymer (X1) and the stirring speed
(X2) on dependent variables percentage mucoadhesion,
drug entrapment efficiency, particle size and the time
required for 80% drug dissolution (t80).
Determination of amoxicillin
Amoxicillin was estimated by a UV/Vis spectrophoto-
metric method (Shimadzu UV-1700 UV/Vis double beam
spectrophotometer, Kyoto, Japan). Aqueous solutions of
amoxicillin were prepared in phosphate buffer (pH 7.8)
and absorbance was measured on a Shimadzu UV/Vis
Table 1. Amoxicillin mucoadhesive microspheres batches using 32 full factorial design layout.
Variable levels in coded form In-vitro wash-off test (% mucoadhesion after)
Batch code X1 X2 1 h 5 h 10 h Drug entrapment efficiency (%) Particle size (mm) t80 (min)
J1 1 1 57 50 45 26 99 592
J2 1 0 55 49 44 21 93 645
J3 1 1 40 35 29 20 86 727
J4 0 1 80 72 60 56 109 502
J5 0 0 77 70 55 52 101 542
J6 0 1 71 65 50 41 94 582
J7 1 1 90 80 72 47 112 299
J8 1 0 81 75 64 41 110 308
J9 1 1 73 64 50 34 99 340
Translation of coded levels in actual units.
Variables level: drug-to-polymer-to polymer ratio (X1) (amoxicillin-ethyl cellulose-carbopol-934P), Low (1) 1 : 3 : 0.5, Medium (0) 1 : 3 : 1, High (þ1)
1:3:1.5; Stirring speed (X2), rpm, Low 800, Medium 1000, High 1200.
All the batches were prepared using 2% v/v Span 80 and stirring time of 3 h.
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spectrophotometer at 272 nm. The method was validated
for linearity, accuracy and precision.
Drug entrapment efficiency
Two-hundred milligrams of accurately weighed micro-
spheres were crushed in a glass mortar-pestle and the
powdered microspheres were suspended in 10 mL phos-
phate buffer (pH 7.8). After 24 hs the solution was filtered
and the filtrate was analysed for the drug content.
The drug entrapment efficiency was calculated using the
following formula: Practical drug content/Theoretical
drug content 100. The drug entrapment efficiency for
batches J1–J9 is reported in Table 1.
Particle size of microspheres
The particle size of the microspheres was determined by
using an optical microscopy method41. Approximately 300
microspheres were counted for particle size using a cali-
brated optical microscope (Labomed CX RIII, Ambala,
India). The particle size of microspheres of batches J1–J9
is reported in Table 1.
In vitro wash-off test for microspheres
The mucoadhesive properties of the microspheres were
evaluated by in vitro wash-off test, as reported by Lehr
et al.42. A 1 1 cm piece of rat stomach mucosa was tied
onto a glass slide (3 inch-by-1 inch) using thread.
Microspheres were spread (50) onto the wet rinsed
tissue specimen and the prepared slide was hung onto
one of the groves of a USP tablet disintegrating test appa-
ratus with continuous oxygen supply. The disintegrating
test apparatus was operated whereby the tissue specimen
was given regular up and down movements in the beaker
of the disintegration apparatus, which contained the gas-
tric fluid (pH 1.2). At the end of 30 min, 1 h and at hourly
intervals up to 12 h, the number of microspheres still
adhering onto the tissue was counted. The results of
in vitro wash-off test after 1, 5 and 10 h of batches J1–J9
are shown in Table 1. Also, results of in vitro wash-off test
of amoxicillin-loaded carbopol-934P mucoadhesive
microspheres of batch J4 is shown in Figure 1.
Scanning electron microscopy
Scanning electron photomicrographs of drug-loaded
carbopol-934P mucoadhesive microspheres were taken.
A small amount of microspheres was spread on a
glass stub. Afterwards, the stub containing the sample
was placed in the scanning electron microscope (JSM
5610 LV SEM, JEOL, Datum Ltd, Tokyo, Japan) chamber.
A scanning electron photomicrograph was taken at the
acceleration voltage of 20 KV, chamber pressure of
0.6 mm Hg, at different magnification. The photomicro-
graph of batch J4 is depicted in Figure 2.
The photomicrographs of in-vitro wash-off test results
after 2 h and 8 h are depicted in Figures 3 and 4,
respectively.
Drug release study
The drug release study was carried out using USP XXIV
basket apparatus (Electrolab, TDT-06T, India) at
37C 0.5C and at 100 rpm using 900 mL of phosphate
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Figure 1. Percentage mucoadhesion of amoxicillin-loaded carbopol-
934P mucoadhesive microspheres (batch J4) after 1, 5, 10 and 12h.
Figure 2. Scanning electron photomicrograph of amoxicillin-loaded
carbopol-934P mucoadhesive microspheres (batch J4).
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buffer (pH 7.8) as a dissolution medium (n¼ 5) as per USP
XXVI dissolution test prescribed for amoxicillin tablets.
Microspheres equivalent to 100 mg of amoxicillin were
used for the test. Five millilitres of sample solution was
withdrawn at pre-determined time intervals, filtered
through a 0.45 mm membrane filter, diluted suitably and
analysed spectrophotometrically. An equal amount of
fresh dissolution medium was replaced immediately
after withdrawal of the test sample. Percentage drug dis-
solved at different time intervals was calculated using the
Lambert-Beer’s equation. The t80 was calculated using the
Weibull equation43. The average values of t80 for batches
J1–J9 are mentioned in Table 1. The percentage drug
release of batch J4 in pH 1.2 and pH 7.8 is shown in
Figure 5.
Data fitting
An attempt was made to fit the dissolution data into the
Hixon-Crowell43 model represented:
m ¼ ð100Þ  1
3
 
 k  t
 3
ð2Þ
where k is Hixon-Crowell constant [mass/(time)]1/3.
In this model the percentage drug unreleased vs. cube
root of time is linear.
The data was treated with the Korsmeyer-Peppas
model44 to characterize the mechanism of drug release:
Mt
M/
¼ Kptn ð3Þ
where Mt/M! represents the fraction of drug released at
time t and Kp is the kinetic constant characterizing the
polymeric system and n stands for the diffusion exponent.
The dissolution data was also analysed using the
Weibull equation43 to determine the kinetics of drug
release from different batches of mucoadhesive
microspheres:
m ¼ 1  exp ðt  ti Þ b
a
 
ð4Þ
Figure 3. In-vitro wash-off test of amoxicillin-loaded carbopol-934P
mucoadhesive microspheres (batch J4) on rat stomach after 2 h.
Figure 4. In vitro wash-off test of amoxicillin-loaded carbopol-934P
mucoadhesive microspheres (batch J4) on rat stomach after 8 h.
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Figure 5. In vitro dissolution of amoxicillin from mucoadhesive micro-
spheres of batch J4 (-¨- pH¼ 1.2 and -g- pH¼ 7.8).
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where a is the scale parameter which defines the time
scale of the process, ti is the location parameter which
represents the lag period before the actual onset of disso-
lution process (in most cases ti¼ 0) and b is the shape
parameter. In this model the plot of log of time vs. In
(1m) is linear.
The results of F-statistics were used for the selection of
the most appropriate model. Results of F-statistics and
summary of results of regression analysis are shown in
Tables 2 and 3, respectively.
The curve fitting, simulation and plotting was per-
formed in Excel (Microsoft Software Inc., USA) and
Sigma plot version 10.0 (Sigma plot software, Jangel
Scientific Software, San Rafael, CA). The effects of inde-
pendent variables on the response parameters were visua-
lized from the contour plots. Numerical optimization
using the desirability approach was employed to locate
the optimal settings of the formulation variables so as to
obtain the desired response45. An optimized formulation
was developed by setting constraints on the dependent
and independent variables. The formulation developed
was evaluated for the responses and the experimental
values obtained were compared with those predicted by
the mathematical models generated. Counter plots show-
ing the effect of drug-polymer-polymer ratio (X1) and stir-
ring speed (X2) on percentage mucoadhesion, particle
size, drug entrapment efficiency and t80 appear in Figure 6.
In vivo clearance of H. pylori
The H. pylori infected animal model was established
according to Qian’s method (China Patent, CN
1304729A). Briefly, 0.3 mL of broth containing 109
CFU ml1 of H. pylori, isolated from patients with gastritis
and gastric ulcer, was inoculated into the stomachs of
6-week-old male Wistar rats. Then, the rats were fed for
4 weeks. H. pylori infection in rat was detected using the
‘golden standard’ culture, W-S stain and rapid urease test,
etc. The rapid urease test was carried out by collecting
and transferring the bacterial colonies into small tubes
containing 0.5 mL of mixture of phosphate buffer, urea
Table 2. Results of models fitting of batch J4.
Hixon-Crowell Korsemeyer and Peppas Weibull
Time (min) Cumulative
percentage release
Calculated cumulative
percentage release
Residual
square
Calculated cumulative
percentage release
Residual
square
Calculated cumulative
percentage release
Residual
square
0 0 6.86 47.00 — — — —
60 11.0 10.57 4.51 14.01 1.71 11.69 1.01
120 35.0 26.00 0.48 25.45 0.02 25.98 0.45
180 42.1 39.54 1.29 36.09 5.35 39.61 1.45
240 50.2 51.32 0.77 46.23 35.64 51.70 0.25
300 60.2 61.46 0.43 56.02 22.80 61.98 1.38
360 66.1 70.08 8.30 65.55 2.72 70.48 10.73
420 69.9 77.31 10.32 74.85 0.56 77.34 10.53
480 72.3 83.27 5.63 83.97 9.45 82.80 3.60
540 80.4 88.09 3.19 92.94 44.07 87.07 0.58
600 90.2 91.87 12.43 101.77 40.51 90.36 25.39
SSR 94.41 162.88 55.43
F-value 10.49 20.36 6.92
Correlation coefficient 0.9889 0.9935 0.9931
R2 0.9780 0.9871 0.9863
Slope 0.0046 0.8611 1.2745
Intercept 0.1038 2.38 3.17
Table 3. Summary of results of regression analysis.
Coefficient b0 b1 b2 b11 b22 b12 R
2
% Mucoadhesion 77.66 15.33 7.16 0 10.0 2.5 0.9803
Drug entrapment efficiency 50.11 9.16 5.66 1.75 18.16 0.66 0.9954
Particle size 102.33 7.16 6.83 0 1.5 1.5 0.9824
t80 536.22 169.5 42.66 23.5 56.83 8.66 0.9994
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(2% w/v) and phenol red (0.03% v/v). If the solution colour
turned into red in several minutes, the urease test was
regarded to be positive, which indicated the presence of
H. pylori. While if the solution colour did not turn red
in several minutes, the urease test was regarded to be
negative, this indicated the absence of H. pylori.
Single-dosage administration
To determine the dose for H. pylori clearance, mucoadhe-
sive amoxicillin microspheres and amoxicillin powder
were orally administered to the H. pylori infected
rats at the dosages of 4.0, 7.5 and 15 mg kg1 (n¼ 2).
Physiological saline was given to rats as control (n¼ 2).
One day after administration of drug to the H. pylori
infected rats, they were killed and their stomachs were
removed and cut. Then, the gastric tissue was daubed on
the modified Skirrow’s medium. The plates were incu-
bated for 3 days at 37C under microaerobic conditions.
H. pylori clearance effect was judged by both bacterial
colony counts and rapid urease test. The rapid urease
test was carried out by collecting and transferring the
bacterial colonies into small tubes containing 0.5 mL of
mixture of phosphate buffer, urea (2% w/v) and phenol
red (0.03% v/v). If the solution colour turned into red
in several minutes, the urease test was regarded to be
positive, which indicated H. pylori detection. H. pylori
clearance effects of amoxicillin at different doses in differ-
ent formulations (n¼ 2) are shown in Tables 4 and 5.
Multidose administration
To determine whether the mucoadhesive amoxicillin
microspheres could completely eradicate H. pylori, a mul-
tidose administration therapy was carried out. Briefly,
amoxicillin was orally administrated twice a day for
3 days at a dose of 3.5 mg kg1 in the form of either amox-
icillin mucoadhesive microspheres or powder (n¼ 2).
Physiological saline was given to rat as control (n¼ 2).
One day after administration the H. pylori infectious rats
were killed and their stomachs were removed and cut.
Then, the gastric tissue was daubed on the modified
Skirrow’s medium. The H. pylori clearance effect was stu-
died using the same method as described for single doge
administration. H. pylori clearance effect of amoxicillin
at different doses in different formulations is shown in
Figure 7.
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Figure 6. Counter plot showing the effect of drug-polymer-polymer ratio (X1) and stirring speed (X2) on percentage mucoadhesion (a), particle size (b),
drug entrapment efficiency (c) and t80 (d).
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Results and discussion
Preliminary trials
The mucoadhesive microspheres of amoxicillin using
carbopol-934P and ethyl cellulose were prepared by
emulsion-solvent evaporation technique. Carbopol-934P
was selected as a polymer for the preparation of mucoad-
hesive microspheres owing to its biodegradable and
mucoadhesive properties. Ethyl cellulose was used as
carrier polymer. Different concentrations of span 80
from 1–3% v/v were used as emulsifying agent.
Significant effect of concentration of span 80 was observed
on percentage mucoadhesion, particles size and drug
entrapment efficiency. Results showed that increase in
the concentration of span 80 increase the particles size
and percentage mucoadhesion but decrease the drug
entrapment efficiency. At 1% v/v, percentage mucoadhe-
sion, particles size and drug entrapment efficiency were
66%, 80 mm and 65%, respectively, but irregular shape of
microspheres was observed. While at 3% v/v, percentage
mucoadhesion, particles size and drug entrapment effi-
ciency were 82%, 210mm and 38%, respectively; spherical
shape of microspheres was observed but particles were
coalesced. Therefore, 2% v/v of concentrations of span
80 was used for further study.
One of the important factors related to microspheres
as reported by Lee et al.46 is the viscosity of the polymer
solution. Polymer concentrations of 0.5%, 1% and 2% w/v
were selected for preliminary trials. Flake formation was
observed when ethyl cellulose and carbopol-934P concen-
tration was used at a level of 0.5% w/v, whereas maximum
sphericity was observed at the 1% w/v level. Non-spherical
microspheres were found when polymer concentration
was used at the 2% w/v level. Therefore, 1% w/v of ethyl
cellulose and carbopol-934P each in ethanol was found
to be the optimum concentration for the polymer solution.
A 1 : 1 mixture of heavy and light liquid paraffin was found
to be suitable as a dispersion medium.
Preliminary trials batches were prepared to study the
effect of the time for stirring and stirring speed on the
Table 4. H. pylori clearance effect of amoxicillin at different doses in different formulations (n¼ 2).
Doses (mg kg1)
Colony counts 4 7.5 15
Amoxicillin mucoadhesive microspheres 20 26 8 6 2 2
(23 4.24)* (7.0 1.41)* (2 0)*
Amoxicillin powder 72 84 25 33 5 30
(78 8.48)* (29 5.65)* (18.0 16.97)*
Physiological saline 98 90 99 85 105 80
(94 5.65)* (92 9.89)* (92.5 17.67)*
*Figure showed mean SD.
Table 5. In vivo clearance of H. pylori after the administration of amoxicillin powder, mucoadhesive amoxicillin
microspheres and physiological saline (n¼ 2).
Mucoadhesive amoxicillin microspheres Amoxicillin powder Physiological saline
H. pylori 1 2 1 2 1 2
Condition / / þ/þ þ/þ þ/þ þ/þ
Negative () means neither bacterial colony was found nor rapid urease test was positive; (þ) means either bacterial colony
was found or rapid urease test was positive.
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Figure 7. H. pylori clearance effect of amoxicillin at different doses in
different formulations.
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percentage mucoadhesion, drug entrapment efficiency
and characteristics of the microspheres. Increase in the
time for stirring from 1 to 3 h showed an increase in
percentages of mucoadhesion, but a decrease in drug
entrapment efficiency and particles size. Thus, 3 h of
stirring time was selected for further study. Since stirring
speed has a significant effect on percentage mucoadhe-
sion, drug entrapment efficiency and particles size, it
was selected as an important factor for further study.
On the basis of the preliminary trials a 32 full factorial
design was employed to study the effect of independent
variables (i.e. drug-to-polymer-to-polymer ratio [X1] and
the stirring speed [X2]) on dependent variables percentage
mucoadhesion, drug entrapment efficiency, particle size
and t80. The results depicted in Table 1 clearly indicate
that all the dependent variables are strongly dependent
on the selected independent variables as they show a
wide variation among the nine batches (J1–J9). The fitted
equations (full models) relating the responses (i.e. percen-
tage mucoadhesion, drug entrapment efficiency, particle
size and t80) to the transformed factor are shown in
Table 3. The polynomial equations can be used to draw
conclusions after considering the magnitude of coefficient
and the mathematical sign it carries (i.e. positive or nega-
tive). The high values of correlation coefficient (Table 3)
for the dependent variables indicate a good fit. The equa-
tions may be used to obtain estimates of the response
since small error of variance was noticed in the replicates.
Factorial equation for percentage mucoadhesion
The in vitro mucoadhesiveness test showed that the per-
centage of mucoadhesive microspheres remaining on the
stomach mucosa (Table 1). Figure 1 showed that even after
12 h, 52% microspheres were adhered to the gastric
mucous layer. The mucoadhesive microspheres of all the
batches of the factorial design were spherical (Figure 2,
batch J4) and free flowing.
The linear model generated for percentage mucoadhe-
sion was found to be significant with an F-value of 29.96
(p5 0.0001) and R2 value of 0.9803:
% Mucoadhesion ¼ 77:66 þ 15:33X1
 7:16X2  2:5X1X2  10X22 ð5Þ
The counter plot (Figure 6(a)) shows that the in vitro
wash-off test for percentage mucoadhesion of micro-
spheres increased from 40 to 57 and 73 to 90 at lower
and higher levels of drug-to-polymer-to-polymer ratio,
respectively, as stirring speed decreased. Results of equa-
tion indicate that the effect of X1 (drug-to-polymer-to-
polymer) is more significant than X2 (stirring speed).
Moreover, stirring speed had a negative effect on the
percentage mucoadhesion (i.e. as the stirring speed
increased, the percentage mucoadhesion decreased).
This finding may be attributed to the change in particle
size that affects mucoadhesion. As the drug-to-polymer-
to-polymer ratio increases, the percentage mucoadhesion
also increases; because more amounts of polymer results
in higher amount of free –COOH groups13, which are
responsible for binding with sialic acid groups in mucus
membrane and thus results in increase in mucoadhesive
properties of microspheres. In vitro mucoadhesive test
showed that amoxicillin mucoadhesive microspheres
adhered more strongly to gastric mucous layer and could
retain in gastrointestinal tract for an extended period of
time (Figures 3 and 4.). Figure 4 showed that even after 8 h,
some of the microspheres were adhered to the gastric
mucous layer. All factorial batches showed more than 50
mucoadhesion even after 10 h.
Factorial equation for particle size
The linear model generated for particle size was found to
be significant with an F-value of 33.6 (p5 0.0001) and R2
value of 0.9824:
Particle size ¼ 102:33 þ 7:16X1  6:83X2
 1:5X1X2  1:5X22 ð6Þ
The counter plot (Figure 6(b)) shows that the particle size
of microspheres increased from 86.0 to 99.0 mm and 99.0 to
112mm at lower and higher levels of drug-to-polymer-to-
polymer ratio, respectively, as stirring speed decreased.
Results indicate that the effect of X1 (drug-to-polymer-
to-polymer) is more significant than X2 (stirring speed).
This means, as the stirring speed increased, the particle
sizes decreased, which directly affected the percentage
mucoadhesion.
Thus, one can conclude that the amount of polymer
(carbopol-934P) and stirring speed directly affects the
percentage mucoadhesion and particles size.
Factorial equation for drug entrapment efficiency
The drug entrapment efficiency and t80 are important vari-
ables for assessing the drug loading capacity of micro-
spheres and their drug release profile, thus suggesting
the amount of drug availability at site. These parameters
are dependent on the process of preparation, physico-
chemical properties of drug and formulation variables.
The linear model generated for drug entrapment efficiency
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was found to be significant with an F-value of 40.70
(p5 0.0001) and R2 value of 0.9954:
Drug entrapment efficiency ¼ 50:11 þ 9:16X1
 5:66X2  0:66X1X2
 1:75X21  18:16X22 ð7Þ
The counter plot (Figure 6(c)) shows that the percen-
tage drug entrapment efficiency of microspheres
increased from 20.0 to 26.0 and 34.0 to 47.0 at lower and
higher levels of drug-to-polymer-to-polymer ratio, respec-
tively, as stirring speed decreased. However, at medium
level of drug-to-polymer-to-polymer ratio, as stirring
speed decreased, percentage drug entrapment efficiency
of microspheres showed an increase from 41.0 to 56.0. The
results of this equation indicate that the effect of X1 (drug-
to-polymer-to-polymer) is more significant than X2 (stir-
ring speed). Moreover, the stirring speed had a negative
effect on the percentage drug entrapment efficiency (i.e. as
the stirring speed increased, the particle size decreased
and thus drug entrapment efficiency decreased).
Factorial equation for t80
The linear model generated for t80 was found to be signif-
icant with an F-value of 115.91 (p5 0.0001) and R2 value
of 0.9994:
t80 ¼ 536:22  169:5X1 þ 42:66X2
 23:5X1X2  56:83X21  8:66X22 ð8Þ
The counter plot (Figure 6(d)) shows that the percentage
drug released in vitro from microspheres decreased from
727 to 592 min and 340 to 299 min at lower and higher
levels of drug-to-polymer-to-polymer ratio, respectively,
as stirring speed decreased. The results depicted in
Table 3 indicate that the percentage drug released
in vitro is highly dependent on the drug-to-polymer-to-
polymer ratio and stirring speed. The drug-to-polymer-
to-polymer ratio has a negative effect on t80, while stirring
speed has a positive effect on t80, because as the particle
size decreases the drug release decreases.
A numerical optimization technique using the desir-
ability approach was employed to develop a new formula-
tion with the desired responses. Constraints like
maximizing percentage mucoadhesion, drug entrapment
efficiency, particle size and release at the end of 12 h in
addition to minimizing the t80 were set as goals to locate
the optimum settings of independent variables in the new
formulation. The optimized microsphere formulation (J10)
was developed using a 1 : 3 : 1.25 drug-to-polymer-to-poly-
mer ratio and 950 rpm stirring speed. The optimized
formulation was evaluated for percentage mucoadhesion,
drug entrapment efficiency, particle size and drug release.
The results of experimentally observed responses and
those predicted by mathematical models along with the
percentage prediction errors were compared. The predic-
tion error for the response parameters ranged between
0.50–2.15%, with the value of absolute error of
1.36 0.70%. The low values of error indicate the high
prognostic ability of factorial equation and counter plot
methodology. The drug release from the optimized formu-
lation was found to be low t80 (410 min), thus, batch J4
was selected for further study, which exhibited a high t80
of 502 min and seemed to be a promising candidate for
achieving drug release of up to 12 h. The drug release
profile of batch J4 is shown in Figure 5. The figure reveals
that drug release rate slowed after 4 h. The study focus was
the preparation of mucoadhesive microspheres, thus the
microspheres of batch J4 were also evaluated in simulated
gastric fluid USP (pH 1.2). In vitro release test showed that
amoxicillin released faster in pH 1.2 hydrochloric acid
than in pH 7.8 phosphate buffer, but the results indicated
that no significant difference was observed between dis-
solution profiles at pH 7.8 and pH 1.2 as the f2 (similarity
factor) value was 63.48.
The results of curve fitting of best batch into different
mathematical models are given in Table 2. The mechan-
ism of drug release from the microspheres was found to be
diffusion controlled because plots of percentage cumula-
tive drug release vs square root of time were found to be
linear with the regression coefficient (R2) values ranging
from 0.9780–0.9871 for the best batch. Results of F-statis-
tics are shown in Table 2. The release profile fitted to
Weibull equation F-value was found to be 6.92. The
value of correlation coefficient was found to be 0.9931.
The values of slope and intercept were found to be 1.27
and 3.17, respectively. The release profile fitted to
Korsmeyer-Peppas equation, F-value was found to be
20.36. The value of correlation coefficient was found to
be 0.9935. The values of slope and intercept were found
to be 0.8611 and 2.38, respectively; and release profile
fitted to Hixon-Crowell equation, F-value was found to be
10.49. The value of correlation coefficient was found to
be 0.9889. The values of slope and intercept were found
to be 0.0046 and 0.1038, respectively. The results of
F-statistics were used for the selection of the most appro-
priate model, thus it was concluded that the release profile
fitted best to Weibull equation (F¼ 6.92).
In vivo study
At present, most studies of mucoadhesive formulations
loading amoxicillin for anti-H. pylori focused on prolong-
ing the gastric retarding time. The stability of amoxicillin
in acidic medium was neglected. In fact, lots of antibiotics,
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such as erythromycin, clarithromycin, were reported with
strong in vitro H. pylori clearance effect but with poor
in vivo results. Ogwal and Xide47 suggested that one of
the reasons was due to their instability in acidic
medium. Amoxicillin was also reported to be unstable in
mediums with pH below 248–50. Amoxicillin can be quickly
absorbed after its conventional dosage forms are orally
administered. Therefore, its residence time in the stomach
is expected to be short34, which might cover up its short-
coming of being unstable in acidic medium. However, for
the mucoadhesive microspheres, which would stay in the
stomach for a much longer time, the stability of amoxicillin
should be seriously considered. This study found that
amoxicillin microspheres were more stable in pH 1.2
HCL than amoxicillin powder.
From the result of the in vivo H. pylori clearance test, it
was observed that, with the increase of amoxicillin’s doses,
the H. pylori clearance effect was enhanced in mucoadhe-
sive amoxicillin microspheres formulation. In the single
dosage administration test, it was found that the total
colony counts decreased markedly with the increase of
the amoxicillin dose in both groups. Means, 4 mg kg1
dose of amoxicillin mucoadhesive microspheres
administrated colony counts were 23 4.24 and on
increase in the doses to 7.5 and 15 mg kg1 colony
counts were 7.0 1.41 and 2 0, respectively. On admin-
istrating Amoxicillin powder 4 mg kg1 dose colony counts
were 78 8.48 and on increase in the doses to 7.5 and
15 mg kg1 colony counts were 29 5.65 and
18.0 16.97, respectively. While in the case of physiologi-
cal saline 4 mg kg1 dose administrated colony
counts were 94 5.65 and then increases in the doses to
7.5 and 15 mg kg1 colony counts were 92 9.89 and
92.5 17.67, respectively. Physiological saline did not
show any decrease in colony count. However, the ratio
of colony counts between amoxicillin powder and
mucoadhesive microspheres increased rapidly from
3.39 at 4 mg kg1 to 9.0 at 15 mg kg1 (Table 4, Figure 7).
This phenomenon indicated that, with the increase in
dose, mucoadhesive amoxicillin microspheres showed
more effective clearance of H. pylori than that in the
case of amoxicillin powder. It is inferred that this might
be due to the lack of repetition of drug administration.
Therefore, another multidose administration regimen
was tried. The results showed that, at the dose of
3.5 mg kg1, when amoxicillin microspheres, powder or
physiological saline was administrated, respectively,
to the H. pylori infectious rat twice a day for three
consecutive days (Table 5). Neither H. pylori colony was
found nor was urease test positive in rats whom
mucoadhesive amoxicillin microspheres were admini-
strated. It is concluded that the mucoadhesive amoxicillin
microspheres showed a more complete H. pylori
clearance effect.
Conclusion
The Amoxicillin mucoadhesive microspheres developed
employing a 32 full factorial design showed high
percentage mucoadhesion, drug entrapment efficiency
and exhibited a sustained release property for peroral
use in the form of capsules. Drug-to-polymer-to-polymer
(amoxicillin-ethyl cellulose-carbopol-934P) and stirring
speed significant influence on percentage mucoadhesion,
drug entrapment efficiency, particle size and t80. The opti-
mized formulation, developed using the desirability
approach, showed more effective H. pylori activity of
mucoadhesive amoxicillin microspheres compared to
amoxicillin powder and physiological saline, which
might indicate a potential use of mucoadhesive amoxicil-
lin microspheres in treating H. pylori infection.
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